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Abstract 
Flow induced aggregation occurs during the manufacturing process of 
biopharmaceuticals. An understanding of the effects of extensional flow is 
required as a means of predicting the response of experimental protein 
molecules to flow conditions during the down-stream manufacturing 
operations. Adequate prediction methods allow for elimination of proteins 
susceptible to flow induced aggregation, reducing development costs. 
An experimental device is designed and implemented to subject the proteins 
BSA, β2-microglobulin (β2m), granulocyte colony stimulating factor (G-CSF), 
and three monoclonal antibodies (mAbs) to a defined and quantified flow field 
dominated by extensional flow. CFD analysis is used to accurately 
characterise the flow field throughout the geometry. Through simulation and 
bespoke post-processing it is possible to determine the magnitude of 
extensional strain which the fluid is subjected to. The device is then modified 
to allow for a comparison to be made between the strain and shear which is 
inherent in any flow device.  
The work shows that the device induces protein aggregation after exposure 
to an extensional flow field for 0.36 – 1.8 ms, at concentrations as low as 0.5 
mg ml−1. Correlation is drawn between the extent of aggregation and the 
applied strain rate, as well as protein concentration, structural properties, and 
sequence of the protein. 
A method of equating the forces present within the flow to those experienced 
by a single molecule within the fluid continuum are also presented. 
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1. Introduction 
Protein aggregation due to flow induced shear is a widely debated topic and 
despite a lengthy history of debate, a satisfactory conclusion has yet to be 
produced. The question is largely based around whether the body forces in a 
fluid flow act upon the protein molecules in the solvent in such a way as to 
alter their structure and, therefore, their biological performance. The body 
forces discussed widely in current literature are referred to collectively as 
“shear” forces. The ambiguous use of the term “shear” has led to some 
confusion around the topic as, within the discipline of fluid mechanics, “shear” 
has a very specific definition which fails to include the vast majority of flow 
conditions which theoretically could provide the necessary forces to damage 
proteins. Whatever the mechanism, degradation of protein stock during 
processing has a major influence on manufacturing costs. A means of 
predicting the behaviour of a protein throughout the manufacturing procedure 
would allow manufacturers to modify/ tune their machinery or, in the case of 
biopharma development, select a molecule which is more likely to survive. 
Such a method could use a well-defined flow in a microfluidic device to induce 
forces similar to those present in manufacturing equipment. 
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1.1. Aims 
Determine the effects of fluid forces on protein molecules during the 
manufacturing and processing stages of biopharmaceutical development and 
production. Develop a method of screening proteins for susceptibility to 
aggregation and/or deactivation during the manufacturing procedure. 
1.2. Objectives 
 Develop a model understanding for flow induced protein deformation 
using CFD, experimental and biological methods. 
 Determine what aspects of flow are likely to result in the deactivation 
of protein in solution. 
 Perform a detailed CFD study to model types of flow present in protein 
manufacture: 
 Gain an understanding of protein characterisation methods and select 
the appropriate methods to assess the effects of flow on proteins. 
 Develop and test an experimental method to produce predictable and 
repeatable aggregation/ inactivation in protein samples and draw a 
comparison to predictions from CFD as a validation method. 
 Go on to develop a method for screening a range of proteins from the 
formula development stage of a biotic drug to assess which strands are 
likely to survive the manufacture process as a means to reduce costs 
of development and production. 
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1.3. Thesis Structure 
The problem will be identified from a comprehensive literature review which 
will form the background section of the thesis. From this, it will be clear what 
specific questions need to be asked. The theory required to address these 
questions with then be presented. This will include information about 
characterisation methods and previous flow devices.  
The design of an experimental device will then be documented. A CFD study 
will be conducted to validate the applicability of the device and explore the 
limitations of the device. The results of which will be presented here and will 
be used to inform the experimental method. 
Due to the nature of the current work, the computational characterisation of 
the flow cell device will happen in parallel with the device design and 
development. This stage will include the selection of a suitable control system 
as well as off-the-shelf components.  
In the current work, the computational methods are presented first, followed 
by the results from the computational study. The computational results are 
then used as the validation and basis for the experimental design. Although in 
reality, these two sections are conducted in tandem. They are presented in 
this order to emphasise the importance of understanding the fluid forces 
present during the experimental study. 
The comprehensive experimental method follows. This will document which 
variables are being investigated, what the limitations are, what 
characterisation methods will be used and what can and cannot be obtained 
from the results. A series of control experiments will also be carried out to 
address any issues raised during the CFD study. 
The results from the experimental work will then be presented and discussed 
in light of what is known from the CFD study. Concluding remarks will then be 
made with suggestions for future work. 
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2. Literature Review 
This review is aimed at the engineer. It is the opinion of the writer that the 
relatively young world of the biopharmaceutical industry may appear 
somewhat abstract from an engineering (particularly a fluid dynamics) 
perspective. The structure is therefore as follows: a broad introduction will give 
an overview of the field and a summary of the problem at hand. The 
background of the pharmaceuticals industry will then be presented to give 
context to the current work. The development and manufacturing procedures, 
of protein-based biopharmaceutical products will then be covered during 
which attention will be paid to the fluid mechanics at play and the current 
perspectives within the literature. From this, certain inherent shortcomings 
within the literature will become apparent from a fluid mechanics context. 
Finally, a solution will be explored which takes inspiration from the related field 
of DNA analysis, and the more obscure field of polymer processing. 
2.1. Protein modelling for fluid mechanics 
Proteins are long chain-like molecules of “links” called amino acids. There are 
twenty-two amino acids which are assembled in specific orders to create 
bespoke proteins. An amino acid within a protein sequence is referred to as a 
residue. As such, the “size” or length of a protein can be given in terms of the 
number of residues. A protein has a specific job in an organic system, and as 
such, it has a specific shape, often suited to adhere to a unique bonding site. 
This is known as a conformational match and is often likened to a key fitting a 
lock. Proteins are usually globular, in that they fold, and curl up to give a 
minimal surface area. The folding pattern is mostly controlled by the 
hydrophobic effect which acts to contain the reactive, hydrophilic region on 
the inside of the fold to minimise contact with the solvent. However, some 
proteins can in fact form highly elongated structures [10]. These structures are 
deformable and can be manipulated by mechanical forces which are often 
present within the protein’s native environment. If a mechanical force is 
applied to a ligand or receptor (the active part of the protein) the resulting 
deformation can alter the conformational match, weakening the functionality 
of the protein, as illustrated in Figure 2-1 [11].  
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Even with the relatively advanced position that DNA modelling in flow seems 
to be in, there are still large assumptions being applied. Two models of note 
are the bead-spring and bead-rod assumption [12]. The bead-rod assumption 
takes each monomer as a “mass point” attached together by freely jointed 
rigid links [13]. The term “free-draining” was used to describe the models. The 
definition of “free-draining” molecule, Schroeder states that it is one that “does 
not induce perturbations in the solvent velocity”, though it is probable that a 
long polymer chain would have a notable effect on the flow field. This is a 
reasonable concept when the structure of an organic molecule is considered. 
The natural state of a long-chain molecule is coiled up, in a flow the interior 
monomer units would be protected or “shielded”[12] from the forces of the 
flow. As the molecule is extended, however, it unravels and more units 
become susceptible to fluid forces. 
 
2.2. Protein Aggregation and Pathways 
The pathways to protein deactivation and aggregation have been researched, 
with sensitivities to environmental factors such as temperature and pH well 
documented [14]. Aggregation has been found to propagate through the 
partial unfolding of the complex native structure of any given protein [15]. The 
native structure is largely driven by the order of hydrophilic and hydrophobic 
regions, with hydrophobic section confined to the centre of the protein [16, 
17]. The partial unfolding of the native structure exposes the hydrophobic core 
Figure 2-1: “A good conformational match shown in (a) can change if 
the receptor deforms under force (b).”[1] 
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regions which can then bond with exposed regions in neighbouring proteins 
[18]. The agglomerated proteins likely become inactive, and insoluble [19, 20]. 
The aggregated mass of protein, when exposed to harsh fluid processing 
environments such as stirring, pumping or filtering, can then be broken up into 
protein fragments [21]. These fragments then form nucleation sites for the 
basis of aggregation seeding, where functional proteins adhere to protein 
fragments to form new agglomerates. 
The effects of fragment seeding is documented in the formation of amyloid 
fibrils [22] and is particularly topical in the study of neurodegenerative 
diseases [23].  
Bee et. al. 2011 summarised, also, the effects of materials and surfaces on 
proteins in solution. This is evident particularly in the field of 
biopharmaceuticals, where proteins are exposed to a wide variety of materials 
Figure 2-2: Many physical degradation pathways of proteins are made 
possible through exposure to interfaces, foreign particulates, or 
leachables. This figure shows a vial as one example [5]. 
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throughout their manufacture and storage [24]. One such concern is the action 
of adsorption, where a protein may become attached to a solid surface [25]. 
The surface may be the side of a vessel, a pipe, or a stirring or pumping 
impellor. Adsorption may be driven by the same hydrophobic forces which 
dominate protein-protein aggregation [26]. The associated protein could bind 
to the surface reversibly or irreversibly. An irreversibly bonded protein would 
then be subject to the same possibilities of nucleating further aggregation, or 
fragmenting and seeding agglomeration in the wider fluid environment. These 
aggregation pathways are well demonstrated by Error! Reference source 
not found. [5]. 
 
2.3. Introduction to biopharma 
Traditional pharmaceuticals are organic chemicals such as acetaminophen 
(Paracetamol) or ketamine with relatively low molar masses. For example, the 
fore mentioned drugs have molecular masses of 151Da and 238Da 
respectively. Some drugs were discovered in nature, such as aspirin (salicylic 
acid) which was derived from willow tree bark around 200 years ago[27], and 
are now mass produced by chemical synthesis. These drugs make up the 
chemical-based pharmaceutical industry [28]. 
Another branch of pharmaceuticals uses pre-existing biological sources such 
as hormones or blood products as raw materials for manufacturing 
therapeutics. An historic example of this is Insulin; first successfully 
demonstrated as a subcutaneous injection in a human patient in 1923, 
Insuline, as it was then known, was a slightly acidic alcohol solution of raw 
beef pancreas which was harvested from a fresh bovine sample and injected 
into the arm of a severely diabetic 14-year-old boy. Although the effects of 
diabetes had been well known for some time and the search for a method of 
alleviating the symptoms had been ongoing for 30 years prior to this 
successful trial, the mechanism and structure of insulin was not fully 
understood until the late 1950’s with radically new formulations being 
introduced to market as late as the 1970’s [29].  
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Vaccines and immunology form another example of biological therapeutics. 
By the late 1700’s it had been recognised that survivors of Smallpox were 
protected against re-contracting the disease. It was becoming understood that 
exposure to a somehow “weakened” virus could grant patients immunity 
against a potentially lethal strain. The earliest medical practice of exposure to 
infected material to ward off Smallpox, practiced in Asia, was to inhale pox 
material as a form of controlled inoculation known as variolation which was 
shown to dramatically reduce fatalities. The practice became well established 
in the UK throughout the 18th century. The term vaccine was first coined By 
Edward Jenner in his 1801 publication “the Origin of the Vaccine Inoculation” 
in which he documents his administering of the non-lethal virus, cowpox, as a 
preventative method to the contraction of  smallpox [30].  
The success and subsequent distribution of smallpox vaccine across the 
globe is now legend, but despite that monumental leap forward in human 
pathology, the science of immunology was still considered to be in its infancy 
until the late 1970’s. The subsequent eradication of Smallpox and birth of 
Molecular Immunology in 1980 marked the revolution [31] in biological 
therapeutics which paved the way for modern day biotechnology. 
Products of biotechnology such as insulin and vaccine, as well as any 
therapeutic derived from blood, toxins or allergens are termed “biologics” (or 
“biological medicinal product”). This label encompasses most (but not all) 
biopharmaceuticals [28].  
The first major steps into Genetic Engineering (GE) were taken in 1971 with 
the proposal from Stanford researcher Paul Berg to combine genes from a 
tumour virus SV40 with E-coli DNA using a complex prototype method which 
would combine the features of both organisms into one strand. The potential 
of what was intended to be nothing more than an academic exercise was 
realised almost immediately as Berg’s proposal triggers a series of 
discussions regarding ethics and safety implications around the study of 
recombinant DNA (rDNA). It was known that the small animal tumour virus 
SV40 could also act upon individual human cells. If its genes could be 
attached to the DNA of E-coli, a bacteria which can thrive in the human gut, it 
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was thought that the tumour virus could then replicate in humans. Berg 
postponed his research and published a series of guidelines for the use of 
rDNA technology [32].  
Since the 1950’s, a large number of biomolecules which occur naturally within 
the body have been discovered to have medicinal properties, but because of 
the relatively small quantities in which they are produced in nature, their large 
scale therapeutic application was rendered impractical [28].  A means of mass 
production was required if these antibodies were to become a practical form 
of therapeutic treatment. The answer was given over the following years with 
the discovery of rDNA and monoclonal/ hybridoma technologies.  
In 1972 Herbert Boyer from the University of California, San Francisco and 
Stanley Cohen, another Stanford researcher, successfully tested a simple 
method for producing rDNA using E-coli plasmids to produce a strain of E-coli 
that was immune to both tetracycline and kanamycin antibiotics [33]. This is 
recorded as the advent of Genetic Engineering and rDNA technology. 
The potential of rDNA flourished when it was combined with the development 
of monoclonal antibodies (mAbs) and hybridoma technology. Lymphocytes 
are white blood cells, capable of producing the antibodies which make up the 
immune system. The existence of antibodies, the immune system and the role 
it plays was discovered during the 1890’s but it wasn’t until the 1960’s that the 
importance of lymphocytes was understood. The average human possesses 
~1×1012 lymphocytes making up approximately 1% of our body mass [34]. 
The ability to manufacture antibodies from adapted B-lymphocytes (or B-cells, 
an antibody with a binding area specific to a single antigen) to produce 
monoclonal antibodies (mAb) was realised by the development of hybridoma 
technology [35]. 
The first mAb, produced in 1975 by Georges Köhler via hybridoma, was the 
result of combining a B-cell which produced a known antibody, with a 
myeloma cell [34], a mutation which results in the myeloma plasma producing 
only a single antibody as opposed to the many antibodies produced by regular 
plasma cells. The result was an “immortalised” B-cell which output only a 
single type antibody [34]. This paved the way for the mass production of 
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antibody based biopharmaceuticals with the first FDA approved antibody 
entering the market in 1986 [35].  
In 2009 the number of mAbs produced made up more than 30% of all 
biopharmaceuticals manufactured [36] and represented a market value of 
over $30 billion, with growth figures far in excess of any other therapeutic on 
the market [35]. Currently, therapies of biopharmaceuticals are taken over a 
relatively large treatment time, and at high dosages, with any one consumable 
mAb requiring a production rate of 100-1000kg/yr [36]. 
There is a clear requirement, therefore, for a method of screening potential 
candidates for manufacturability early in the development stages. This would, 
at the very least, provide an estimate of processing viability. At best, potential 
candidates could be rated on their likelihood to survive the plant; information 
which could be used along with efficacy studies to identify ideal market 
candidates. 
Pharmaceutical development and manufacture is now a recognised industry 
and the steps from formula to marketing have become very well defined. A 
detailed account can be found in any number of texts[28, 37]. With 
biopharmaceuticals, the game changes substantially with the cultivation and 
processing of biologically active raw material and the need for the final product 
to adhere to all of the previous quality requirements of classical 
pharmaceuticals. The production cycle of a biopharmaceutical varies from 
drug to drug. Again, for a fuller understanding, the reader is directed to texts 
such as Crommelin [37]. But for the purposes of the current work, a generic 
summary will be made with the assumption that it can be applied universally. 
The production of biopharmaceuticals can be separated into two stages, the 
first of which is the development stage. Various different compounds of the 
drug are optimised and tested against a range of requirements including 
clinical trials. A therapeutic compound can exist in many different variations of 
the same chemical formula. Each version could carry a subtle alteration on 
others such as a unique chiral centre. The same variations occur in the 
proteins used for biopharmaceuticals. As such, each small change may 
produce a different efficacy or a variation on a desired outcome. These subtle 
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characteristics also affect the structure of the protein and its ability to fold 
easily or resist physical stress. To that end, a number of variations need to be 
explored with every new drug to establish which are the most effective, the 
least evasive and the easiest to manufacture. During this stage only a limited 
amount of the various lines are required and so production is on a scale much 
smaller than that required for commercial purposes.  
The second stage is the manufacture stage. This only takes place on a single 
variant of the protein after all other development lines have been ruled out. 
The scale of production is much larger than that required for development; 
however the overall scale varies from drug to drug depending on demand, 
complexity, raw materials, etc. 
Carrying many variations of compound from stage one, all showing medical 
efficacy, but having different structures, through all the different levels of 
testing is very cost intensive. As yet, no method of testing multiple compounds 
for their response to flow induced aggregation exists. It is currently the industry 
norm to take the most medically viable variants forward to testing without 
considering the manufacturability of the drug until the scale-up phase. At this 
point it can become clear that the most effective drug may in fact be extremely 
temperamental to mass production due to its response to adverse flow 
conditions. It may be a viable option to select a variant with less stringent 
manufacture requirements. 
2.4. Current perspectives 
Protein aggregation is a general term used to describe denaturation, or the 
loss of biological activity due to mis-folded protein molecules. Mis-folded 
proteins can become inactive or accumulate and clump together, often 
irreversibly [38]. Flow induced protein aggregation during the manufacture 
and processing of protein-based biopharmaceuticals, on an industrial scale, 
has been widely reported since the introduction of biotechnological drugs into 
mainstream therapeutics [39-41]. However the mechanism by which flow 
induced aggregation occurs is still unclear. A large body of experimental 
research [2, 42] has been presented by the biopharma and biotech fields 
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around the effects of fluid-mechanical shear on the performance of protein 
solutions. A sizable range of findings have been produced for a substantial 
number of protein-based products; stretching from naturally occurring, and 
relatively common, proteins such as albumin [8] and enzymes such as 
lysozyme [8, 43] and alcohol dehydrogenase (ADH) [44], to bioengineered 
antibodies such as immunoglobulin G, (IgG) destined to become bio-
therapeutics [24]. The results presented over time have often proved 
contradictory with little correlation drawn between protein composition, 
mechanical structure, mechanical forces, energy dissipation or absorption 
within the fluid medium. The only flow characteristic of interest in previous 
work is maximum shear stress or shear rate. For example, Tirrell and 
Middleman proposed in 1975 that enzymes could be temporarily deactivated 
be exposure to shear, and demonstrated both permanent and temporary 
inactivation of urea [2, 45]. Whereas, in 1979, Thomas and Dunnill [44] 
demonstrated a distinct lack of deactivation after exposure to shear for up to 
5 hours. The experiment was carried out on urease, as well as catalase and 
ADH. This is typical of previous work, as reviewed recently by Thomas and 
Geer [2]. 
Performance of proteins in the aforementioned work was measured in various 
ways. In studies related to enzymes, the performance was measured by 
comparing the ability of the stressed samples to perform their biological 
function with that of a native, unaltered molecule. Similarly in studies 
concerning therapeutic proteins, the performance was measured by 
assessing the efficacy of the drug, where efficacy is defined as the maximum 
response that can achieved during clinical testing [46]. In terms of protein 
performance to adverse environments however, a measure of performance 
can achieved by gauging the amount of protein that survives the given 
conditions. These could be pH, temperature or physical stress, amongst 
others. In this instance, performance is measured by assessing the amount of 
monomeric protein that remains in solution after stressing. For the current 
work, it is the latter method that is used to evaluate the performance of protein. 
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An identifiable cause for contention within the literature lies with some 
considerable margins for error introduced within the experimental procedure 
or with the application/ interpretation of fluid-mechanical engineering theory. 
Work has been criticised for the inclusion of air-liquid interfaces when 
conducting rheological shear experiments. It is known that surface tension can 
induce aggregation in presence of shear or mixing. Bee et al. [5] noted that 
aggregation of β-lactoglobulin and human serum albumin, reported to have 
been induced by agitation in a 2003 paper [47] was observed in the presence 
of an air-liquid interface and therefore cannot be attributed to shear. The 
values of shear quoted in the bulk of reviewed literature are generally the 
maximum shear, occurring at the walls of the experimental device. It is 
important to note that the shear in this region is not typical of shear values in 
the bulk of the flow and the overall contribution of maximum shear to the fluid 
depends on the volume of fluid and the geometry of the test device. 
It seems that the cause of aggregation during processing may well lie within 
the characteristics of the flows induced by manufacturing procedure coupled 
with the properties of the individual proteins; either their mechanical (tertiary-
quaternary) structure or their chemical composition. But to date, the emphasis 
has been largely directed toward the nature of the proteins with only a brief 
summary of the flow conditions provided; usually defining the maximum shear 
stress or shear strain and the exposure time of the solution to an applied load. 
In fact, understanding the effects of flow on biological material is proving 
problematic across a range of fields. Damage to blood (haemolysis) flow 
through ventricular assist devices is known to induce aggregation in the blood 
(thrombosis). Yet, the mechanism by which this occurs in complex flow is still 
under investigation[48]. Furthermore, thrombus formation has been linked to 
the aggregation of blood platelets which is exacerbated by the presence of a 
contraction in the flow, such as a build-up of arterial plaque [49]. A contraction 
introduces a particular phenomenon into the flow mechanics. Due to 
conservation of mass a fluid must accelerate at a contraction. This causes an 
extension of the fluid element within the flow. A considerable body of work [9, 
50] around the application of extensional flow fields to DNA molecules has 
been presented in which the characteristics of the flow are well defined, 
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controllable and repeatable to the extent where a single DNA molecule can 
be non-destructively unravelled and scrutinised down to the individual 
nucleotides [9]. In order to achieve this, the destructive capability of 
extensional flow in relation to long-chain/ polymer-like molecules had to be 
understood in order for it to be mitigated. The use of extensional flow to control 
protein aggregation has been touched on before with success [51]. This raises 
questions around whether the types of flow used to analyse proteins in 
solution, which are historically based around viscometric [43] and rheological 
[24]  studies, are truly the best approach to stressing proteins.  
Gaps in the current understanding of flow induced protein aggregation 
therefore appear to be located around the characterisation of flow of the 
protein solution and how the flow interacts with the protein molecules. The 
models used to characterise these flows seem to be invariably Newtonian with 
no discussion around the possibility of non-Newtonian phenomena occurring, 
either universally throughout the solution or locally at points where the flow 
tends to converge, typically around filters or filling operations. Studies into the 
effects of convergent flow on proteins are scarce and far from comprehensive, 
but do suggest a trend toward increased aggregation. A large body of work 
has however been done around the effects of having particles suspended in 
fluids in relation to Stokes number and Brownian motion which could be drawn 
upon in this area. 
2.5. Previous flow studies 
The current debate within the literature is whether the likelihood of a protein 
to undergo activity loss during production can be related to magnitude of 
activity loss within a high-shear environment.  
A review of previous work, published in 2010 by Thomas and Geer [2], 
summarises a large body of research dating back to work as early as 1970 
where the first mention of shear relating to activity loss is reported by Charm 
and Wong [52]. The precedent is discussed whereby fluid mechanics within 
protein manufacture equipment is commonly examined by way of the shear 
rate or shear stress [2]. These properties will be discussed in full at a later 
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section but it is worth noting at this point that a typical shear rate has yet to be 
identified within the industrial process [2]. Furthermore, the experimental 
application of shear to proteins is somewhat abstract when considered from a 
manufacture perspective. Manufacture involves pumps, filters and stir tanks; 
all of which possess extremely random, non-uniform “shear” environments. 
Whereas the experimental shear devices are uniform in nature. Some 
examples of high-shear devices are given below.  
 Thomas and Geer came to the conclusion that “shear” (in this case referring 
to a wide range of hydrodynamic phenomena which will be discussed in detail 
later) is unlikely to be the sole cause of protein denaturation, proposing a 
series of alternative mechanisms for activity loss in proteins. This conclusion 
does hold based on the reviewed literature. Examples include the reviewed 
work conducted by Lencki et al. [2, 53] which concluded that denaturation 
caused by shear may enhance coagulation. But the presence of a moving 
gas-liquid interface allows for the possibility that proteins were denatured at 
the surface and mixed back into the solution. The conclusion was drawn that 
fluid shear plays a negligible role in protein aggregation, as proved by an 
extensive number of experimental studies.  
Thomas and Geer fall short with the assumption that shear related effects 
encompass all interfacial and hydrodynamic phenomena whilst failing to 
present a proper definition of a high-shear environment [2]. Distinction must 
be made between mechanical shear forces and interfacial phenomena. 
Effects of interfacial phenomena are well documented and surfactants can be 
used to control them, either to prevent adsorption at a filter interface or to 
relieve hydrophobic effects and surface tension at a gas-liquid boundary [54]. 
Despite the long line of evidence presented for and against the effects of shear 
and its link to protein production, no clear consensus has yet been reached 
within the field of biologics and biopharmacology. A number of models have 
been presented in an attempt to apply some emphasis on the mechanical 
properties of long chain molecules in flow and some predictions have been 
made (see chapter Error! Reference source not found.) but even with these 
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predictions, the effects of shear on protein in solution is still a cause for 
contention. 
This is particularly interesting when studied in a broader context, 
encompassing the use of similar biological products such as DNA 
characterisation. The requirement of a method for analysing individual strands 
of DNA resulted in a solution which utilises extensional flow to unravel the 
long-chain molecule without incurring any damage to the strand whilst passing 
it under a laser at a controlled, steady speed. A schematic is shown in Figure 
2-3. This allowed each individual nucleotide to be read and sequenced in real-
time [9]. It is interesting to note that the work by Larson et al. [9] devotes a 
section to specifying the flow conditions that gives the maximum extension to 
the molecule without resulting in denaturation due to scission. This implies a 
substantial understanding of the stresses required to cause irreparable 
damage to long-chain molecules which is very much of interest in the current 
work. Similar experiments on DNA in extensional flow fields can be seen in 
the work by Schroeder [12] in which the link between hydrodynamic 
Figure 2-3: An example of a funnel device for high strain rate flows 
with a superimposed graphic of DNA responding to extensional 
flow. (B) graphic of DNA stretching in a pure elongational flow 
with a strong strain rate along the polymer [9]. 
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interactions and molecule characteristic length was explored. The ability to 
accurately predict unfolding and extension was demonstrated with success.  
What follows is a description of popular methods used in the study of flow 
induced aggregation in proteins and enzymes. The section gives an overview 
of the types of work which have been carried out. In later sections the theory 
required to adequately critique these methods will be presented. Following on 
from that, a critical discussion of previous methods will be presented as part 
of the design process for the bespoke experimental setup used in the current 
work. 
2.5.1. Coaxial (Weissenberg Couette) Viscometer 
A coaxial viscometer is a rotating cylinder within a loosely fitting housing. The 
sample is placed in the gap between the cylinder and the housing. When the 
cylinder in rotated a shear force is applied to the sample proportional to the 
radial velocity. The device is used predominantly in rheology to test the 
viscosity of fluids such as lubricants. The intensity of the shear force is 
measure as the shear rate, which is the rate of deformation in the sample. The 
units of shear rate are reciprocal seconds (s-1). In coaxial viscometer studies, 
samples are often exposed to a shearing environment for extended, 
continuous lengths of time. The exposer time is often varied and reported as 
an experimental variable. An example of a coaxial viscometer is shown in 
Figure 2-4a. 
Charm and Wong [52] subjected the three enzymes catalase, rennet and 
carboxypeptidase, to shear in a coaxial viscometer. It was determined that 
these enzymes lose activity with respect to shear rate and exposure time. It 
was even reported that activity loss due to laminar flow through a tube could 
be predicted for these enzymes using viscometric data alone. 
In contrast, Thomas et. al. [44] used a coaxial viscometer to determine the 
effects of shear on alcohol dehydrogenase (ADH) at shear rate of 683 to 744 
s-1, with an exposure time of 5 hours. This study reported no loss of activity in 
the supernatant, whilst a precipitate formed at the surface of the sample. The 
precipitate was found the contain a small percentage of the original protein. 
The results were compared to those of a lower concentration sample of ADH 
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which was stirred in a reactor vessel for 15 hours and produced only a small 
reduction in protein activity. The peak shear rates for the reactor vessel 
impellor blades were reported to be 9000 s-1. 
Charm and Wong then used shear rate as a vernacular for the collective 
effects of flow, pumping and mixing in their 1981 study on the effects of shear 
on enzyme activity [43]. A coaxial viscometer similar to that in Figure 2-4 was 
used to stress several enzymes and their function loss was measured. This 
concluded that shear could indeed deactivate proteins and could also be used 
as a proxy to determine the effects of other flow fields on protein deactivation 
[43]. 
Similar studies carried out on lysozyme at shear rates >14 s-1 reported protein 
unfolding [55, 56], and ADH, urease and catalase have all been found to form 
particulates in coaxial viscometers at shear rates of 683 s-1 [44, 56, 57]. 
2.5.2. Parallel plate rheometer 
A parallel plate rheometer suspends a fluid sample between a stationary base 
plate and a parallel rotating plate. The rotating plate produces a velocity 
potential which is experienced by the sample as shear. As with the coaxial 
device, samples are exposed to shearing environments of a given shear rate 
for a given time. An example of a parallel plate rheometer is shown in Figure 
2-4b. Another variant of the plate rheometer is the cone-plate rheometer, 
which uses a rotating cone to generate the velocity potential. 
This method has been shown to induce degradation and loss of activity on 
multiple enzymes including α-amylase at 120 s-1 [58], fibrinogen at 290 s-1 
[59], and catalase and rennet at 91.5 s-1 [60]. 
Furthermore, there is a history of this method being used to study proteins of 
interest to the biopharmaceuticals industry with Glycoprotein Ib and IIb-IIIa 
being shown to unfold at large shear rates of 8200 s-1 [61], and von Willebrand 
factor (VWF) demonstrating aggregation at a shear rate of 6700 s-1 [62] 
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Examples of plate rheometer studies with antibodies include subjecting 
antistreptavidin immunoglobulin (IgG1), a humanised monoclonal antibody, to 
shear rates of 2000s-1 for up to 300s [24]. At concentrations greater than 
100mg/mL a small increase (0.3%) of aggregation was observed directly after 
exposure. After 1 week of storage, however, the level of aggregation was 
undetectable. 
 
2.5.3. Four roll mill 
The four roll mill comprises four cylinders, or rollers which are submerged 
vertically in a reservoir containing the sample fluid. The rollers can be rotated 
in different directions to control the type of flow field induced in the sample 
[63].  
The four roll mill is presented as an extensional flow device. In fact the four 
roll mill combines the boundary layer shear of the rotating cylinders which 
propagate in such a way as to generate the velocity potential required to 
produce a stagnation point. As a result, comparatively large volumes of fluid 
are commuted though high shear environments compared to the limited 
volume of fluid which typically passes through the slow moving fluid region in 
and around the stagnation point [8, 63]. A comprehensive CFD study of the 
flow profile is shown in Figure 2-5 [8]. 
This apparatus in the study that produced Figure 2-5 was used to stress three 
proteins; Hen egg-white lysozyme, Bovine serum albumin, Alcohol 
dehydrogenase (ADH). Shear and strain rates as high as 400 s-1 were 
Figure 2-4: Viscometers produce high shear flows. (a) Narrow gap 
coaxial cylinder viscometer. (b) Cone-and-plate viscometers. 
[2] 
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generated, although the study is careful to point out that the average stress 
rates throughout the sample do not exceed 30 s-1 [8]. Solutions of the proteins 
were tested in relatively high sample sizes, as befitting the nature of the 
device. Aggregation, detected using absorbance at a range of wavelengths, 
was seen to increase with roller rotational speed, and hence, with stress rate. 
Formation of larger particles was seen to correlate with speed. ADH, the 
largest of the three, was shown to be the most affected. 
 
  
 
 
 
 
 
 
Figure 2-5: “Velocity profile for the different flow configurations (a) 
elongation (b) hybrid and (c) rotation for water (Re 155) in the 
four-roll apparatus calculated with CFD. Arrows indicate the 
rotation direction of the rollers.” [8] 
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2.5.4. Opposed jets 
An opposed jets device primarily consists of two identical fluid inlets facing 
each other over a short distance. Both inlets expel or draw in jets of fluid at 
the same rate so that a stagnation point forms where the jets meet at the 
centre of the breach. An example is shown in Figure 2-6. The fluid is then 
forced to turn through 90° and travel away from the stagnation point in a 
perpendicular direction to the axis of the jets. This produces a velocity gradient 
tangential to the direction of flow, otherwise known as an extensional flow field 
[64]. 
Opposed jets are often submerged in a reservoir of the fluid to be studied. A 
two-dimensional variation on the opposed jets is the cross-slot device. This 
device consists of a plate with four channels etched into it which meet to form 
a cross. As with the opposed jet device, two of the channels facing each other 
provide the incoming mass flux. The fluid is required to turn a right-angle to 
exit through either remaining channel resulting in a stagnation point at the 
centre [65].  
 
Figure 2-6: Example of an opposed jets experiment schematic (left) and 
photograph showing extended polymer chains (right) [64]. Note 
that in this instance, fluid is being drawn into the jets as opposed 
to being sprayed out; both are common arrangements. 
 
The cross slot device is not widely used in protein or enzyme studies. 
Examples are largely limited to polymer investigations. Haward et al. [66] used 
such a device to generate an extensional region measuring 435 s-1 to 
manipulate polymers in solution. 
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Examples closer to bioprocessing include the novel use of a nanofluidic cross 
slot device to trap a single strand of DNA in the stagnation point and unfurl it 
using the extensional flow region using a strain rate no grater that 1 s-1 [67]. 
2.5.5. Capillary Rheometer 
Capillary devices subject fluid to shear by forcing it though a narrow tube, or 
capillary. The pressure differential across the capillary and the cross sectional 
dimensions are required to calculate the shear [56, 68]. Capillary rheometers 
operate at Re Numbers typically in the laminar region, below Re = 3000. Shear 
rates in excess of 105 s-1 are achievable for short time periods [4, 56]. Short 
residence times have been linked to partial protein unfolding [56, 69] with 
multiple passes through said devices used to increase the residence time [59]. 
This however, is a point of contention in the current work which will be 
explored in later sections. 
The capillary rheometer has been used to demonstrate shear induced activity 
loss in catalase at shear rates of 67 s-1 [52] and also at 4600 s-1 [57].  
No loss in activity was recorded when cytochrome C was subjected to 20,000 
s-1, however [4]. 
More recently, the capillary rheometer has been employed as a method of 
characterising high concentration biopharmaceuticals in terms of 
“Syringeability”, or usability by the end user. Such devices are also concerned 
with assessing any non-Newtonian effects that syringing might incur [70]. The 
effects of soluble aggregates and reversible self-association on high 
concentration monoclonal antibodies have also been investigated using 
capillary rheometers [71]. 
2.5.6. Microchannel devices 
Microchannel, or microfluidic, devices include any device that have a 
characteristic or defining dimension ≤1000 µm. Typically, microchannel 
devices are made by molding or etching a series of pathways into a glass or 
polymer substrate. This allows for flexibility in the geometries which can be 
produced, although generally speaking, many of the devices discussed 
earlier, particularly cross slot devices, could also fit into this category. 
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A prime example of a microchannel device designed to manipulate molecules 
using fluid flow is given by Larson et al. [9] who present a 2D funnel etched 
into a plate. The funnel employs mass conservation to cause fluid to 
accelerate downstream, producing an extensional flow profile as it goes. This 
extensional region is used to unfurl a DNA molecule in a similar manner to 
that seen with the cross slot example. 
A similar example in the field of protein aggregation within extensional flows 
is presented in which spider silk is spun from artificially produced spider 
dragline silk proteins [51]. The work discusses, rather elementarily, how 
convergent micro-channels cause unfolding and irreversible aggregation 
resulting in fibre formation. What is particularly noteworthy is that these 
examples do not deal in earnest with the relationship between flow and the 
denaturation, but simply focus on applications of seemingly well-defined 
phenomena of long-chain biological molecules in extensional flow fields. To 
move on from this, a sound understanding of the mechanics within shear and 
extensional flow is required, which will now be discussed. Interestingly 
however, only a small number of studies within the biopharma field explore 
the fluid mechanical theory in any great detail, with the emphasis being placed 
mainly on the folding kinetics of the proteins themselves. 
  
- 24 - 
 
 
2.6. Frequently used proteins 
Cytochrome c is a small protein of only 104 residues and contains natural 
fluorophores. This makes it a useful protein to study for unfolding as the 
flourophores only fluoresce when the hydrophilic centre of the structure is 
revealed, indicating unfolding. In a study by Jaspe & Hagan [4] a solution of 
cytochrome c was passed through a narrow capillary of inner diameter 150µm 
at speeds of up to 10ms-1 to induce shear. No evidence of shear induced 
aggregation was detected on any timescale. The findings were reviewed by 
Ashton et al. [55] in which the findings were compared to a similar globular 
protein, lysozyme with a viscous fluid medium, glycerol. In this case 
conformational change (unfolding) was witnessed under simple, laminar shear 
flow, although this change was reversible. 
Lysozyme is also reported to have been exposed to well defined extensional 
flow fields in a paper by Simon et al. [8]. Lysozyme was chosen as a “model 
protein” in this case, no doubt due to the ease and repeatability demonstrated 
by Ashton et al. Under extensional flow, an increase in particles of size >1µm 
was detected indicating denaturation in the form of agglomeration. The 
population of large particles increased with extensional intensity and 
interfacial effects (both solid-liquid and liquid-gas) were ruled out. The time 
dependency of the aggregate population is not discussed although the nature 
of large particle aggregates is commonly stable and therefore time 
independent. The same experiment was conducted with two larger proteins; 
bovine serum albumin and alcohol dehydrogenase (ADH). In this instance the 
results were similar to those observed for lysozyme only the population of 
larger particles was higher for the larger molecules indicating aggregation due 
to extension is more prevalent in longer chain proteins. Aggregation was 
highest in the case of ADH. 
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2.7. Protein characterisation methods 
In the study of proteins, the term “characterisation” describes a means of 
analysing or probing an aspect or structural arrangement which portrays some 
property or function of the molecule. A vast array of characterisation methods 
exist for protein analysis. In this study we are interested in detecting whether 
a protein is in its native, folded state or if it has undergone some structural 
deformation, reducing its functionality or rendering it inactive. As previously 
mentioned, for the purpose of this study the characterisation methods can be 
divided into two types.  
Type one will be classified as “ex situ”, where a protein solution is subjected 
to an adverse flow field, is extracted, and sometime later is scrutinised by 
some characterisation method. Therefore type one can only detect time 
independent, irreversible changes, or reversible changes with relatively long 
timescales – typically in excess of 30 minutes for current methods.  
Type two characterisation methods are classified as “in situ” as they are 
designed to probe the space within the flow field as the experiment is in 
progress. In this situation it is possible to measure time dependent, reversible 
conformational changes, either in real-time or in a timeframe which would be 
unachievable using ex situ methods.  
Primarily, a selection of ex situ characterisation methods will be presented. 
These methods are generally less complicated to apply as the techniques are 
well documented, standardised and the equipment is stand-alone and readily 
available. In comparison, in situ methods require custom equipment and 
techniques. The current experiments, as previously mentioned, are tailored 
towards ex situ characterisation as a means of testing for severe levels of 
damage or inactivation as a proof of concept. 
2.7.1. Light obscuration 
Denaturation of proteins can occur as aggregation resulting in the formation 
of relatively large particles. These can be detected in a sample using light 
obscuration. Light obscuration measures the amount of light detected after it 
passes through a sample. The detector is calibrated using a set of polymer 
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beads of a known size and concentration. In the previously mentioned study 
by Simon et al. [8] this method was used to identify particles larger than 1µm 
indicating denaturation for 3 types of proteins commonly studied in flow 
induced aggregation experiments. 
2.7.2. Circular dichroism spectroscopy 
Circular dichroism (CD) spectroscopy measures changes in protein 
secondary structure by use of far UV absorbance. Proteins absorb left and 
right circular polarised UV light at different affinities based on their structures. 
Therefore, a protein can be identified by analysing the difference in 
absorbance between the two types of polarised light. As the absorbance is 
based on structure, a denatured protein will produce a difference to spectra to 
its naturally folded counterpart. Strong signals are typically associated with 
commonly seen structural properties such as α-helices and β-sheets. Analysis 
of tertiary structure and binding sites is also possible. CD spectroscopy is 
often compared to techniques such as X-ray crystallography and NMR by 
which CD boasts several advantages such as smaller sample sizes, no limits 
on protein sizes and the non-destructive nature of the analysis [72]. 
2.7.3. UV/visible spectroscopy 
UV/visible spectrophotometry is used to measure the concentration of 
proteins in the solution. Light is produced by a deuterium (near-UV, 150-
400nm) or tungsten-halogen (visible, 400-800nm) light source and passed 
through a monochromator. Light that passes through sample is detected by a 
photomultiplier/ photodiode. A reference (produced by analysing the buffer 
alone) is subtracted from the final result to measure the absorbance of the 
protein. The technique can be used to measure aggregation by taking a 
measurement before and after stressing to draw a comparison. A stressed 
sample may need centrifuging to remove non-soluble aggregates. UV/visible 
spectrophotometry is only applicable to proteins with aromatic residues [73]. 
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The concentration of proteins in solution can be determined from absorbance 
using  
 𝐴 = −𝑙𝑜𝑔ଵ଴ ൬
𝐼
𝐼଴
൰ Equation 2-1 
 
where 𝐴 is the absorbance, 𝐼଴ is the initial intensity of light and 𝐼 is the intensity 
of light after passing through the solution. The absorbance is linearly 
dependent on concentration as shown by the “lambert-Beer Law” [73] 
 𝐴 = 𝜀𝑐𝑙 Equation 2-2 
 
which relates absorbance to the molar concentration 𝑐, and the path-length 
𝑙 (𝑐𝑚) with the use of the molar absorption coefficient  𝜀 (𝐿 𝑚𝑜𝑙ିଵ𝑐𝑚ିଵ). 
For measuring the concentrations of proteins, absorption usually has a 
maximum at 275-280nm due to the absorbance of the aromatic residues, 
tryptophan (Trp) and tyrosine (Tyr) (And to a lesser extent cysteine (Cys) i.e. 
disulphide bonds). The absorbance coefficient of these residues can vary 
slightly (<5%) depending on their “microenvironment”; changes from polar to 
nonpolar environment i.e. whether the residue is buried or exposed to the 
solution [73]. 
The absorption coefficient is calculated for a particular wavelength as a linear 
combination of all the individual contributions from the residues. The number 
of each contributing residue ൫𝜂்௥௣, 𝜂்௬௥ , 𝜂஼௬௦൯ is counted and multiplied by its 
respective average molar absorbance value in its folded state (5500, 1490 and 
125 𝐿 𝑚𝑜𝑙ିଵ𝑐𝑚ିଵ respectively) [73]. 
𝜀ଶ଼଴(𝐿 𝑚𝑜𝑙ିଵ𝑐𝑚ିଵ) = 5500 × 𝜂்௥௣ + 1490 × 𝜂்௬௥ + 250 × 𝜂஼௬௦ 
  Equation 2-3 
 
The chain of peptide groups that make up the protein all absorb in the far-UV 
(180-230nm) range. In addition to this, the aromatic side-chains absorb in the 
near-UV (240-300nm) range and cysteine residues (disulphide bonds) absorb 
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at around 260nm. Peptides present in a folded protein are in an immobilised 
asymmetric structure. In this state, residues are seen to demonstrate circular 
dichroism; a phenomena by which left- and right-handed circularly polarised 
light are absorbed differently [73]. 
2.7.4. Light scattering spectroscopy  
Light scattering (LS) spectroscopy, dynamic light scattering (DLS), light 
scattering by particles (LSP) or Rayleigh scattering (RS) spectroscopy is used 
to determine the hydrodynamic radius of protein from measuring its diffusion 
coefficient in solution. It is capable of  measuring the actual change in average 
macromolecule size whereas other techniques look for localised markers 
within the structure e.g. UV spec [74]. 
2.7.5. Size-exclusion chromatography and multi-angle laser-
light scattering 
Size-exclusion chromatography and laser-light scattering (SEC MALLS) is a 
technique for relative molecular weight determination based on UV/Vis 
detection. It consists of a chromatographic column with multi-wavelength 
detector and light-scattering with refractive index detection [75]. 
2.7.6. In situ characterisation methods 
Ultimately, in situ methods are a target for the current research and some of 
the work reviewed has presented some techniques worth consideration. The 
cytochrome c visited in the previous section shows increased fluorescence 
upon unfolding. In the case of Jaspe & Hagen [4] the solution was illuminated 
with an ultraviolet laser which was incident on the silica, i.e. transparent, 
capillary. In this setup the unfolding was measured whilst protein was 
travelling through the high-shear environment. In situ UV/visible spectroscopy 
measurements was performed during stress testing in a four-roll mill [8]. 
Raman spectroscopy is increasingly being applied to protein conformational 
studies as it is sensitive to changes in secondary structure, hydrophilic 
exposure of side-chains and able to identify disordered structures.  The 
technique also allows protein to be continuously exposed to stress 
environments as shown in Figure 2-7 [55]. 
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Figure 2-7: An experimental setup of a flow cell similar to a coaxial 
viscometer with in situ Raman spectroscopy laser and optics. [1] 
 
2.8. Summary 
Proteins are highly sensitive to a range of variables. Many studies have been 
carried out to identify the effects of environmental changes such as 
temperature, pH and concentration. As a result, thesis conditions are now well 
understood. The same is not yet true of flow. in this chapter, the efforts made 
to quantify the effects of fluid forces on long-chain molecules have been found 
to be insightful, but not yet complete. A number of techniques have been 
applied to investigate the response of a range of proteins to various flow 
profiles.  The following sections of this thesis will further develop on the ideas 
that have been introduced so far, drawing inspiration from previous studies. 
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3. Theory 
The theory section consists of two separate parts; 1) fluid mechanics and 
corresponding analytical methods including CFD, and 2) protein aggregation 
theory with characterisation methods which includes particle tracking and 
absorption/emission spectroscopy. In previous studies attempts have been 
made to combine the two with varying degrees of success [76-78]. In the 
following sections, a formal introduction will be made to both subjects.  
In the first section, the knowledge required to make a detailed fluid mechanical 
model will be discussed. Due to the nature of filters and fill-finish operations 
as discussed in the literature review, this will centre around the idea of slow, 
laminar flows in viscous-dominated regimes. Previous studies exploring the 
relationship between flow and protein aggregation have shown a propensity 
toward shear dominated flow. The properties of shear will, therefore, be 
discussed here.  
Further afield in studies related to fluid effects on longer, less structured 
molecules, such a DNA and polymers, an interest has been raised in 
extensional, strain-dominated regimes in laminar flow. The properties of 
extensional flow will also be discussed. 
It will be seen that both shear and extension are present in some form in the 
majority of laminar flow systems. The deformation of an incompressible fluid 
element in a continuum can be described by a single function which can 
simultaneously describe the combined effects of both shear and strain, and 
also allow the two effects to be uncoupled to measure their individual 
contributions towards protein aggregation.  
The methods used to calculate and model fluid behaviour will also be 
introduced, although further detail will be presented on this in the dedicated 
Numerical Modelling and Computational Fluid Dynamics chapter. 
In the second part of this chapter protein aggregation theory will be presented. 
The mechanisms which make proteins susceptible to aggregation are 
explored, and detection and characterisation methods will be described. 
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3.1. Fluid mechanics 
This chapter provides a detailed discussion into the fluid mechanics used 
within this thesis. A classical definition of both shear and extension dominated 
flows are given and a literature review of fluid mechanics and long-chain 
molecules is presented. 
A large body of work based around the effects of shear on proteins has been 
presented by previous literature. Thomas and Geer [2] present a definition for 
“shear” (expressed in inverted commas) as any mechanical or hydrodynamic 
force, and in some broader cases, it even extends to interfacial phenomena. 
This trend of using the term “shear” synonymously with any fluid force is still 
prevalent in 2016 [79]. According to Rathore [42], “shear” is prevalent 
throughout the manufacture process (“Shear” in this instance referring to any, 
and all, hydrodynamic forces!). From formulation and filtration, drug product 
filling, through to delivery devices. “Shear” is considered to drastically affect 
proteins during manufacture, to the extent where a characterisation method is 
called for to evaluate the structural stability of proteins under processing 
conditions [80]. Currently, rheometers are used to conduct shear 
characterisation over comparable exposure times as a means of assessing 
whether a drug is suitable for manufacture [81-83]. But it is becoming 
increasingly evident that the response of a long-chain molecule to shear alone 
is not necessarily indicative of manufacturability. 
The terms “strong” and “weak” were coined in field of polymer processing 
(1975-76) as a means of classification of flows by their ability to stretch and 
align macromolecules suspended in solution or fibres in suspension 
corresponding to extension or simple shear respectively [84, 85]. In fact, 
extensional flow has been a widely researched topic to the point where it has 
almost fallen under the category of “classical” fluid mechanics. It is 
understandable to assume that it has failed to attract the attention of 
researchers from biopharmaceutical backgrounds over the past few decades. 
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3.1.1. Shear vs. extensional flow within biopharmaceutical 
manufacture 
Shear flow is present in all laminar flow pipes and tubes, for instance, in blood 
vessels and arteries, or the pipes used to pump biological materials around 
during a manufacturing procedure. It is a phenomenon caused by the no slip 
condition observed between the fluid and the fluid boundary at the pipe wall 
as shown in Figure 3-1. This no slip condition was observed experimentally in 
the early days of fluid mechanics and holds for all fluids, with the exception of 
rarefied gas and conditions where the molecular path is similar or smaller than 
the pipe diameter. Since we are pumping fluid we know that the velocity of the 
fluid cannot be zero across the whole pipe cross-section, in fact the velocity 
of the fluid increases the further away from the wall the fluid is. This produces 
a velocity profile where two adjacent streamlines are never carrying fluid at 
the same velocity. This difference in velocity between two adjacent fluid 
elements is known as shear. 
Shear stress is at its maximum at the capillary wall. Denoted as 𝜏௪, this is 
calculated as 
 𝜏௪ =
𝑑∆𝑝
4𝐿
 Equation 3-1 
where 𝑑 is the capillary diameter, ∆𝑝 is the change in pressure, and 𝐿 is 
capillary length. 
  
 
 
 𝑉𝑒𝑙𝑜𝑐𝑖𝑡𝑦 𝑝𝑟𝑜𝑓𝑖𝑙𝑒 
Figure 3-1: Shear flow in a pipe or tube with a characteristic 
velocity profile. Notice how any two fluid elements on adjacent 
streamlines are never travelling at the same velocity. 
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Pressure drop in a laminar flow regime is calculated by 
 ∆𝑝 =
32𝜇∆𝐿𝑢௠
𝐷ଶ
 Equation 3-2 
Extensional flow is caused by a contraction in the flow geometry. If the fluid is 
assumed to be incompressible it must accelerate to satisfy mass 
conservation. As the fluid accelerates, the fluid element will be subjected to a 
velocity profile as part of the front of the element will always be traveling faster 
than the rear. This causes the fluid element to stretch out as it passes through 
a contraction. The phenomenon exerts strain on any fluid element passing 
through the extensional region. In its simplest form, fluid strain can be 
expressed in the same fashion as its solid mechanical counterpart. After time, 
𝑡, strain, 𝜀௧, is the ratio of the increased length due to stretching, 𝐿௧ − 𝐿଴, over 
the original length 𝐿଴. 
 𝜀௧  =
𝐿௧ − 𝐿଴,
𝐿଴,
 Equation 3-3 
  
Figure 3-2: (Top) Contraction in a flow geometry resulting in 
acceleration and therefore extensional flow. The arrow lengths are 
proportional to fluid velocity. (Bottom) Average fluid velocity v is 
plotted against position z, demonstrating the acceleration of the 
fluid. 
v 
z 
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3.1.2. Rate of Deformation 
The intensity of a shear or strain region is often presented in terms of rate of 
deformation, these are termed the shear rate and strain rate. These can both 
be expressed as a ratio of deformation to the size of the deformed fluid 
element 
 𝛾 =
𝑑𝑥
𝑑𝑦
 Equation 3-4 
 
For an extensional flow, the strain rate is then defined as 
 ?̇? =
𝑠ℎ𝑒𝑎𝑟 𝑠𝑡𝑟𝑎𝑖𝑛
𝑡𝑖𝑚𝑒 𝑡𝑎𝑘𝑒𝑛
=
𝛾
𝑑𝑡
=
𝑑𝑥
𝑑𝑡𝑑𝑦
=
𝑑𝑢
𝑑𝑦
 Equation 3-5 
 
The formal definition for an extensional flow is then 
 𝑭(𝑡) = 𝑹(𝑡)𝑼(𝑡) Equation 3-6 
 
Where 𝑭 is the deformation tensor, 𝑹 the (orthogonal) rotation tensor and 𝑼 
the (positive definite symmetric) right stretch tensor. The flow is defined as 
extensional when there is a fixed orthogonal coordinate system in which 𝑼(𝑡) 
has diagonal components. 
Alignment is seen to be of relative importance to the strength of the flow as 
any confined flow is going to have a shear, and therefore a rotational 
component regardless of the size of contraction [84]. 
Strain 𝜀 is a measure of mechanical extension. Therefore rate of strain 𝜀̇ is the 
time derivative of 𝜀. A 3-dimensional fluid element undergoing strain in one 
direction, much like an elastic solid, will experience proportional elongations 
in the remaining directions. To describe this in 3-dimensions, the rate of strain 
tensor is used: 
 𝑑௜௝ =
1
2
൫𝑢௜௝ + 𝑢௝௜൯ Equation 3-7 
 
Where 𝑢 is the scalar component of velocities. This can be expanded such 
that 
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 𝑑௜௝ =
⎣
⎢
⎢
⎢
⎢
⎢
⎡
𝜕𝑢ଵ
𝜕𝑥ଵ
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଶ
+
𝜕𝑢ଶ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଷ
+
𝜕𝑢ଷ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଵ
+
𝜕𝑢ଵ
𝜕𝑥ଶ
൰
𝜕𝑢ଶ
𝜕𝑥ଶ
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଷ
+
𝜕𝑢ଷ
𝜕𝑥ଶ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଵ
+
𝜕𝑢ଵ
𝜕𝑥ଷ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଶ
+
𝜕𝑢ଶ
𝜕𝑥ଷ
൰
𝜕𝑢ଷ
𝜕𝑥ଷ ⎦
⎥
⎥
⎥
⎥
⎥
⎤
 Equation 
3-8 
 
where 𝑥௜ denote a specific direction. For uniaxial, homogenous, simple 
extension the flow is assumed to have no vorticity. If 𝑥ଵ is taken to be the 
direction of maximum 𝜀̇ i.e. the frame of reference is such that the deformation 
is purely symmetric in that direction, the rate of strain tensor 𝐷௜௝ is becomes 
 𝑑௜௝ =
⎣
⎢
⎢
⎢
⎡
𝜀̇ 0 0
0 −
1
2
𝜀̇ 0
0 0 −
1
2
𝜀̇⎦
⎥
⎥
⎥
⎤
 Equation 
3-9 
 
where the rate of strain 𝜀̇ can be expressed as extension over time: 
 𝜀̇ =
𝑑𝜀
𝑑𝑡
 Equation 3-10 
 
or as change in velocity over change in position: 
 𝜀̇ =
𝑑𝑢
𝑑𝑥
 Equation 3-11 
 
By taking the latter and by assuming that flow down the central axis of an 
axisymmetric sudden constriction in a pipe consists predominantly of uniaxial 
extension, it is possible to calculate the maximum rate of strain in the region 
in the flow where the ratio of extension to shear is at a maximum. A 
comparison can then be drawn between rate of strain and aggregation in 
proteins in solution. 
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Deformation tensor 
The deformation tensor 𝑑௜௝  is a 2nd order tensor that determines how a fluid 
element deforms as it travels along a flow. 
 𝑑௜௝ =
1
2
൫𝑢௜௝ + 𝑢௝௜൯ Equation 3-12 
𝑜𝑟 
 𝑑௜௝ =
⎣
⎢
⎢
⎢
⎢
⎢
⎡
𝜕𝑢ଵ
𝜕𝑥ଵ
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଶ
−
𝜕𝑢ଶ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଷ
−
𝜕𝑢ଷ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଵ
−
𝜕𝑢ଵ
𝜕𝑥ଶ
൰
𝜕𝑢ଶ
𝜕𝑥ଶ
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଷ
−
𝜕𝑢ଷ
𝜕𝑥ଶ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଵ
−
𝜕𝑢ଵ
𝜕𝑥ଷ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଶ
−
𝜕𝑢ଶ
𝜕𝑥ଷ
൰
𝜕𝑢ଷ
𝜕𝑥ଷ ⎦
⎥
⎥
⎥
⎥
⎥
⎤
 Equation 3-13 
 
A 2nd order tensor can be decomposed into two parts; a symmetric and an 
anti-symmetric part as discussed by Jaspe and Hagen [4]: 
 
𝜕𝑢௜
𝜕𝑥௝
=
𝜀̇
2
+
Ω̇
2
=  
1
2
ቆ
𝜕𝑢௜
𝜕𝑥௝
+
𝜕𝑢௝
𝜕𝑥௜
ቇ +
1
2
ቆ
𝜕𝑢௜
𝜕𝑥௝
−
𝜕𝑢௝
𝜕𝑥௜
ቇ Equation 3-14 
 
The symmetric part is the rate of strain tensor: 
 𝜀௜̇௝ =
1
2
ቆ
𝜕𝑢௜
𝜕𝑥௝
+
𝜕𝑢௝
𝜕𝑥௜
ቇ  
 𝜀௜̇௝ =
⎣
⎢
⎢
⎢
⎢
⎢
⎡
𝜕𝑢ଵ
𝜕𝑥ଵ
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଶ
+
𝜕𝑢ଶ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଷ
+
𝜕𝑢ଷ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଵ
+
𝜕𝑢ଵ
𝜕𝑥ଶ
൰
𝜕𝑢ଶ
𝜕𝑥ଶ
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଷ
+
𝜕𝑢ଷ
𝜕𝑥ଶ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଵ
+
𝜕𝑢ଵ
𝜕𝑥ଷ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଶ
+
𝜕𝑢ଶ
𝜕𝑥ଷ
൰
𝜕𝑢ଷ
𝜕𝑥ଷ ⎦
⎥
⎥
⎥
⎥
⎥
⎤
 Equation 3-15 
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And the asymmetric part is the vorticity tensor: 
 Ω̇௜௝ =
1
2
ቆ
𝜕𝑢௜
𝜕𝑥௝
−
𝜕𝑢௝
𝜕𝑥௜
ቇ  
 Ω̇௜௝ =
⎣
⎢
⎢
⎢
⎢
⎢
⎡ 0
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଶ
−
𝜕𝑢ଶ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଵ
𝜕𝑥ଷ
−
𝜕𝑢ଷ
𝜕𝑥ଵ
൰
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଵ
−
𝜕𝑢ଵ
𝜕𝑥ଶ
൰ 0
1
2
൬
𝜕𝑢ଶ
𝜕𝑥ଷ
−
𝜕𝑢ଷ
𝜕𝑥ଶ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଵ
−
𝜕𝑢ଵ
𝜕𝑥ଷ
൰
1
2
൬
𝜕𝑢ଷ
𝜕𝑥ଶ
−
𝜕𝑢ଶ
𝜕𝑥ଷ
൰ 0
⎦
⎥
⎥
⎥
⎥
⎥
⎤
   Equation 3-16 
𝑜𝑟 
 Ω̇ =
1
2
቎
0 𝜔௫య 𝜔௫మ
−𝜔௫య 0 𝜔௫భ
−𝜔௫మ −𝜔௫భ 0
቏ Equation 3-17 
 
As 𝜔௝ are all components of the vorticity vector, such that 
𝝎 = 𝛁 × 𝐮 = ൬
𝝏𝒖𝟑
𝝏𝒙𝟐
−
𝝏𝒖𝟐
𝝏𝒙𝟑
൰ ଙ̂ + ൬
𝝏𝒖𝟏
𝝏𝒙𝟑
−
𝝏𝒖𝟑
𝝏𝒙𝟏
൰ ଚ̂ + ൬
𝝏𝒖𝟐
𝝏𝒙𝟏
−
𝝏𝒖𝟏
𝝏𝒙𝟐
൰ 𝒌෡ 
 𝝎 = 𝜔௫భ𝚤̂ + 𝜔௫మ𝚥̂ + 𝜔௫య𝑘෠ Equation 3-18 
 
A flow is considered to be deforming due to shear if the off-diagonal 
components are non-zero. 
To interpret this in the form of a 2D axisymmetric flow simulation, we use the 
coordinate system and corresponding velocities 𝑥ଵ = 𝑟, 𝑥ଶ = 𝑧, 𝑥ଷ = 𝜑, 𝑢ଵ =
𝑢, 𝑢ଶ = 𝑤 𝑎𝑛𝑑 𝑢ଷ = 𝑣 = 0. Therefore our 2D problem becomes 
 𝑑௜௝ = ൦
𝜕𝑢
𝜕𝑟
1
2
൬
𝜕𝑢
𝜕𝑧
−
𝜕𝑤
𝜕𝑟
൰
1
2
൬
𝜕𝑤
𝜕𝑟
−
𝜕𝑢
𝜕𝑧
൰
𝜕𝑤
𝜕𝑧
൪ Equation 3-19 
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By using CFD to calculate the rate of strain in a fluid of known viscosity, it is 
then possible to relate this to proteins in solution. Assuming that a protein 
molecule can be aligned with the direction of extension, the extensional force 
can be compared to that applied by an atomic force microscope (AFM) 
experiments. These have been used to unfold protein molecules with the an 
unfolding force requirement of about 20 to 150 pN for α-helical and β-sheet 
proteins, respectively [24]. 
3.1.3. Numerical solvers and Navier-Stokes Equations 
Numerical solvers are increasingly used to approximate complex flow systems 
with ever improving accuracy and computational efficiency. Such solvers 
include the finite element method (FEM) and the finite difference method 
(FDM). FEM has the advantage of solving for arbitrarily unstructured 
subdivisions whilst providing approximations for self-adjoint problems, usually 
in advance of a comparative FDM solver [86]. FEM is employed by 
computational fluid dynamics (CFD) packages such as COMSOL. 
Numerical solvers exist to provide approximations based on conservation of 
momentum.  This is achieved by solving the Navier-Stokes equations 
(Equation 3-20) for an incompressible fluid [87] in tandem with the continuity 
equation (Equation 3-21) [88]. 
 𝜌 ൤
𝜕𝒖
𝜕𝑡
+ (𝒖. ∇)𝒖൨ = −∇𝑃 + 𝜌𝑔 + 𝜇∇ଶ𝒖 Equation 3-20 
 ∇ ∙ 𝒖 = 0 Equation 3-21 
 
Navier-Stokes give the equations of motion for a Newtonian fluid taking into 
account viscosity, 𝜇, which can be a function of the fluid’s thermodynamic 
conditions but in this case is assumed a constant. Numerical solutions will be 
covered in greater detail in later chapters. 
3.1.4. Pressure 
It is appropriate to provide validation for a numerical study. In this case, the 
numerical method will be performed alongside an experimental method. For 
a flow to be fully defined, it is important to know which features in the flow are 
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dominant. For example, a slow, Newtonian flow will have a low Reynolds 
number therefore viscous forces will be dominant over inertial forces. Along a 
similar argument, in this flow setup it is evident that there will be a number of 
characteristic conditions which will become dominant in different regions; the 
acceleration and extensional forces will dominate in the rapid contraction, and 
viscous shear forces will become dominant in the capillary tube. To determine 
the relative effects these two flow conditions have on the flow in relation to 
each other, the drop in pressure can be measured across each region and 
compared directly. 
Pressure drop along the capillary tube is proportional to the length of the tube 
section therefore the ratio of pressure drops across the two regions can be 
controlled.  Calculated using the Hagan-Poiseuille equation 
 ∆𝑃 =
128𝜇𝐿𝑄
𝜋𝑑ସ
 Equation 3-22 
 
The pressure drop through a capillary can be calculated and be further backed 
up using CFD by probing the pressures at different lengths along the capillary. 
Determining the pressure drop across the sharp contraction, however, proves 
to be slightly more problematic. Astarita and Greco [89] review Equation 3-23 
from Holmes, Sylvester and Rosen [90] 
 ∆𝑝 = ቆ𝐾 +
𝑘ᇱ
𝑅𝑒
ቇ
𝜌𝑈ଶ
2
 Equation 3-23 
 
where 𝐾 is the Hagenbach correction and ௞ᇱ
ோ௘
 is referred to as the coquette 
correction. 𝑈 is taken as the average downstream velocity. A range of 
numbers are taken from literature ranging from 2.16 − 2.34, with the most 
prominent being quoted as 2.24. 
Astarita and Greco [89]  go on to suggest the modification of the Holmes [90] 
equation with the experimentally derived values specifically for a sudden 
contraction which yield the equations: 
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 𝑅𝑒 < 146; ∆𝑝 =
795
𝑅𝑒
𝜌𝑈ଶ
2
 Equation 3-24 
 𝑅𝑒 > 146; ∆𝑝 = 5.48
𝜌𝑈ଶ
2
 Equation 3-25 
 
Another equation proposed for the pressure drop across a sharp contraction 
which apparently takes into account the development of a vena contracta 
directly after the contraction is accredited to Lighthill [91]. The equation is as 
follows 
 ∆𝑝 = −
?̇?ଶ
2𝜌
ቈ𝑆ଶ ൬
1
𝐶௖
− 1൰
ଶ
+ (𝑆ଶ − 1)቉ Equation 3-26 
 
?̇? is the mass flow rate or mass flux, 𝑆 is the ratio of upstream and 
downstream areas, and 𝐶௖ is stated as the contraction coefficient which is 
the ratio of areas between the vena contracta and the downstream section 
and can be calculated using Equation 3-27 and empirically derived 
constants. 
 𝐶௖ =
𝐴௖
𝐴ଵ
= 1 −
1 − 𝜎
2.08(1 − 𝜎) + 0.5371
 Equation 3-27 
 𝜎 =
𝐴௦௠௔௟௟
𝐴௕௜௚
 Equation 3-28 
 
Circulation 2 (Vena Contracta) Circulation 1 
Figure 3-3: location of vena contracta circulations resulting in 
pressure losses in a sudden contraction. 
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A diagram of the vena contracta can be seen in Error! Reference source not 
found.. 
The pressure equations are summarised in Error! Reference source not 
found. and will be used to validate the numerical study with hand calculations. 
Pressure equation Reference 
∆𝑝 = ቆ𝐾 +
𝑘′
𝑅𝑒
ቇ
𝜌𝑈ଶ
2
 
𝑅𝑒 < 146; ∆𝑝 = ଻ଽହ
ோ௘
ఘ௎మ
ଶ
 , 𝑅𝑒 < 146; ∆𝑝 = 5.48 ఘ௎
మ
ଶ
 
Equation 3-23, 3-
24, 3-25 [89, 90] 
∆𝒑 =
〈𝒖𝟏〉𝟐
𝟐
ቈ൬𝟏 −
𝟏
𝑪𝒄
൰
𝟐
+ 𝟏 − 𝝈𝟐቉ 
𝐶௖ =
𝐴௖
𝐴ଵ
= 1 −
1 − 𝜎
2.08(1 − 𝜎) + 0.5371
 
𝜎 =
𝐴௦௠௔௟௟
𝐴௕௜௚
 
Equation 3-27, 3-
28 [92] 
∆𝑝 = −
?̇?ଶ
2𝜌
ቈ𝑆ଶ ൬
1
𝐶௖
− 1൰
ଶ
+ (𝑆ଶ − 1)቉ Equation 3-26 [91] 
Table 3-1: summary of pressure loss equations for validating numerical 
methods. 
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3.2. Proteins 
A major barrier to the development of biopharmaceuticals is their challenging 
manufacture process. Monoclonal antibodies are often expressed in 
mammalian cell lines, such as Chinese Hamster Ovary (CHO), to allow for the 
correct post-translational modifications to be made [93]. A typical mAb is 
shown in Figure 3-4. 
 
 
Throughout the manufacture cycle, to purification and formulation, biologics 
are susceptible to degradation through temperature, chemical modifications 
and mechanical processes, resulting in the formation of aggregates [5, 38, 94, 
95]. A typical expression and purification profile for a mAb-based 
biopharmaceutical is shown in Figure 3-5. 
Figure 3-4: Schematic of an IgG-type monoclonal antibody.  Each block 
represents a β-sheet rich immunoglobulin domain. The heavy 
chains are in dark blue, whilst the light chains are represented in 
light blue. The two halves of the antibody are connected by 
disulfide bridges. The Fc domain is the ‘crystallisable’ region as it 
is readily crystallised. Most glycosylation takes place in this 
region. The Fab domain is the antigen-binding domain, with the 
antigen binding represented by the convex end sections. The two 
domains are connected by a flexible hinge region, which gives 
these molecules conformational flexibility, facilitating target 
binding [7].  
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3.2.1. Aggregation 
The presence of aggregates or particulates in a finished biopharmaceutical 
product is indicative of degradation [95, 96].  Regulators specify the threshold 
of impurities that can be present in biopharmaceutical formulations, with 
aggregate levels typically lower than 1% [97]. It is suggested that 
biopharmaceutical aggregates, particularly those in the sub-visible range of 
0.1-10µm, could potentially trigger immunological responses in the patient. 
The severity of this response in vivo could range from loss of efficacy to mild 
allergic reactions and even anaphylaxis [3, 95]. The exact mechanisms of the 
immunogenicity, nor its extent, are known for all biologics. They are often 
identified in clinical trials [97]. 
Aggregates are defined as any multimeric species made up of partially 
unfolded protein monomers [3]. Aggregates range in size up to limit, typically, 
of 100 nm. Aggregates of this size are often soluble and can form either 
reversibly or irreversibly, depending on the monomer properties and its 
environment [54, 95, 98]. The larger an aggregate grows, the greater its 
propensity to drop out of solution. Insoluble aggregates are termed 
particulates in order to differentiate them from their smaller, soluble 
counterparts [94]. Many proteins, including biopharmaceuticals, are widely 
thought to aggregate according to established models such as the Lumry-
Eyring Model. These models attempt to explain aggregate formation and 
growth through kinetics. A schematic of how a biopharmaceutical could 
aggregate is shown in Figure 3-6. 
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Proteins are folded nascent polypeptide chain that form defined three-
dimensional structures, a process made thermodynamically favourable by the 
hydrophobic effect [95]. Any perturbation of the native three-dimensional 
structure may expose internal hydrophobic amino acid residues to the solvent. 
Association between two monomers in this state could lead to agglomeration 
and the forming of aggregates. The effects of pH, temperature and reagents 
such as urea and guanidine hydrochloride on protein structure are well 
documented [99]. 
3.2.2. Aggregation characterisation 
The use of many different biophysical and biochemical techniques have 
become routine in assessing the quality of biopharmaceutical products. 
Through these techniques the extent to which a protein has aggregated can 
be quantified as well as whether or not the biopharmaceutical has the correct 
secondary structure. The physicochemical properties of a protein aggregate, 
in addition to the relative abundance in formulation, are indicative of which 
methods are suitable for quantification and characterisation [100]. 
Broadly, the methods used to characterise aggregation of biopharmaceuticals 
can be defined in three categories: separation-based techniques, light 
Figure 3-6: Schematic of a protein aggregation mechanism. The native 
(folded) protein can oligomerise into its native quaternary 
structure. Alternatively, stresses such as temperature and pH can 
perturb the native protein, causing it to unfold. Unfolded protein 
can form dimers and trimers before forming multimeric species or 
soluble aggregates. Both types of oligomeric species can 
precipitate as an amorphous aggregate or fibril [3].  
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scattering/obscuration techniques and spectroscopic/spectrometric 
techniques. All three methods are used in assessing the effects of extensional 
flow on aggregation. Specifically, the techniques used in this study are 
analytical ultra-centrifugation (AUC), nanoparticle tracking analysis (NTA), 
and absorbance spectroscopy at the 280 nm wavelength (A280), respectively. 
These will be described in further detail here. 
Analytical Ultra-Centrifugation 
Analytical Ultra Centrifugation (AUC) is used to separate monomeric proteins 
from their oligomers/aggregates to quantify species and is applicable to those 
of biopharmaceutical importance [101].  
In AUC, a centripetal force is used to accelerate the sedimentation of very 
small particles in a precipitate [102]. The technique separates the insoluble 
material and concentrates it into a pellet, leaving a supernatant sample in 
solution. 
AUC is a routine method of determining the molecular weight and size of 
proteins, requiring little sample preparation [100]. The concentration of protein 
is then detected with UV absorbance spectroscopy measurement (seen in 
later sections). However, the technique is not without with issue; the operator 
requires a high level of training, the data analysis is complex [102], the 
equipment is expensive, and process is time consuming [100, 103].  
Nanoparticle Tracking Analysis 
Many new techniques have been developed in recent years to aid the 
quantification of nanoparticles. Nanoparticle Tracking Analysis (NTA) is a 
technique which utilises camera images to visualise and track the motion of 
particles which dynamically scatter laser light within the confines of a defined 
field of view [104, 105]. 
For proteins, the lower limit of resolution for the technique is 40 nm [104]. 
Though this appears disadvantageous in comparison to DLS, where the 
scatter from an incoming beam is used to infer the size distribution of the 
particles [106], NTA is capable of distinguishing between particles in a 
polydisperse sample with greater sensitivity. Where DLS can only distinguish 
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between particles that have a three-fold size difference, NTA can distinguish 
between particles which have a 1.25-fold size difference [6]. 
Furthermore, the instrument will determine the concentration of each size of 
particle based on the defined sample size illuminated by its laser [104]. This 
is useful for capturing any smaller aggregates present in the sample that may 
be missed using DLS. Finally, NTA tracks particles individually, whereas DLS 
is an ensemble technique; hence the latter may not fully represent the 
aggregated nature of the sample [104]. A schematic of the apparatus is shown 
in Figure 3-7. 
 
However, NTA cannot visualise or quantify native protein monomers due to 
their size, although new techniques such as Taylor-Dispersion Analysis are 
being developed to address this [107]. The use of NTA as an orthogonal 
method for the detection and quantification of protein nanoparticles has been 
used effectively by many in previous studies [104, 108, 109]. 
Absorbance spectroscopy 
Absorbance spectroscopy is often used as a convenient and time effective 
method for quantifying the concentration of protein in a solution. Concentration 
is determined through measuring the absorbance of UV light at a wavelength 
of 280 nm, referred to as A280. More specifically, the technique measures the 
Figure 3-7: NanoSight instrument configuration [6] 
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concentration of the aromatic residues tryptophan and tyrosine, and 
disulphide bonded cystine with in the solution [110]. Relating this to a 
concentration requires a knowledge of the protein structure. i.e. the number 
of UV light absorbing bonds in the protein. This property is often expressed as 
a value termed absorptivity [111] or, more commonly, as the protein’s mass 
extinction coefficient (ε280) which expresses absorbance in terms of the path 
length of light passing through a sample [112]. 
The absorbance (A) is logarithmic relationship between the intensities of light 
transmitted (I) and received (I0) though the sample, noted previously in 
Equation 2-1 and Equation 2-2: 
𝐴 =  −𝑙𝑜𝑔ଵ଴
𝐼଴
𝐼
 
When conducting A280 spectroscopy, the mass extinction coefficient (ε280), the 
light source intensity (I), and the pathlength (l) though the sample are known, 
so the absorbance can be calculated using the Beer-Lambert law: 
𝐴 =  𝜀 𝑐 𝑙 
Where c in the protein concentration [113]. 
3.3. Summary 
In order to explore the effects of fluid flow on protein aggregation, a range of 
theory is required. The mechanics that govern fluid flow through laminar 
systems has be presented, along with the mathematics that governs fluid 
element deformation and numerical methods for flow simulation. 
A discussion around the physical properties of proteins has also been 
presented, with an emphasis on aggregation pathways. The means to 
characterise aggregation has also been explored.  
The following sections will rely on the information presented in this chapter, 
beginning with the development of a numerical model to characterise an 
experimental flow device. 
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4. Numerical Modelling and Computational Fluid 
Dynamics 
4.1. Introduction 
The purpose of this section is to document the design and implementation of 
the computational model used to characterise the experimental flow device. 
As discussed in previous sections, this thesis is presented such that a 
computational fluid dynamics (CFD) model was used to determine the design 
of a device. In practice, the development of the device occurred in tandem 
with the CFD study, with the CFD results heavily influencing design choices 
and device usage. As a result, some aspects of the CFD model, such as 
capillary and syringe geometries, are assumed in this section. The design 
methodology behind these choices is covered as part of Chapter 6. The 
decision to structure this thesis in such a way is to highlight the importance of 
having a fully defined flow system in order to address the question of how 
protein molecules interact with a given flow field. It is also to emphasise the 
point that flow analysis is a critical part of this study as opposed to a mere 
discussion point. 
The CFD chapter is separated into two sections; the theory section and the 
application section. CFD theory is concerned with CFD as a tool. The 
concepts of conservation are dealt with here. Conservation of mass, 
conservation of momentum and conservation of energy. 
In the application section the use of CFD is discussed in relation to the current 
problem. The CFD solver is scrutinised for applicability and a post-process 
method designed for use alongside physical experimentation is discussed. 
The current problem is then introduced. The geometry is developed, and 
assumptions are made and justified. 
Finally, post processing is discussed. This concerns with how the data that 
the CFD solver produces is manipulated into useable results. 
It is worth noting that the molecular level is not modelled in CFD. This section 
is applicable only on the fluid bulk; the fluid matter is dealt with as a continuum. 
During the discussion in Chapter 8, a case will be made to bridge the gap 
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between the interaction of long-chain molecules and the fluid continuum, as it 
is treated here.  
4.2. Theory and Methodology 
A finite element numerical solution in CFD is found by discretizing a problem 
into a finite number of volumes or nodes and assigning discrete values to each 
node. A solver is then used to give an approximate solution a set of 
fundamental equations with respect to the values of each node, together with 
information from neighbouring nodes. An error is calculated, each node is 
updated, and another iteration is carried out until a solution is obtained within 
an acceptable error. A problem can be based in one, two or three dimensions. 
The problem can be steady state or time dependent depending on the model. 
CFD is governed by three fundamentals, conservation of mass, conservation 
of energy and Newton’s second law. These fundamentals of fluid dynamics 
are expressed by the Navier Stokes equations, which incorporate viscosity, 
heating and mass transfer. 
Newton’s second law constitutes the theory of momentum. The momentum of 
an object remains constant unless acted upon by an external force, or 𝐹 =
𝑚𝑎. Newton’s second law is applied to the fluid to govern the conservation of 
momentum. Mass is conserved whilst taking compressibility into account. 
These characteristics form the continuity equation. 
The continuity equation is expressed as the application of Reynold’s transport 
theorem and divergence theorem to a fixed arbitrary control volume. The mass 
flux at the volume control surface is taken into account to allow for matter 
flowing into and out of a control volume. 
 𝜕𝜌
𝜕𝑡 + ∇ ∙ (𝜌𝒖) = 0  
For an incompressible fluid, the density 𝜌 does not change, and so the 
continuity equation simplifies to  
 ∇ ∙ 𝒖 = 0  
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Forces or stresses acting on a fluid element result in changing the momentum 
of the fluid by accelerating or warping it. A fluid element can be accelerated 
and warped along multiple axes simultaneously. 
 There are two types of force that can act to change the momentum of a fluid 
element; a body (or mass) force, which acts on the entire control volume, and 
a surface force, which acts on the fluid via a boundary of a surface. Examples 
of body or surface forces are gravity and pressure, respectively. 
This is expressed as the Navier-Stokes equation, reiterated here: 
 𝜌 ൤
𝜕𝒖
𝜕𝑡
+ (𝒖. ∇)𝒖൨ = −∇𝑃 + 𝜌𝑔 + 𝜇∇ଶ𝒖 Equation 3-20 
 
where డ𝒖
డ௧
 determines the change of velocity with time, (𝒖. ∇)𝒖 governs 
convective transport, ∇𝑃 is the pressure gradient term, 𝜌𝑔 is the body force 
term, and 𝜇∇ଶ𝒖 is the viscous diffusion term. 
4.3. Problem Brief 
The purpose of the computational method is to produce and test a model with 
an extensional flow region that would be easily reproduced or represented 
experimentally. An extensional flow can be created with a sudden contraction. 
A contraction can be constructed by attaching a narrow bore capillary to a 
relatively wide bore syringe. The syringe plunger then provides the pressure 
differential required to drive the flow profile. 
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Through a systematic design process (Chapter 6), the syringe chosen was the 
Hamilton 1001 RN Valco gastight borosilicate syringe with a maximum volume 
of 1 ml and a bore diameter of 4.61 mm. This was to be mated to a 75 mm 
borosilicate capillary with a bore diameter of 0.3 mm. A second identical 
syringe will be mated to the downstream end of the capillary to capture the 
sample after stressing, and to return the fluid in the opposite direction if 
required. The maximum plunger velocity to be modelled is 24 mms-1, whilst 
the fluid conditions can match those of water. The glass walls and plungers 
can be considered smooth. This can be modelled by connecting two wide tube 
sections via an abruptly narrower section of tube, as shown in Figure 4-1. 
4.4. Software 
4.4.1. COMSOL Multiphysics 
COMSOL Multiphysics is a simulation platform designed for engineering 
analysis of a range of different problems. Its CFD module consists of a high 
level user interface which allows for step-by-step design of complex models. 
The package pre-processor is used to create geometries, define the flow 
parameters and build the mesh. The CFD solver uses a finite element method 
(FEM) to approximate and solve complex flow problems. A built-in post-
processer is available to support some data analysis. The data can also be 
extracted for use in other post-processor applications. The package used for 
this model was COMSOL Multiphysics 5.3. 
 
Sudden contraction 
causing acceleration 
and extension 
 
  
Direction of 
flow 
Figure 4-1: Schematic of problem to be modelled. Two pipes of 
diameter 4.61 mm are connected with a narrow pipe of 0.3 mm 
which form abrupt step up and step down constrictions. 
Syringe 1 
Syringe 2 
Capillary 
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4.4.2. MATLAB 
MATLAB is a numerical programming environment developed for data 
manipulation and visualisation, matrix manipulation, algorithm implementation 
and the creation of user interfaces. COMSOL has been designed to link with 
MATLAB so that it can be controlled using script. It is also useful for extracting 
data post-process to allow for more involved data processing. In the current 
work, a post-processer was written in MATLAB R2017a to allow for 
visualisation of the strain-rate profiles in the 2D models.  
4.5. Pre-Processor 
Two CFD models were compiled; the first was an open pipe system with the 
step-down constriction, the second model was a closed system with an 
additional expansion to simulate the down-stream syringe, and moving 
boundaries to simulate the syringe plungers. The models will be referred to as 
the open model and the closed model respectively.  
The open model was designed to solve problems that only arise as a product 
of the contraction, such as calculating strain rate, measuring the propagation 
of the extensional flow field. It then became apparent that the expansion 
region into the downstream syringe combined with the proximity of the 
downstream syringe plunger face could potentially have an effect on 
aggregation propensity. The closed model was produced to investigate this 
potential. 
Both models share some properties and as such, the assumptions, 
approximations and simplifications can be combined for both.  
4.5.1. Universal assumptions 
Each computer model will have its own unique properties, but for the majority 
of work some universal assumptions and simplifications can be defined. The 
properties of the fluid are defined in Table 4-1 from both models and remain 
constant for the duration of the testing. These properties will be recognisable 
as those of water at 25 °C. These were used because the protein samples to 
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be tested will be of such low concentration that the rheological properties will 
be indistinguishable from water. 
Both geometries are comprised of axially symmetric sections which allows for 
both problems to be solved as 2D axisymmetric models. This reduces 
complexity, computation and post-processing time without compromising the 
fundamental physics of the problem. 
The fluid will be assumed to be incompressible and isothermal. These are 
justified because the pressures and speed involved are small enough for any 
changes in density of temperature to be negligible. 
Property Value Units 
Temperature 25 °C 
Density 997 kgm-3 
Viscosity 8.9 x10-4 Pa·s 
Table 4-1: Fluid properties applied to CFD modelling in this section 
 
The problem is assumed to remain laminar throughout. The fact that it is 
laminar is demonstrated by the low Reynolds Number (Re), given by Equation 
4-1. 
 𝑅𝑒 =  
𝜌𝑢𝐿
𝜇
 Equation 4-1 
 
where the density 𝜌 and viscosity 𝜇 are defined in Table 4-1, the characteristic 
length scale 𝐿 is taken as the diameter of the section, and the velocity 𝑢 in the 
average flow velocity at that section. For a syringe plunger velocity of 8 mms-
1, Re varies from as low as 41.31 in the syringe barrel up to 634.86 in the 
capillary. Throughout the device Re remains below 2000 up to plunger speeds 
of 25 mms-1 which satisfies the laminar flow assumption for the current 
application. 
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The surface finish on all of the geometry walls are polished glass with the 
exception of the plungers which are PTFE, a smooth, dense polymer. All walls 
will be approximated to a smooth, no slip boundary condition. 
4.5.2. Single constriction open model 
To characterise the extensional flow field at the constriction, a simplified model 
was created to exclude the downstream syringe barrel or plunger surface. The 
pressure differential of the plunger was modelled as a fully developed laminar 
flow with a constrained average velocity equal to that of the desired plunger 
velocity. 
 
4.5.2.1. Geometry 
The geometry was modelled as two rectangles which represent a 2D slice 
though the flow profile, as shown in Figure 4-3. The height of the large 
rectangle was equal to the radius of a syringe barrel, while the  narrow 
rectangle was set to the height and length equal to the radius and length of 
the capillary. 
 
 
 
  
 
Figure 4-2: Schematic of the single contraction open model to be 
modelled in CFD 
 
  
 
 
Figure 4-3: A “slice” of the flow field that can be modelled in a 2D 
axisymmetric domain for efficient computation. 
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4.5.2.2. Boundary conditions 
The boundaries that simulate the glass walls of the flow channel were imposed 
with a no slip condition. This constrains flow velocity at this boundary to zero 
as is true in any real sold surface. The boundary that simulates the symmetric 
axis, however, does not constrain the fluid velocity, it simply imposes zero 
mass flux; no fluid may move across this boundary. This flow outlet is located 
at the downstream end of the capillary. This boundary consists of a zero 
pressure outlet; fluid may flow out of the channel if the pressure gradient is 
positive. The inlet is defined as an established laminar flow inlet. This means 
that the fluid passing into the channel is conditioned to travel parallel with the 
axis of symmetry. This is not true of fluid at the pace of the upstream plunger 
in the real condition, but is a fair approximation given that this problem is only 
concerned with the region of flow around the constriction. The boundaries to 
the model were define as in Figure 4-4. 
 
4.5.2.3. Mesh 
The mesh used for the single constriction open model is a free quadratic 
mesh. This meshing parameter divides the flow profile into a series of 
rectangles of varying sizes. The mesh was globally restricted to elements with 
dimensions of 0.9 – 65 µm with a maximum size ratio of 1:1.1 between any 
neighbouring elements. This is defined as the maximum element growth rate 
[114]. As the geometry is relatively elongated, the elements’ dimensions were 
scaled into rectangles to the ratio 2:5 (axial : radial). This allows for increased 
accuracy though the narrow capillary section at low computation cost. 
Figure 4-4: COMSOL CFD package 2D axisymmetric model of two long 
rectangles representing a sudden and substantial constriction in a 
pipe flow. The axis of symmetry is marked as the dashed red line. 
Lamina inflow 
boundary 
No-slip wall boundary 
Symmetric axis 
Pressure outlet 
boundary 
Flow 
direction 
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The boundary layers were constructed of 5 elements with the element growth 
rate increased to 1:1.2 to allow for denser meshing in areas of greater velocity 
gradients. The mesh can be seen in Figure 4-5. 
 
4.5.2.4. Model summary and conclusions 
The open model delivered some success in that it highlighted regions of high 
strain rate around the constriction region. Details of the findings are presented 
in chapter 5. It was found however, that improvements could be made around 
skewing the mesh so that a greater number of elements could be employed 
around in the corners which form the constriction region. This will be taken 
into account in the closed model.  
4.5.3. Constriction-expansion closed model 
The previous open model was a useful tool in highlighting regions of high 
strain that are present at an abrupt constriction. In the constriction-expansion 
closed model, the effects of expansion region into the downstream syringe will 
now be modelled. The pressure differential used to drive the flow profile will 
also be improved by introducing a moving wall to simulate an advancing 
plunger. the receding downstream plunger will also be modelled. Analysis 
Figure 4-5: Free quadratic mesh used for single constriction open CFD 
model. Flow direction from top to bottom, units in mm. 
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from the initial open model will also be used to make improvements to the 
constriction region. 
4.5.3.1. Geometry 
The geometry was modelled from two large rectangles with a height equal to 
the radius of a syringe barrel. The length of the rectangles was then varied to 
simulate the effect of advancing and receding syringe plungers. A third narrow 
rectangle of a height and length equal to the radius and length of the capillary 
was used to connect the two syringe rectangles. A schematic of the section 
can be seen in Figure 4-6. 
 
 
4.5.3.2. Boundary conditions 
As with the open model, the boundaries that simulate the glass walls of the 
syringe and capillary are set as no slip to constrain the velocity at the walls to 
zero. The axis of symmetry is set to allow zero mass flux without constraining 
velocity. In terms of boundary conditions, the only dramatic change between 
the models in the inlet and outlet; or in this case, the lack of. The volume of 
the closed model is fixed, with a moving wall in place of the laminar flow inlet 
seen in the open model. A second moving wall is applied to the downstream 
wall of the downstream syringe. Both walls are set to allow zero mass flux 
across the boundaries and have a no slip condition enforced. Both walls are 
set to move at the same velocity to ensure volume is conserved. In this 
instance, both moving walls act as advancing and receding syringe plungers. 
To model the moving boundaries, each was given a set velocity and solved 
for the instantaneous case. As such, the model used was quasi-steady as 
opposed to fully transient. This decreased computation time and reduced the 
 
Figure 4-6: A “slice” of the flow field that can be modelled in a 2D 
axisymmetric domain for efficient computation. 
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model complexity whilst maintaining validity. To obtain a stable solution, the 
simulation was solved for 1 mms-1 and the speed was incrementally increased 
by 1 mms-1 using the result from the previous iteration as an initial solution for 
the increased velocity. This allowed for convergent results up to plunger 
speeds of 25 mms-1. For a closed model, pressure needs to be constrained at 
a point inside the domain for gauge pressure throughout the system to be 
calculated against. A point on the advancing moving wall was selected for the 
reference pressure point constraint such that all pressures calculated in the 
domain would be relative to this point. The boundary conditions are illustrated 
in Figure 4-7. 
 
4.5.3.3. Mesh 
For the closed model an unstructured triangular mesh was implemented. This 
allowed for smoother application of mesh density skewing. To aid in meshing, 
the domains were separated into smaller regions as shown in Figure 4-8. 
Globally, mesh element dimensions were limited to between 460 nm and 156 
µm, with a maximum element growth factor of 1.05. The mesh density in the 
capillary and at the capillary inlet was increased by 50% while the mesh 
density at the downstream syringe plunger stagnation point was increased by 
300%. The corners that form the capillary inlet and outlet were also given an 
Moving wall and 
pressure point constraint 
Moving wall No slip boundary wall Axis of symmetry 
Flow direction 
Figure 4-7: Schematic of the constriction-expansion model. In this 
instance the upstream syringe plunger is fully receded and so the 
upstream syringe barrel (left) is near its full capacity, represented 
by the domain being very long. The downstream syringe plunger is 
almost completely compressed resulting in the downstream 
syringe barrel (right) domain being very short. The blue lines 
represent the plungers which are configured as moving walls. 
These move left to right simultaneously. Units are in mm. 
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additional increase in element density by decreasing the minimum element 
size by a factor of 0.15 in these regions. These areas of increased mesh 
density are highlighted in Figure 4-9 i) – iv). 
 
 
Figure 4-8: the domain was divided into sections to allow for 
meshing density to be skewed to better reflect the flow 
complexity of different regions. 
Upstream syringe Downstream syringe 
Domain segregated into 
areas of varying complexity 
Flow 
direction 
Flow
 
Direction 
i) ii) 
iii) 
iv) 
Capillary inlet 
Capillary outlet 
Figure 4-9: Free triangular mesh used in the constriction-
expansion closed model CFD simulation. i) The upstream 
syringe feeding into the capillary inlet. ii) Increased mesh 
density at the corner of the constriction at the capillary 
inlet. iii)  Increased mesh density at the location of a 
stagnation point on the downstream syringe plunger. iv) 
increased mesh density at the capillary outlet. Units in 
mm. 
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4.6. Post-Processor 
The post-processor refers to the method of data manipulation used to present 
the solver data. The CFD package in COMSOL has a built in post-processor 
which is sufficient for presenting and extracting data that is generic to most 
CFD applications. These data include flow direction and streamlines, velocity 
contours, and pressure fields. As such, COMSOL was used to acquire these 
data. In the current study, however, much emphasis has been placed on strain 
rate, which COMSOL does not readily provide. The data required to produce 
strain rate contour plots is available, as it is a displacement derivative of 
velocity. As such, MATLAB was utilised to extract and process the necessary 
data and produce graphics for use in post-process analysis. 
To analyse the strain rate in MATLAB, data pertaining to the direction and 
velocity of flow was extracted for each coordinate point in the domain. At each 
point the frame of reference was then aligned with direction of travel such that 
the anti-symmetric part of the deformation tensor in Equation 3-13 equated to 
zero. This allowed for the deformation tensor to be solved for extensional flow 
only using the symmetric part of the deformation tensor given in Equation 
3-15. By translating the coordinate system to the direction of travel, the strain 
rate was calculated along a streamline such that the differential equation could 
be calculated in one dimension at each point using Equation 3-11 reiterated 
below. 
 𝜀̇ =
𝑑𝑢
𝑑𝑥
 Equation 3-11 
 
The point strain rates were then plotted as a strain rate contour diagram. To 
quantify the results so that different scenarios could be compared, a 
characteristic strain rate needed to be selected. To do this, the maximum 
strain rate along the axis of symmetry was used. This was chosen because 
flow travelling along the axis of symmetry is irrotational, as such the universal 
coordinal system could be used to analyse the strain rate through the 
contraction, allowing for direct comparison between scenarios. 
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4.7. Plan of Numerical Experiments 
The numerical investigation to be carried out is outlined in this section.  Before 
the model can be used for investigation it must first be validated. Validation of 
a numerical model incorporates two stages; the first stage requires that the 
model performs independently of its numerical approximation, the second 
stage requires that the model conforms with current fluid mechanical theory. 
Once the validity of the model has be confirmed, it will be used to characterise 
the flow field of the proposed experimental device via a range of numerical 
experiments. 
4.7.1. Mesh dependence study 
The accuracy of any numerical model is dependent on the resolution of the 
approximation used to simulate a physical system. In this instance a fluid flow 
is approximated by a number of finite fluid elements. To ascertain whether the 
numerical solution is independent of the mesh density, a series of numerical 
studies will be carried out. In each study, the mesh density will be increased. 
The number of mesh elements will be recorded along with the maximum strain 
rate along the symmetric axis. Mesh independence will have been achieved 
when maximum strain rate no longer varies with mesh density. The results will 
be presented in Chapter 5. 
4.7.2. Validation of model 
To validate the model, the pressure drop at the constriction and along the 
capillary will be calculated in accordance with current fluid mechanical theory. 
A comparison will be drawn between the numerical and theoretical values. 
The findings will be presented in Chapter 5. 
4.7.3. Numerical experimental plan 
4.7.3.1. Characterisation of an abrupt 90° constriction 
The flow field at a 90° constriction will be characterised for a range of inlet 
velocities. Streamline plots will be used to analyse the direction of flow, whilst 
velocity contour and strain rate contour plots will be produced to identify 
regions of high strain rate. Maximum strain rate will be plotted against plunger 
velocity.  
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4.7.3.2. Effects of constriction angle on strain rate 
The flow field of constriction angles of 45°, 30°, and 15° will be characterised 
for a range of inlet velocities. Streamline plots will be used to analyse the 
direction of flow, whilst velocity contour and strain rate contour plots will be 
produced to identify regions of high strain rate. Maximum strain rate will be 
plotted against plunger velocity for the various angles. 
4.7.3.3. Downstream syringe investigation 
An investigation into the flow profile generated in the downstream syringe is 
to be carried out. The investigation will include the characterisation of the flow 
field using streamline plots and velocity contour plots. An analysis of how the 
stagnation point at the downstream syringe plunger varies with displacement 
from the syringe outlet will be presented. This will utilise strain rate contour 
plots.  
4.8. Summary 
Two CFD models have been created to characterise and define the flow 
profiles generated in an experimental flow device. The device has been 
designed to determine the effects of extensional flow on protein molecules in 
dilute solution. As such, the importance of quantifying the forces present within 
the flow have been addressed in this section. These include gaining 
information on the magnitude of strain rate at the constriction as well as 
understanding the flow properties present in the downstream section of the 
device. 
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5. Computational Results 
Prior to this chapter, the theory of CFD was discussed along with a 
methodology that would be used to analyse and validate the experimental 
setup. Two CFD models were compiled; the first was an open system with a 
single constriction, the second model was a closed system with an additional 
expansion to simulate the down-stream syringe, and moving boundaries to 
simulate the syringe plungers. The models will be referred to as the open 
model and the closed model respectively. 
The section will begin with validation and mesh dependence studies to 
address the issue of error inherent within any numerical approximation.  
The abrupt 90° constriction profile will then be analysed in terms of 2D 
axisymmetric streamline and velocity contour profiles. The flow profile will then 
be examined in terms of acceleration and strain rate.  
A variation on the model will be used to introduce inlet/outlet angles to the flow 
geometry. This is proposed as an experimental method of reducing strain rate 
whilst holding shear constant within the capillary and offers a way of 
decoupling the effects of strain and shear. 2D axisymmetric plots of 
streamlines, velocity contours and strain rate contours will be presented for 
constriction angles of 45° and 30°. 
A quantitative measure of strain rate will be used to examine the relationship 
between plunger (inlet) velocity and strain rate. A characteristic measure of 
strain rate will be recorded for the 90°,  45° and 30° inlet angles for 
comparison. The effect of the angle reduction on the capillary outlet will also 
be addressed.  
The transition region from extension-dominated to shear-dominated flow will 
be evaluated in terms of velocity profiles with respect to the radial direction. 
The resultant impact this has on shear within the capillary will then be 
presented. 
 The model will then be used to address phenomena downstream of the 
capillary outlet. The 2D axisymmetric flow profile will be presented in terms of 
streamline and velocity contour plots for the downstream syringe. It will be 
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shown how this flow region develops over time, and as a function of plunger 
velocity. The effects of a stagnation point on the boundary representing the 
downstream syringe plunger will be assessed in terms of strain rate. The 
impact of the stagnation point on the total fluid bulk will be analysed by 
measuring the volumetric flow rate associated with regions of high strain at 
varying distances from the stagnation point. 
5.1. Validation 
CFD is a numerical approximation to a physical fluid system build upon 
several carefully considered assumptions and simplifications, and solved 
through a methodical numerical approach. Large fluid domains are discretised 
into many smaller elements, whose properties are determined largely by the 
properties of their neighbours. Dividing a fluid element into fewer elements will 
reduce computational time required to solve the global model. This may, 
however, reduce the accuracy of the approximation. By systematically 
increasing the number of elements within the model, and reporting a value of 
interest to the study, it is possible to determine an appropriate mesh density 
that optimises computational time without compromising on model accuracy. 
In this model, strain rate is an important feature. Strain rate is also subject to 
large gradients and sudden gradient changes due to its relation to 
acceleration, making it highly sensitive to model resolution. For these reasons, 
it was chosen as a suitable parameter for a mesh dependence study. 
5.1.1. Single constriction open model mesh dependence study 
The single constriction open model was an early “proof of concept” model, the 
density of the mesh was incrementally increased and solved for maximum 
strain rate. The number of domain elements was recorded and plotted against 
the maximum strain rate within the model. 
The results of the mesh refinement study for model-1 can be seen in Figure 
5-1. The mesh density was varied from 1635 to 65905 domain elements over 
eighteen independent approximations.  For coarse meshes, reported values 
for maximum strain rate along the axis varied from 8341s-1 to 15029s-1. Strain 
rate values appeared to converge around 12700s-1 between domain element 
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counts of 13000 and 30000 before shifting suddenly to values around 11700s-
1 for element counts more than 30000. Seven approximations returned 
maximum strain values between 11684s-1 and 11762-1 for domain element 
counts between 42312 and 65905. The percentage error in this region is 
therefore 0.66%. 
This model indicated that the numerical approach converged on a solution 
and produced an initial estimate for a characteristic maximum strain rate along 
the axis of 11700s-1. 
5.1.2. Constriction-expansion closed model mesh dependence 
study 
The second, closed system model, was built to include the effects of moving 
walls, as a result of the motion of the syringe plunger. The domain was 
constructed in sections to allow for regions of complex flow formations to be 
meshed with greater density than areas of slow or uniform flow. Tuning the 
mesh in such a way allows for greater accuracy without excessive 
computational cost.  
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Figure 5-1: Mesh density refinement study for model 1. The mesh was 
systematically refined whilst all mesh-independent parameters 
were held constant. The model was then solved and the maximum 
strain rate along the axis of symmetry was reported. This was 
correlated to the number of domain elements used to construct the 
mesh. 
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Areas of high mesh density include the extensional flow region around the 
capillary inlet, the relatively narrow capillary, and the downstream syringe face 
on which a stagnation point forms. A mesh dependence study was carried out 
for the closed model by systematically increasing the mesh density in the 
extensional flow and capillary regions and solving for maximum strain rate in 
the extensional region along the axis. The number of elements required to 
mesh the high density regions were recorded only. A coarser mesh was then 
constructed outside of the refined regions and solved, with maximum strain 
rate being recorded. 
Figure 5-2 shows the results from the model-2 mesh refinement study. Strain 
rates were seen to be erratic for mesh elements below 5000 and converge 
from 10000 onward. A typical value for strain rate was given as 10300s-1 with 
a range of +/- 110s-1 for element counts between 10- and 40-thousand. This 
accounts for an error of 1.07%. The disparity between models 1 and 2 is 
approximately 1400s-1 which equates to 12%. 
Mesh refinement continued past apparent convergence due to discrepancies 
seen in other aspects of the model. Figure 5-3 shows a plot of strain rate along 
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Figure 5-2: Mesh density refinement study for the extensional flow and 
capillary domains of model-2. Elements required to mesh this 
section only were recorded, a coarser mesh was then constructed 
in the remaining regions and the model was solved for a 
characteristic strain rate. 
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the axis of symmetry within the capillary for two mesh densities, both of which 
fall within the apparent region of convergence. Yet the plot for lower mesh 
density shows a series of artefacts within the capillary which appear to be the 
subject of mesh dependence. Increasing the element count across this region 
has ensured mesh independence. 
 
5.2. Flow profile for an abrupt 90° constriction 
Post processing of CFD data allows for a visual representation of the flow 
field. Streamline plots show the direction and path of a given fluid element 
while velocity profiles show relative velocities anywhere within the fluid 
domain. Pressure is also an important characteristic and will be plotted in 2D. 
This information defines the fluid properties anywhere in the domain, and 
allows for more complex information, such as strain rate, to be derived 
mathematically and visualised by the reader. 
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Figure 5-3: Strain rate profiles along the axis of symmetry in the z 
direction for inlet velocity of 8mms-1. A comparison is made 
between simulation results for models with 10322 and 3673 discrete 
elements. It can be seen that although the values of maximum 
strain rate are in agreement, the lower element count is still 
resulting in mesh-dependent artefacts which disappear with 
increased mesh density. 
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5.2.1. Streamline plots for 90° constriction 
From Figure 5-4 the streamlines are seen to be even, equidistant and present 
all characteristics of laminar flow. The bulk of fluid travels parallel to the 
domain boundary along the majority of the syringe barrel as well as along the 
capillary. No great variation in streamline profile can be seen for plunger 
velocities between 8 mms-1 and 16 mms-1. Fluid close to the axis of symmetry 
travels along a largely straight path. The streamlines become more tortuous 
with greater free-stream radial displacement. Fluid near the syringe barrel wall 
is forced to make a near-90° turn as it approaches the end of the barrel. The 
fluid remains within close proximity of a no-slip boundary as it travels near-
parallel to wall of the syringe hub section. The fluid then makes another, small 
radius 90° turn in order to enter the capillary. A recirculation can be seen in 
the corner adjacent to the capillary inlet, common with a forward-facing step 
geometry .This will contribute to pressure losses over the total system as 
energy is required to drive the recirculation with no useful gain to the system. 
A smaller recirculation, a vena contracta, is also present just downstream of 
the capillary inlet, on the outer boundary. 
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D
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Figure 5-4: 2D axisymmetric streamline plot for various plunger 
velocities (as stated) showing path of fluid as it approaches the 
narrow capillary producing an abrupt 90° constriction. Note (i) the 
small recirculation occurring in the corner adjacent to the capillary 
inlet, and (ii) the extended path-length for fluid traveling along the 
peripheries of the syringe barrel. 
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5.2.2. Velocity magnitude for 90° constriction 
Although the average syringe velocity (upstream of the capillary) in Figure 5-5 
(16 mms-1) is twice that of Figure 5-5 (8 mms-1), this disparity is invisible on 
the current scale as inlet velocity is an order of magnitude smaller than the 
average velocity in the capillary. Maximum velocity increases with plunger 
velocity while velocity at the wall remains zero, as expected. Velocity gradient 
is therefore greater for higher plunger velocities, resulting in larger shear 
stress. Noticeable velocity increase ahead of the capillary inlet can be seen to 
protrude further upstream with increased plunger velocity.  
A region of high velocity fluid can be seen (especially clearly in Figure 
5-5(16mms-1)) just within the corner which forms the capillary inlet. This region 
is in stark contrast to the relatively slow moving fluid immediately upstream, 
and either side of it. When considered alongside the corresponding streamline 
plot in Figure 5-4(16mms-1) it can be seen that this fluid is travelling almost 
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Figure 5-5: 2D axisymmetric velocity profile for 90° constriction for 
various plunger velocities (as stated). Note the high velocity in the 
corner which forms the capillary inlet. Note also, the length of 
capillary required for the flow along the axis to reach maximum 
velocity. 
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perpendicular to the capillary before abruptly changing direction to flow near 
parallel with the capillary. It is clear than this sudden change in direction 
occurs in tandem with an abrupt change in velocity. 
5.2.3. Pressure profiles for 90° constriction 
Figure 5-6 gives the pressure distribution across a 2D sectional view of the 
90° constriction. A large drop in pressure occurs over the abrupt constriction.  
In Figure 5-6 a region of low pressure can be seen immediately downstream 
of the corner which forms the inlet of the capillary. This is due to the 
momentum of the fluid travelling thought the inlet preventing it from changing 
direction and flowing into this region readily. This is consistent with laminar 
flow theory discussed in the theory chapter.  
Pressure was measured in the CFD model for comparison to hand 
calculations as a means of validation. In Chapter 3 a number of equations 
were identified to calculate the pressure loss of flow through a contraction and 
along a capillary. Given the dimensions of the flow geometry, the velocities 
kPa 
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Figure 5-6: 2D axisymmetric pressure profile at the 90° constriction for 
various plunger velocities. 
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used, and the resultant Reynolds Number, it was decided that Equation 3-23 
is the most applicable. The equations in reiterated below. 
 ∆𝑃௖௢௡௧௥௔௖௧௜௢௡ = ቆ𝐾 +
𝑘ᇱ
𝑅𝑒
ቇ
𝜌𝑈ଶ
2
 Equation 3-23 
 
For the Hagenbach correction 𝐾, the value of 2.24 was used as according to 
Sparrow and Lin [115]. The value used for the Couette correction 𝑘ᇱ was 38.3 
as given by Weissberg [116] and Holmes [117]. 
The pressure loss in the capillary was calculated using the Hagan-Poiseuille 
equation reiterated below. 
 ∆𝑃௖௔௣௜௟௟௔௥௬ =
128𝜇𝐿𝑄
𝜋𝑑ସ
 Equation 3-22 
  
The total pressure loss over the contraction and the 16 mm capillary section 
in the model is given by the sum of these two losses such that 
 ∆𝑃௧௢௧௔௟ = ቆ𝐾 +
𝑘ᇱ
𝑅𝑒
ቇ
𝜌𝑈ଶ
2
+
128𝜇𝐿𝑄
𝜋𝑑ସ
 Equation 5-1 
 
 
The calculated values for each plunger velocity plotted in Figure 5-7 are 
presented in Error! Reference source not found. along with the 
corresponding Reynold numbers and pressure losses from CFD predictions. 
Comparing these two results in terms of percentage difference show good 
agreement between calculated and modelled pressure losses with error 
ranging from 1.57% for low speeds down to 0.44% for the highest plunger 
speeds. 
It can be seen in these results that the pressure loss at the contraction and 
along the capillary are concurrent with theoretical findings, thus validating the 
CFD model. 
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Plunger 
velocity 
(mms-1) 
Syringe 
Reynolds 
Number 
Hand 
calculated 
pressure loss 
(kPa) 
Pressure loss 
from CFD (kPa) 
Error 
(%) 
8 41.31 15.20 14.96 1.57 
10 51.64 20.24 20.01 1.15 
12 61.97 25.79 25.57 0.84 
14 72.30 31.83 31.64 0.59 
16 82.63 38.37 38.2 0.44 
Table 5-1: CFD validation comparing hand calculated pressure losses 
to those obtained from CFD modelling 
 
 
  
Figure 5-7: Pressure profile along the axis of rotation in the z direction 
for various plunger velocities as stated. In this instance, the 
positive z direction indicates the direction of flow with negative 
values indicating a location upstream of the contraction within 
the syringe barrel. The capillary is 16 mm in length, starting from 
z = 0 mm. 
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5.2.4. Strain rate profiles for 90° constriction 
Figure 5-8 shows the magnitude of strain rate in 2-dimensions as fluid passes 
through the transient extensional flow region at the 90° capillary inlet. The 
visualised range has been limited to 2.5x104 s-1 to highlight the relevant strain 
rates for the majority of flow without being skewed by uncharacteristically high 
strain regions located at the corner around the capillary inlet. High strain can 
be seen in the corner, with a distinct streak extruding along the capillary in the 
direction of flow. The high strain region is also seen to balloon out toward the 
axis of symmetry with decreasing, yet still considerably high strain rates at the 
geometric centre. A discussion concerning the formation of the high strain rate 
region follows in later sections. 
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 Direction of flow 
Figure 5-8: 2D axisymmetric strain rate profile for 90° constriction for 
various plunger velocities (as stated). Not the high strain rate 
around the corner forming the inlet to the capillary. 
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5.3. Flow profile for reduced-angle constrictions  
The angle of the capillary inlet was varied to explore strain rate as a variable 
independent of shear rate. The angled inlets are characterised below in terms 
of streamline plots, velocity contours plots, and strain rate contour plots. 
5.3.1. Streamline plots for reduced-angle constrictions 
Figure 5-9 shows the streamline plots of capillary inlets with various angles at 
velocities of 8 and 16 mms-1. The reduction in capillary inlet angle removes 
the recirculation from the outside corner. This shows the gradual change in 
direction, and the lack of any recirculation.  
 
  
8 mms-1 16 mms-1 
8 mms-1 16 mms-1 
Figure 5-9: 2D axisymmetric streamline plot for 45° and 30° 
constrictions for plunger velocities 8 and 16 mms-1. 
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5.3.2. Velocity profiles for reduced angle constriction 
Figure 5-10 and Figure 5-11 show the velocity contour profiles for capillary 
inlet angles of 45° and 30°. Plunger velocities of 8, 12, and 16 mms-1 are 
plotted. When compared to the 90° constriction, the higher velocities (>1ms-1) 
are seen to be present further upstream of the capillary inlet. This is due to 
the reducing cross-sectional area which requires the average velocity over the 
cross-section to increase gradually with axial displacement to satisfy mass 
conservation. Velocity is low (~0ms-1) at the angled inlet wall due to the no-
slip friction condition. The high contrast region near the corner of the capillary 
inlet is still present as with the 90° constriction. 
There is a high contrast between the near-zero velocity along the angled wall 
and the corner at the capillary inlet. From the streamline plots, it can be seen 
that fluid traverses from the slow region directly into the fast region. High strain 
rate can be expected in the region.  
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Figure 5-10: 2D axisymmetric velocity profile for 45° constriction for 
various plunger velocities (as stated). 
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Figure 5-11: 2D axisymmetric velocity profile for 30° constriction 
for various plunger velocities (as stated). 
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5.3.3. Pressure profiles for reduced-angle constrictions 
Figure 5-12 and Figure 5-13 show the pressure contour plots for capillary 
inlet angles of 45° and 30°. Plunger velocities of 8, 12, and 16 mms-1 are 
plotted. 
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Figure 5-12: 2D axisymmetric pressure profile for 45° constriction 
for various plunger velocities (as stated). 
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Figure 5-13: 2D axisymmetric pressure profile for 30° constriction 
for various plunger velocities (as stated). 
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5.3.4. Strain rate profiles for reduced-angle constrictions 
Figure 5-14 and Figure 5-15 show the strain rate contour plots for capillary 
inlet angles of 45° and 30°. Plots were produced for inlet velocities of 8, 12, 
and 16 mms-1. 
As with the 90° constriction, strain rate is highest in the corner that forms the 
capillary inlet. Maximum strain rates in this area are ~20% lower for the 45° 
angled constriction when compared with the 90° constriction in Figure 5-8. 
Maximum strain rate at the corner of the capillary inlet are ~40% lower for the 
30° angled constriction when compared with the 90° constriction in Figure 5-8. 
High strain can be seen at the angled inlet wall which increased with velocity. 
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Figure 5-14: 2D axisymmetric strain rate profile for 45° constriction 
for various plunger velocities (as stated). 
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Figure 5-15: 2D axisymmetric strain rate profile for 30° constriction 
for various plunger velocities (as stated). 
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5.4. Quantifying strain rate data 
A characteristic strain rate should be defined to allow for comparison between 
different geometries. The maximum strain rate anywhere in a given field is not 
necessarily representative of the strain experienced by the fluid bulk. The 
maximum strain rate may occur at a boundary or corner. Due to the nature of 
laminar flow, this region of high strain rate will have very low flow rate through, 
or near it.  
A measure of the maximum strain rate along the centre of the channel is used 
as a characteristic strain rate of the device. This would be informative as the 
velocity will be at its highest in, and around, this part of the channel, which 
would account for the majority of mass transit through the domain. There is 
no shear present in this region, nor has the fluid had to deviate far from its 
initial direction, resulting in a largely irrotational flow. These make for good 
conditions to measure extensional flow. Furthermore, because the current 
model is axisymmetric, the centre of the channel lies on the axis of symmetry. 
This makes for simple recording of accurate data as the fluid properties are 
easily accessible at the boundaries with minimal post-processing. 
5.4.1. Strain rate as a function of displacement 
It is clear from the work presented in this chapter that analysing strain rate 
and its effects requires a well-defined method in order for multiple geometries 
or devices to be examined and compared. It would not be appropriate to 
simply take the maximum reported strain rate from a CFD post processor as 
this is evidenced to occur in some extremity of the flow field in a region of 
small mass flux which would have little to no bearing on the response of the 
fluid bulk. It is also the case that such high strain rates in extremely localised 
regions are often numerical artefacts, the products of approximate velocity 
gradients at imposed boundary conditions. 
It would be possible to define a characteristic strain rate as the strain rate 
associated with a region of high volumetric flow rate or a mass transit 
weighted-average across a particular cross-section. A method for calculating 
this is discussed in a later section. 
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For the current work a characteristic strain rate is taken as the maximum strain 
rate experienced along a streamline located on the axis of rotational 
symmetry. This was chosen because the flow through this region is irrotational 
and void of shear effects. The average velocity along the axis is also higher 
than for any other region in the domain, indicating that acceleration, and 
therefore strain, will be present and predictable. The axis of symmetry also 
corresponds with a domain boundary on the model, which allows for 
straightforward data extraction without complex post-process manipulation. 
Figure 5-16 shows a graph of total velocity (u) plotted against displacement 
along the device in the z-direction (Sz). As the flow is laminar along an 
axisymmetric geometry, the fluid along the centreline does not vary from a 
straight path and so total velocity is equal to the x component of velocity only 
(u = uz). The strain rate along this same streamline is plotted below, also with 
respect to Sz. Strain rate is proportional to acceleration and so the magnitude 
of strain rate is seen to map the gradient of velocity. The maximum strain rate 
along the axis of symmetry occurs when the velocity gradient (i.e. the 
acceleration) is greatest. This will be referred to as the characteristic strain 
rate here-in. 
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Figure 5-16: i) Schematic of flow profile with contraction located the Z = 
0 coordinate. ii) Velocity and strain rate profile in the z-direction 
for a 90° contraction with plunger velocity 8 mms-1. The velocity 
profile along the axis of symmetry in the z-direction is plotted in 
blue (measured against the left axis) whilst the corresponding 
strain rate along the axis is plotted in orange (in relation to the 
right axis). The horizontal axis measures the distance from the 
capillary inlet with the positive direction indicating the direction of 
flow (i.e. negative z position represents flow within the syringe 
barrel immediately upstream of the capillary). 
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5.4.2. Strain rate as a function of plunger velocity 
In Figure 5-17 the maximum value of strain rate along the axis of symmetry is 
plotted against plunger velocity. The characteristic strain rate increases 
linearly with plunger velocity, producing values in excess of 104 for plunger 
velocities above 6 mms-1. This is compared to the characteristic strain rate 
verses plunger velocity for the two reduced angle inlet geometries. As 
expected, a reduction in strain rate is observed with decreasing inlet angle. 
 
Figure 5-17: Characteristic strain rate plotted for constriction angles of 
90°, 45° and 30°. 
5.5. Transition from extension- to shear-dominated flow 
Shear invariably plays an integral role in any laminar flow regime. With regard 
to this, it is important to investigate shear in this device. In order to understand 
shear, the velocity profile will be analysed. In a converging extensional flow 
regime, there is an overall acceleration in the fluid bulk as the mass flow rate 
must be conserved. It is also known that laminar flow through a capillary is 
expected to generate a familiar parabolic velocity profile with respect to radial 
position 𝑆௥. These two effects are, however, contradictory as upstream of the 
constriction the fluid which must be travelling at the highest velocity is that 
which is located at greater values of 𝑆𝑟. This discrepancy results in a 
transitionary phase at the capillary inlet where a fluid is initially seen to be 
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travelling faster nearer to the wall. This results in a region where shear is 
higher than that which is expected in an established capillary flow.  
Figure 5-18 shows the radial velocity profile at the capillary inlet for various 
plunger velocities. For a plunger velocity of 2 mms-1 there is a subtle increase 
in velocity with radial displacement before velocity gradually curves off to zero 
at the boundary. With increased plunger velocity, the gain in fluid velocity with 
radial displacement becomes more apparent. The reduction to zero at the 
boundary also becomes steeper. This is evident of high shear. 
 
Figure 5-18: Absolute velocity U profile with respect to radial 
displacement from the axis of symmetry at the capillary inlet, given 
for increasing values of upstream velocity U∞. 
 
Figure 5-19 takes a plunger velocity of 8 mms-1 and measures the resulting 
radial velocity profile at various positions along the capillary. The graph shares 
one set of data with Figure 5-18; plunger velocity of 8 mms-1 at Sz = 0 mm. 
It can be seen from Figure 5-19 that at the entrance to the capillary, the highest 
velocity fluid, travelling at 2.3ms-1, is located over 0.13 mm away from the axis 
where fluid is only travelling at 1.8ms-1. This discrepancy is seen to reduce as 
fluid travels along the capillary, and the no-slip condition begins to exert its 
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influence. As the fluid travels through the first 0.2mm, the discrepancy 
between velocities at the axis and near the boundary reduces. After the fluid 
has travelled 0.2mm along the capillary, it can be seen that the fluid located 
at the axis now has the greatest velocity. Shear forces are now dominating 
the flow regime. It is not until 4mm along the capillary, however, that a truly 
parabolic velocity profile has developed. 
 
Figure 5-19: Absolute velocity U profile with respect to radial 
displacement from the axis of symmetry Sr taken at incremental 
distances (given in legend) from the capillary inlet. Average inlet 
velocity U∞ = 8 mms-1. Sr = 0 lies on the axis of symmetry, and Sr = 
0.15 indicates the capillary wall. 
 
Figure 5-20 shows the radial velocity profile immediately after capillary inlet at 
distances 0, 0.4 and 4 mm following (i) 45° and (ii) 30° inlet angle. For 45°, at 
0 mm the velocity highest velocity fluid, located near the wall at 𝑆𝑟 = 0.125 is 
2.198 ms-1 and the velocity at the axis is 0.185 ms-1, whereas, for 30° the 
respective velocities are 2.133 ms-1 and 0.191 ms-1. The percentage 
disparities between 45° and 30° with respect to 90° maximum and axis flow 
velocities are 7.66% and 10.9% respectively. 
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Examining the velocity profile for the inlet, shown in Figure 5-19 at 0mm, it is 
seen that the highest velocity flow 𝑢0𝑚𝑎𝑥 = 2.198𝑚𝑠−1is located at 0.125𝑚𝑚 
from the axis. The velocity at the axis is 𝑢0𝑟=0 = 0.181𝑚𝑠−1. From Figure 5-19 
it can be seen that the important locations are 0mm where the transition phase 
begins, 0.02mm where shear begins to dominate and location of maximum 
velocity shifts to the axis, and 4mm where the velocity profile takes on the 
characteristic parabola and stabilises for the duration of the capillary. 
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Figure 5-20: Radial velocity profile immediately after capillary inlet at 
distances 0, 0.4 and 4mm following a i) 45° and ii) 30° inlet angle. 
Flow inlet velocity 8 mms-1. The transition from extension-
dominated to shear-dominate regimes produce very similar 
velocity profiles over the same length scales as for the 90° inlet 
angle. The only noticeable differences are the maximum and 
minimum velocities at 0mm. 
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Interestingly, the distance required for shear to dominate does not vary with 
inlet angle or plunger velocity. 
It is important to note that these graphs do not start at zero z-displacement. 
This is because there is a numerical artefact at the Sz = 0 which produces an 
unrealistic spike in shear which is only present for the first 10’s of microns. 
The high shear at the inlet is in agreement with the steep velocity profile seen 
near the boundary in Figure 5-18. The steady reduction to a constant shear 
value with respect to z-displacement is in agreement with the reduction in 
gradient of the velocity profiles seen in Figure 5-19. 
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5.5.2. Stagnation point within the downstream syringe 
As this study is aimed at assessing the effects of flow on a biological material, 
it is important to note that, in the current study, it is not possible to assess the 
state of the material in-situ. This means that the bulk material is required to 
experience the entirety of the conditions within the fluidic device before it can 
be analysed. Therefore, any other potentially adverse flow conditions need 
examined to assess whether they will have any effect on protein stability. One 
such region of concern is the fluid exiting the capillary and impacting the 
plunger. The following results explore this. 
Figure 5-21 shows the development of the flow field in the downstream syringe 
as it recedes from the capillary outlet. The flow profile is depicted for a plunger 
velocity of 2 mms-1. It can be seen that as the fluid leaves the capillary it 
continues in a straight line until it encounters the syringe plunger, where it is 
forced to make an abrupt right-angled turn. At this point, a stagnation point 
develops. 
In Figure 5-22 the same plunger position is repeated for increasing plunger 
velocities. It can be seen that the complexity of the flow profile grows with 
velocity. This is indicative of the increased energy present in the flow field, 
and the growing intensity of the stagnation point with plunger velocity. 
As fluid leaves the capillary it is travelling two orders of magnitude faster than 
anything else in the region, including the receding plunger face. The incoming 
fluid forms a jet along the centre of the downstream syringe which impacts on 
the downstream syringe plunger, causing it to turn through 90° and flow 
radially out toward the syringe walls. The high speed jet flow combined with 
the radial flow sets up a series of recirculations driven by viscous interaction. 
As the plunger recedes and the cavity volume increases, the elongated 
geometry causes the recirculating flow to deform in order to fill the available 
space. 
As the jet velocity increases with plunger velocity, the kinetic energy drives 
stronger recirculations and a second region of recirculation is seen to develop 
at the syringe wall. Size and definition grow with increased plunger velocity. 
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When the plunger in the downstream syringe is near the capillary outlet, this 
effectively causes a second extensional flow region around the stagnation 
point which has formed on the on the plunger face exactly opposite the 
capillary outlet. The phenomena can be thought of as a fluid jet meeting a 
perpendicular, flat target. 
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Figure 5-21: 2D axisymmetric streamline plot showing the flow field 
development as the downstream syringe plunger recedes at 2 
mms-1. Measurements are given in mm. 
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Figure 5-22: Streamline plots showing the development of the 
flow fields for various plunger velocities for a given 
downstream plunger position (60 mm). 
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Figure 5-23: 2D axisymmetric velocity profile of the jet of fluid leaving 
the capillary outlet and impacting the downstream syringe 
plunger, before turning through 90°. In this instance, the 
downstream plunger is located 5mm from the capillary outlet. 
Profiles are shown for a range of plunger velocities (as stated). 
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It is important to note that the streamline positions in Figure 5-25 are 
measured in the radial direction at the capillary outlet only. The path naturally 
deviates radially up- and downstream of this point. For the transitory 
extensional flow region, maximum strain rate is shown to increase with 
distance from the axis. For the stagnation point region, maximum strain rate 
decreases with distance from the axis. The intensity of strain around the 
stagnation point also decreases universally as distance from the outlet jet 
increases. 
By comparing the flow rates at varying distances from the axis, it can be seen 
that the highest throughput occurs at 1 mm from the origin. Stagnation strain 
rates drop below transitory strain rates universally for radii greater than 0.06 
mm. This accounts for approximately 67% of the flow at any given time. For 
downstream plunger distances within 8 mm of the outlet jet, 27.9% of fluid 
experiences greater strain at the stagnation point than through the transitory 
m
m
D
irection of flow 
8 mms-1 10mm s-1 12 mms-1 14 mms-1 16 mms-1 
Figure 5-24: 2D axisymmetric strain rate profile of the jet of fluid 
leaving the capillary outlet and impacting the downstream syringe 
plunger, resulting in the formation of a stagnation point. In this 
instance, the downstream plunger is located 1 mm from the 
capillary outlet. Profiles are shown for a range of plunger 
velocities (as stated). 
s-1 
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extension region. This drops to below 3.3% for distances of 16 mm as shown 
by the graph in Figure 5-25. 
 
Figure 5-25: A comparison of the maximum strain rates experienced by 
a fluid particle as it travels along a streamline that passes through 
the capillary inlet at a given radial position. The particle experiences 
a transitory strain rate as it passes through the extensional flow 
region, and a stagnation strain rate as it passes near to stagnation 
point on the downstream plunger. The maximum stagnation strain 
rates are given for varying distances of downstream plunger. Inlet 
velocity generated by the upstream plunger moving at 8 mms-1. 
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6. Experimental Design, Methods and Materials 
In the preceding chapters a computational study was described drawing on 
previous literature and fluid dynamic theory. The computational model 
explored the effects of extensional flow in an axisymmetric geometry with a 
step constriction, together with investigating the effects of angled constrictions 
with angles of 45° and 30°. The purpose of these studies was to assess the 
validity of an experimental setup capable of exposing protein in solution to an 
extensional flow field, and to allow an assessment the effects of extensional 
flow on protein aggregation. To do this, the presence of other flow 
characteristics were also documented; (i) the presence and magnitude of 
shear, (ii) the transition of extension to shear and (iii) the presence of a 
stagnation point in the downstream syringe barrel. 
From these simulations, it was possible to produce a methodology for testing 
the effects of extensional flow on protein aggregation, taking into account 
other factors present in the flow. 
To achieve this, the development of a bespoke extensional flow cell is 
presented in this chapter. This will include the production of a specification 
which is used to further analyse existing methodologies from previous studies. 
Using the information from this methodology review, combined with data 
presented in the computational results chapter, a bespoke flow-cell is 
designed. The design includes a mechatronic control strategy as well as 
mechanical and fluid mechanical consideration. 
A standard procedure for using the device is explained in order to remove a 
degree of experimental error. This includes details about assembly as well as 
sample loading and unloading. The formulation of samples is detailed for each 
protein. 
A plan of experiments is also presented in this chapter. This includes a 
justification for each test case. The plan includes a series of experimental 
controls. These were included to satisfy the requirement of decoupling strain 
from shear and downstream factors. 
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The techniques used for measuring and characterising the magnitude of 
aggregation are then be described. 
6.1. Design of experimental equipment 
A method of subjecting soluble protein to clearly defined flow fields was 
required for the current work.  The method had to satisfy a number of 
requirements in order to be scientifically relevant and practically justifiable. 
Several previous methods have been reviewed in earlier sections in terms of 
the work produced; what follows is a brief review of these methods in terms of 
specification in order to assess their viability to the current work.  
6.1.1. Design Scope 
The design scope of the experimental methodology is explained here. Design 
scope is used to define exactly what areas were to be investigated and by 
what means. In the Literature Review section a formal research proposition 
was presented. This section is aimed at adding the necessary boundaries and 
restrictions around that to give the research a defined focus. 
As previously stated, this work was concerned with the contentious topic 
around the effects of extensional flow on proteins. Experimental equipment 
and methodologies were designed in keeping with previously presented 
computational studies. A design specification was developed, with the 
originality of the specification being validated against previous work. 
Equipment and methodologies proposed took into account the complex nature 
of fluid mechanical theory and drew upon the results of the computational 
study. The equipment and methods inevitably had limitations; these were 
understood, discussed and mitigated wherever possible.  A selection of 
proteins was made for experimentation; these included well documented 
proteins which have been used in previous studies as well as clinically 
relevant proteins so as to provide correlation with the biopharmaceutical 
industry. Methods of analysing and characterising protein aggregation ex-situ 
were defined and used. Experiments were carried out using the bespoke 
equipment and samples were characterised using the proposed methods. The 
current method does not include a process for characterising the unfolding 
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and aggregation process in real-time within the flow cell. Nor did the current 
method work toward integration within an ‘online’ characterisation technique. 
The current work did, however, draw conclusions from the ex-situ results as 
the nature of aggregation pathways within the device. Potential methods and 
benefits of in-situ and online characterisation techniques were addressed as 
a topic of potential future study. 
6.1.2. Device Specification 
Presented in this section is a table of requirements for the current method. 
Each specification point is presented in terms of a parameter, the 
requirements of that parameter, and a justification for the stated requirements. 
Definitions of the parameters can be found in the Theory section.  
Parameter: an experimental control, a variable, or a dependent which can be 
held constant, adjusted, or measured as part of the experimental method. 
Requirement: the limits of the parameter which were deemed acceptable to 
the experimental method. 
Justification: the argument as to why a parameter has be specified to fall 
within defined values. 
The flow profile had to contain an extensional, strain-dominated region 
capable of producing a strain-rate in the magnitude of ≥104 s-1. This value is 
typical of shear- and strain-rates presented in previous work [2, 4, 24, 79] as 
well as the forces present in manufacturing equipment [118-122]. 
The maximum Reynolds Number (Re) had to be no greater than Re = 3000. 
This number represents the upper bound of a fully laminar flow regime and 
laminar flow had to be maintained so as to allow for accurate tracking of 
streamlines for statistical analysis. 
The current work also had to include a technique to vary strain independently 
of shear. This was necessary because shear is present in all extensional flows 
and has previously been presented as a major contributor to protein 
aggregation. 
The experimental flow method had to limit sample exposure to gas-liquid 
interfaces during setup and sample recovery, and remove all such interfaces 
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during flow cell operation. Gas-liquid interfaces are well documented in 
producing the necessary surface energies to unfold a protein [123] and as 
such, should not be present in a purely fluid mechanical study. 
The proposed method had to be fully repeatable with flow rates and sample 
volumes being precisely controlled. Strain and shear magnitudes are often 
coupled to flow rate such that accurate control over the device speed will allow 
for detailed mapping of aggregation response against fluid force. 
Protein samples had to only come into contact with materials which were 
chemically inert and hardened against polymer leaching. Failure to achieve 
this may result in proteins adhering to surfaces within the flow cell and  change 
the surface energy, resulting in increased aggregation propensity. 
The method requires a sample volume in the region of 0.5 – 1 ml per 
experiment with a protein concentration in the region of 0.5 – 10 mg·ml-1. 
Experimental therapeutic antibodies are often expensive and time consuming 
to produce prior to plant-scale production. As such, a flow device aimed at 
pre-upscale analysis had to be sympathetic to these limitations. 
The method had to allow for exposure time to extensional flow to be varied 
experimentally without the need to expose the sample to other factors such 
as external materials, gas-liquid interfaces or long periods of time between 
exposures. Such factors were likely to affect aggregation propensity and had 
to be excluded from test procedures. The methodology specification is 
summarised below in Table 6-1. 
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Parameter Requirement Justification 
Flow Profile 
 
 
Must have a strain-dominated 
region within in the flow 
geometry. 
To expose the majority of the fluid 
sample to predominantly 
extensional flow. 
Reynold’s 
Number 
Laminar; typically, Re <3000 A development on the previous 
point; Re further defines the flow 
profile. 
Strain rate ≥ 104 s-1 Industrial processes often produce 
strain values of this magnitude 
[118-122]. 
Shear 
dependence  
The ability to modify the 
amount of extension without 
changing shear 
To demonstrate shear 
independent aggregation. 
Liquid-gas 
interfaces 
Must be limited during setup 
with minimal agitation during 
sample loading. No liquid-gas 
interfaces should be present 
during flow-cell operation. 
Interfacial phenomena introduce 
surface energies which are 
capable of inducing aggregation. 
Repeatability  Must have a control system 
that allows for precise control 
of flow rate across multiple 
experiments. 
To ensure repeatability and direct 
comparison between 
experiments. 
Materials  Must be chemically inert and 
resistant to leaching. 
To reduce the addition of 
interfacial effects into the flow 
profile results. 
Sample 
volume 
0.5 ml < Volume < 1 ml per 
experiment. 
 
Sample size is restricted by cost of 
pharmaceutical antibodies as well 
as characteristic techniques which 
require a minimum volume. 
Exposure 
time or 
exposure 
counts 
Flexible without exposing 
sample to gas interfaces/ 
external materials or factors  
To allow exposure time to be used 
as an experimental control 
without the addition of other 
external factors which may also 
lead to aggregation. 
Table 6-1: Design specification matrix for the experimental method 
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6.1.3. Design review of previous experimental methods 
A specification was proposed for the experimental methodology of the current 
work. It is important now to compare the proposed method to that of previous 
studies. This has two purposes; the first is to critically evaluate the proposed 
method and validate the originality of the work. The second is determine 
whether aspects of previous methods could inform, be adapted, or be 
improved upon to further develop the current work. The next section will be 
broken down into types of flow device and will refer to the Device Specification 
section. A detailed description of the devices and previous studies can be 
found the Literature Review. 
Taylor-Couette Flow Cell 
The Taylor-Couette Flow Cell [43, 55] briefly consists of two concentric 
cylinders of different diameter, one rotating within the static counterpart, with 
a fluid sample contained in the breach between them. The Taylor-Couette 
Flow Cell is purely a shearing flow device and as such is unsuitable for the 
current work. Despite this, it is laminar and void of any complex (from a fluidics 
perspective) pumping equipment. Further shortcomings include the presence 
of a gas-liquid interface and large sample size. 
Four-Roll Mill 
The four-roll mill [50] consists of four rotating cylinders encased within a 
reservoir which contains the sample. The rollers can be rotated in different 
directions in various combinations to produce a range of extensional and 
shearing flows. This allows them to produce high strain rates. Additionally the 
absence of a pump makes for a simple flow history of the sample. However, 
the dimensions of the reservoir and roller configuration means that a large 
volume is required and air-liquid interfaces are often present which are 
challenging to exclude without influencing the flow profile. The extensional 
flow region also takes up a very small section of the overall volume with most 
of the sample dominated by shear flow. This makes if challenging to determine 
what proportion of aggregation is due to extension. Varying extension 
independent of shear would also prove problematic as both are dependent on 
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roller speed. Device geometries would have to be adjustable which introduces 
new variables such as sample volume. 
Opposed Jets 
Opposed jet devices [50] place two nozzles opposite each other and pump a 
sample out of both simultaneously such that a stagnation point is formed 
where the streams converge. This method can produce very high strain rates. 
The sample had to however, be passed through a pump which adds 
complexity the flow history of the sample. Large volume reservoirs are also 
used the store the sample, making this device unsuitable for the current 
method. 
Stenotic Indentation Microchannel 
The stenotic indentation microchannel [49] is an etched 2D path with a 
constriction introduced on one wall. By producing multiple versions of the 
geometry, the strain rate is made to vary. Although, in this instance, varying 
the constriction size alters the minimum cross sectional area, resulting in 
increased strain. The design of the device does lend itself to small sample 
sizes. In this instance, the device is driven by a pump, but could be adapted 
to run from a syringe driver. 
High Viscosity Cylindrical Tubing 
By applying a high mass flux across a narrow, constant cross sectional area 
[43] a region of high shear can be produced. Although this is a simple shear 
device, extensional flow could be achieved with a modified flow geometry. 
Noteworthy aspects of this device include the cylindrical cross section which 
is conducive of a laminar flow regime, and the potential for a small sample 
size. This device does require an external pump, although it could also be 
adapted to use a syringe driver. 
Etched Elongational Microchannel 
Etched elongational microchannels [9] are microns-deep pathways sintered 
into PEEK or glass substrate. Such devices can produce complex geometries, 
and as such can be used to develop varying degrees of extensional flow 
independent of shear. The dimensions involved also accommodate for small 
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sample sizes. The flow cell does, however, require the use of a pump and 
lengths of tubing for the sample to be driven through the device. The 
manufacturing technique of these devices also limits the cross sectional shape 
to a rectangular form. This could complicate the flow profile, and increase 
modelling and simulation time. Following this review of currently available 
defined flow field devices, it is clear that the requirements of this work are not 
met by previous methods.  
 
A summary of the specifications of the above devices is presented in Table 
6-2. It is worth noting that some factors, such as pumps, are external to the 
devices themselves and could potentially be mitigated with the correct choice 
of external factors, but this is beyond the scope of the current work. 
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Device/ method Satisfies specification Fails specification 
Taylor-Couette 
flow cell [43, 55] 
- Low Reynolds number; 
typically, in the region of 
330-1618. 
- Flow cell is self-contained 
with no pumps. 
- Capable of high shear 
rates. 
- Air-liquid interface present 
in the flow cell. 
- Not possible to vary strain 
rate independent of shear 
rate. 
- 390ml per sample, although 
smaller cells could be 
adapted from this method. 
Four-roll mill [50] 
 
- Strain rate up to 15x103. 
- Flow cell is self-contained 
with no pumps. 
 
 
- Air-liquid interface present 
in the flow cell. 
- Large volume. 
- Residence time dependent 
on location relative to 
stagnation point.  
- Large amount of dead space 
in reservoir around rollers. 
Opposed jets [50] 
 
- Strain rate up to 15x103. 
- Hydrophobic siloxane to 
prevent sample 
adsorption. 
- Fluid moved through device 
via a pump. 
- Large volume stored in two 
reservoirs with air-liquid 
interfaces. 
PDMS Stenotic 
indentation 
microchannel [49] 
- Variable strain rate 
independent of shear by 
changing flow cell 
geometry. 
- Small sample size. 
- High shear and complex flow 
profile due to shallow 
channel. 
- Driven by a pump. 
High viscosity 
cylindrical tubing 
[43] 
- Simple, cylindrical flow 
profile. 
- Small sample 
requirement. 
- Driven by a pump 
- other features present which 
are not accounted for, i.e. 
contractions and nozzles. 
- No function to vary strain 
rate independent of shear. 
Etched 
elongational Micro-
channels [9] 
- Small sample sizes. 
- Various geometries allow 
for strain rate to be varied 
independent of shear. 
- Requires a pump or syringe 
to drive fluid across the flow 
cell. 
- Shallow, rectangular cross 
section produces high-shear, 
complex flow profile. 
Table 6-2: Design review summary of previous methods 
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Arising from this study was the requirement for a method of producing the 
pressure differential required to drive a flow cell without introducing the 
complex flow regimes associated with pumps. Atkins & Taylor [50] drive an 
opposed jets apparatus with a peristaltic pump which at low speeds would 
maintain the laminar low in a tube, but still required a reservoir which reduces 
the certainty of flow history across the whole sample. 
Smaller samples with exact precise flow histories could be achieved using a 
syringe driver attached to a flow cell. But again, the sample would likely pass 
through a series of high-shear tubes or expanding - contracting regions before 
reaching the flow cell. After traversing the flow cell the sample would then 
have to be collected. This would be challenging without exposing the sample 
to a liquid-gas interface. 
A concept for an extensional flow device is presented in the following sections 
taking into account these considerations. 
6.1.4. Design of Experimental Equipment 
A solution to the specification laid out for this experiment will now be 
presented. 
Initial concept 
It was proposed that two opposing syringes mated by a single glass capillary 
and driven by a bespoke syringe pump would satisfy the specification 
requirements. A schematic of the initial concept can be seen in Figure 6-1. 
The solution was loaded into one syringe through the capillary by means of 
drawing up the syringe plunger. The free end of the capillary was then 
attached to the nozzle of a fully depressed syringe and sealed. This ensures 
all gas was expelled from the system. The sudden reduction in cross-sectional 
area between the syringe barrel and the capillary produces the abrupt 
contraction necessary to induce extensional flow as discussed in the Theory 
chapter. 
The opposed syringes were then be placed in a bracket which will hold the 
syringes at a fixed distance apart while the plungers were driven by a 
computer-controlled actuator. This ensures accurate and consistent speed.  
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As the entire sample was enclosed within the opposed capillary system 
without the need for an external reservoir, it was possible to pass the full 
sample through the device without the need to consider the effects of stagnant 
fluid or dilution effects. In this way, an accurate flow history was established 
for the entire sample. 
The sample can also be passed back and forth though the opposed syringe 
system multiple times, allowing for aggregation to be measured as a function 
of number of passes or exposure time to strain. 
The use of a narrow capillary and the relatively high flow velocity that this will 
induce results in a high shear rate within the capillary. As discussed in the 
theory section, high strain flow environments are often coupled with regions 
of high shear. The presence of shear in a laminar flow cell is unavoidable, but 
the effects can still be accounted for. A control method for the high shear 
region was proposed in which the length of the capillary, and therefore the 
exposure time to high shear, was reduced whilst holding all other aspects of 
the experiment constant. This identifies any aggregation dependence on 
shear exposure time. A detailed plan for the control experiment can be found 
in the Experimental Plan section. 
 
 
Plunger velocity 
Syringe 
Plunger 
Protein 
solution 
Thin 
capillary 
Abrupt 
contraction 
Figure 6-1: Schematic of equipment setup for the proposed 
experimental method. The fluid sample is shuttled between two 
syringes. 
Motor driven 
Mechanical 
linkage 
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The capillary length control experiment answers the question of shear 
exposure, but does not cover the topic of magnitude. I.e. is aggregation 
triggered by a particular value of shear or strain rate irrespective of exposure 
time? To explore this an experiment was proposed which varies the geometry 
of the inlet angle of the contraction from the syringe barrel to the capillary. To 
do this, a series of bespoke capillary sections were manufactured with angled 
nozzles at either end resulting in a gradual reduction in the flow profile cross-
sectional area. If the length of the capillary section and flow rate remain 
constant, the maximum shear value will stay the same whilst the various 
angles will give different maximum strain-rate values. This identifies whether 
aggregation increases with strain-rate in the presence of constant shear. The 
design of these parts is presented in the Computer Aided Design section of 
this chapter, the experiment itself is explained fully in the Experimental Plan 
section. 
With the use of a computerised control system, the effects of flow rate can be 
explored with high accuracy. The higher plunger velocities results in higher 
strain and shear values which were correlated against aggregation propensity. 
The control system will be discussed in the Control theory section. 
Open-Source and Off-The-Shelf Equipment 
Off-the-shelf (OTS) components have the advantage over custom 
components in that they are readily available, produced to predetermined 
standard, and require only a working understanding of the part by the user. 
The disadvantage of OTS is that the component specification is often based 
on a generic case. This means that the most suitable OTS part will likely be in 
excess of the assembly specification requirement, or may even drive the 
assembly specification. A compromise can be found in the after-market 
modification of OTS components, though it is advisable to limit the complexity 
of after-market modifications.  
Open-source often refers to software which is released for public use as well 
as further development. It also refers to component design. For instance, the 
design of programmable logic controllers (PLC), microcomputers, and other 
areas of mechatronics. The value of open-source electronic hardware design 
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is in the availability of low-cost products which have had countless human-
hours of development, accompanied with many readily available examples of 
how best to use such products. 
Syringes 
A critical part of the design of the rig was the syringes. The syringes were 
required to be gas-tight, but with low a low-friction plunger. The materials had 
to also be chemically inert. 
The syringe chosen for this was the 1 mL model 1001 RN Valco gastight 
syringe produced by Hamilton Syringes. The syringe has a 1 mL capacity and 
a 4.61 mm inner barrel diameter. The fluid path within this syringe encounters 
borosilicate glass and a PTFE coated syringe plunger [124]. The orifice 
diameter was enlarged to take a 1 mm outer diameter borosilicate capillary. 
Capillaries 
Once a syringe has been selected, a capillary can be selected based on the 
relative diameter. The material should be chemically inert with a smooth finish. 
Borosilicate glass is a common material for laboratory glassware due to its 
high thermal shock resistance and, more importantly in this application, its 
high chemical stability and resistance to leaching [125]. A borosilicate capillary 
of length 75 mm, outer diameter 1 mm and inner diameter 0.3 mm was 
selected. This produced a reduction in cross sectional area with a ratio of 
238:1. 
To form a seal around the capillary, a 1 mm compression fitting, Hamilton 
55750-01, consisting of a stainless steel nut, a PEEK cup ferrule and a PFA 
cone ferrule were used to secure the capillary to the syringe.  
Mounting Board 
To secure the two syringes in place, a Thor Labs aluminium optics 
breadboard, MB1560/M, dimensions 150 mm x 600 mm x 12.7 mm was 
selected. A Thor Labs dovetail optical rail, RLA300/M, with two extended 
dovetail rail carriers, RC2/M, were used to locate the syringes. The syringes 
were clamped in place with two small V-clamps with clamping arm, VC1/M 
and PM3/M respectively. This assembly can be seen in Figure 6-2. 
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Bespoke Syringe Driver 
In order to drive the syringe plungers in both directions, a bespoke syringe 
driver was integrated on to the mounting board. The syringe driver requires a 
linear actuator which is covered in the Control theory section, and a purpose-
designed bracket to connect the linear actuator to both syringe plunger which 
is covered in the Computer Aided Design section. The syringe driver also 
requires a linear rail to ensure that all motion was constrained to a single 
direction. To achieve this, an NSK PU series, linear guide rail, 
P1U090600SKN-PCT, was mounted to the optics board. Two corresponding 
NSK linear guide carriages, PAU09TRS, were selected to connect the plunger 
brackets to the rail. 
Computer Aided Design 
Computer aided design (CAD)  was used to design the bespoke parts 
necessary for the current work. These include the brackets used to mount the 
syringe plungers to the linear actuator and linear rail, and the varied angle 
contractions. 
 
 
 
Optics breadboard 
Dovetail rail 
Dovetail rail carrier 
V-clamp 
Figure 6-2: CAD image showing location of dovetail rail, rail carrier 
and V-clamps on Thor Labs optics breadboard with syringes in 
place for reference.  
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Bracket Design 
A bracket was required to transmit the work done by the linear actuator to the 
syringe plunger. Both syringes were mechanically secured to each other via 
a studded steel shaft of 6 mm diameter. The bracket was secured to the shaft 
using a grub screw. Four screws mount the brackets to the linear carriages. A 
threaded hole allows for the drive nut on the linear actuator to attach to the 
bracket. The syringe plunger was secured by clamping the handle between a 
flat plate and two prongs. The brackets was machined from stock aluminium. 
An image of the model can be seen in Figure 6-3. 
Angled geometry design  
The method requires a device that can vary strain rate independently of shear. 
This was achieved by removing the end from a pair of syringes to produce a 
straight, glass tube, and designing a series of fitted funnels to attach the two 
syringes together. The funnels all have different contraction angles but share 
the same capillary diameter and length. 
The first design for an angled flow geometry, shown in Figure 6-4(a) used an 
interference fit and was dependent on the firm clamping of the two opposed 
Location for shaft 
connecting two 
brackets 
Mounting points for 
linear carriage 
Location for 
lead screw nut 
Grub screw to 
secure connecting 
shaft 
Syringe plunger 
handle clamped 
between plate 
and prongs 
Figure 6-3: CAD image of bracket designed the secure the syringe 
plunger to the linear carriage and transmit the work done by the 
linear actuator to the plungers 
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syringes to form a seal. The material chosen was nylon. The part was 
machined from stock bar. The capillary was drilled using a precision 0.3mm 
cutter. The fine diameter of the cutter limits the length of the capillary section 
to 12mm. This was considerably shorter than the capillary proposed for the 
abrupt contraction experiments so a control piece with a right-angled, abrupt 
contraction was proposed to be manufactured in the same fashion. 
The interference fit did not provide an adequate seal, however the material 
and flow channel cutting techniques were both successful and were carried 
forward onto the next design. 
A clearance was added between the interior wall and the capillary, as seen in 
Figure 6-4(b-i) and a flexible PTFE ferrule was added to the end of the syringe. 
A thread was cut into the wall and a collar with a corresponding thread was 
added to a pipe fitting. As the pipe fitting was screwed into the nylon section 
the PTFE ferrule deforms and grips to the syringe, producing a seal, Figure 
6-4b-ii). 
 
6.1.5. Control theory 
With the flow-cell fully defined, a suitable actuator and control system needs 
to be developed. The actuator requires between 50 and 120mm of linear 
Figure 6-4: Designs for an angled contraction. a) used an interference 
fit to form a seal. b) used a threaded collar section to compress a 
PTFE ferrule to form a seal. b-i) shows half of the angled section 
with the threaded attachment and modified syringe in place. the 
cut-through in b-ii) shows the location of the PTFE ferrule. 
a) 
b-ii) 
b-i) 
0.3 mm capillary 
Angled contraction 
PTFE ferrule 
Threaded collar 
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motion, with enough force to drive the fluid in the plunger through the narrow 
constriction as well as overcome the friction of the two plungers. The linear 
actuator had to also produce the motion in a consistent and repeatable 
fashion, including acceleration and deceleration at the end of each pass. The 
distance travelled in each pass had to also be identical. 
Linear actuators 
Linear actuators are available in many forms such as electric, pneumatic, 
hydraulic or a combination of these [126]. Pneumatic linear actuators provide 
fast motion over an accurate displacement but are not good for controlling 
speed. Hydraulic actuators provide good speed control and accurate motion 
but are designed for application requiring large amounts of force and often 
require complex ancillaries such as fluid reservoirs, accumulators and pumps.  
Electric linear actuators have been designed for a wide range of applications 
with most using a brushless motor to drive a leadscrew. The simplest way to 
drive an electric linear actuator is to do so without sensor feedback, requiring 
a highly accurate motor. This was best achieved with a stepper motor. 
Stepper motors 
A stepper motor is a brushless DC electric motor designed for applications 
requiring precise angular positioning and velocity. Stepper motors typically 
have slow rotational speeds with high holding torque. Precise motion was 
achieved using a high number of permanent magnets and coils which allow 
the motor to be actuated and held to an accuracy typically of 1.8°. This 
resolution can be increased to 0.35° at the cost of reduced angular velocity 
and holding torque. 
The rotational motion of a stepper motor was transmitted to a linear actuator 
with a studded lead screw. The pitch of the lead screw determines the linear 
velocity of the actuator, with higher velocities delivering reduced driving force. 
The stepper motor used was the Haydon E28H4. The motor has a step angle 
of 1.8° which corresponds to 225 steps per revolution. The lead screw has a 
thread pitch of 2.8125mm. This translates to a linear displacement of 
0.0125mm per 1.6° step. In order to drive the syringe plunger at 8mms-1, for 
example, the stepper motor must rotate 1024° which requires 640 steps. 
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A stepper motor is a permanent magnet electric motor designed for highly 
accurate rotational speed and position. There is a compromise between speed 
and accuracy, as well as speed and power. 
No. Steps per 
second 
Plunger velocity/ 
x10-3 ms-1 
Average capillary 
flow velocity/ ms-1 
Flow rate/ mls-1 
640 8 1.889 0.134 
800 10 2.361 0.167 
960 12 2.834 0.200 
1120 14 3.306 0.234 
1280 16 3.778 0.267 
Table 6-3: Stepper motor relation to flow velocity 
 
Integrated micro-controllers 
A computer system was required to control the stepper motor that powers the 
linear actuator. The system selected for this was that Arduino Uno R3. The 
Uno is an open source, single board microcontroller [127]. It has a single 
16MHz 8-bit ATmega328/p processor with 32 KB of flash memory [128], 14 
digital input/output pins and a maximum operating voltage of 20 V [129]. 
The microcontroller controls the stepper motor through a stepper motor driver 
board. The driver board used here was the EasyDriver  Stepper Motor Driver 
v4.3 [130]. The driver board connects to a 4-wire bi-polar stepper motor, 
converting a digital 5 V pulse signal from the microcontroller to precise 
rotational motion. The driver board requires a 6 – 30 V power supply, and so, 
can share a 20 V bus with the Uno R3. 
6.2. Final specification of experimental equipment & method 
of use 
6.2.1. Experimental equipment 
The final specification has been modelled in CAD in Figure 6-5. The position 
of the two syringes can be adjusted using the dovetail rail. This allows for 
shorter capillaries to be fitted as well as modified syringes with bespoke flow 
geometry connectors. 
- 114 - 
 
 
The placement of the stepper motor with lead screw allows for the full bore of 
the syringe to be utilised, giving a maximum sample volume of 1 ml.  
The linear rail with carriage system counteracts the torque from the stepper 
motor to effectively convert the rotational motion into a smooth linear motion 
with enough force to drive the syringes. 
 
6.2.2. Method 
The capillary was fitted to a single syringe using a compression fitting. The 
protein solution was drawn into the single syringe very slowly by hand through 
the capillary so as not to damage the protein prematurely. The loaded syringe 
was then positioned in a V-clamp and the empty syringe was placed in the 
opposite V-clamp with the plunger full depressed. A second compression 
fitting was used to secure the empty syringe to the capillary, forming a gas-
tight seal. 
The microcontroller was then programmed to move a set linear distance at a 
constant speed with a small acceleration time so as to fully depress the 
plunger of the loaded syringe, transporting the entire sample to the second 
syringe via the capillary and the extensional flow region. The syringe plungers 
were linked hydraulically through the protein solution such that, as one syringe 
plunger was depressed, the fluid forces cause the other to be expelled from 
Figure 6-5: A computer model of the experimental rig configured for 
extensional flow using glass capillaries 
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its syringe jacket. The syringes were flushed with 2 % (v/v) Hellmanex-III 
solution and MilliQ-grade H2O prior to each run, followed by a final wash with 
0.22 µm-filtered (Merck Millipore) and de-gassed buffer. 
A new capillary was used for each experiment. The capillary was filled with 
buffer from the recently washed syringe so as to remove any air. Due to the 
dimensions of the capillary relative to syringe, the effect on sample 
concentration was negligible. 
In using the angled contraction pieces, the same preparation was applied to 
the modified syringes. The modified syringes, however, have a wider orifice 
allowing for the sample to be pipetted into the barrel with the plunger set to 
the correct displacement. The threaded collar was placed around syringe with 
the PTFE ferrule located around the end of the syringe. The angled 
contraction piece was then screwed in place, compressing the ferrule to form 
a seal. 
The plunger was compressed allowing the sample to flood the flow cell and 
the second syringe was attached with the plunger fully depressed to expel any 
air. 
6.3. Limitations and considerations 
6.3.1. High shear in capillary 
It has been stated that the capillary in the device produces a high shear region 
which could be contribute to the aggregation of protein. To explore this 
possibility, a control experiment was proposed to measure the effects of 
capillary length on aggregation. 
6.3.2. Geometry accuracy 
It was important to draw a comparison between the computer model and the 
experimental device in terms of the experimental flow cell geometry. In the 
capillary configuration , the 90° step contraction was formed by the edge of 
the capillary. The capillaries used in this experiment were etch-cut and fire 
finished. This produces a sharp 90° angle with a slight fillet with a radius in 
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the region of <0.5µm [131]. This size of fillet was negligible and so was not 
included in the computational model. 
6.3.3. Downstream stagnation point 
From CFD studies it was shown that as the plunger recedes from the capillary 
outlet in the downstream syringe, a stagnation point was generated at the 
centre of the plunger face. The intensity of the extensional flow field around 
this point changes with plunger position and plunger velocity. The nature of 
the field was such that the strain rate decreases with radial distance from the 
axis of symmetry. 
It was hypothesised that extensional flow is, in part, responsible for flow 
induced protein aggregation. In order to quantify this, the effect of this 
extensional flow region has to be quantified in terms of its likelihood to induce 
protein aggregation. 
When the downstream stagnation point was compared to the upstream 
extensional flow region in terms of strain rate, it can be seen when the plunger 
was close to the capillary outlet, the peak values in the stagnation point were 
comparable to those seen by the bulk of the fluid traversing the extensional 
flow region. The fact that only a very small volume of fluid passes within the 
effective range of the stagnation point means that it was unlikely for this 
phenomenon to greatly affect the amount of aggregation within the sample.  
To test this, a control experiment was proposed that removes the most 
extreme strain rates from the stagnation point. This would be achievable by 
stopping the plunger before it fully completed a whole pass through the 
syringe. The result would be that the plunger surface will remain at sufficient 
distance from the capillary outlet to allow the out-flowing jet to dissipate energy 
before impacting it. 
Stopping the plunger early would leave a residual volume behind in the 
syringe. The residual volume would not pass through the extensional flow 
region and would therefore not be encouraged to aggregate. Therefore it can 
be proposed that, if the stagnation point has no impact on aggregation, the 
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percentage of insoluble aggregate will be linearly proportional to the size of 
the dead volume. 
6.4. Protein Selection, Specification and Formulation 
Credit is due to L. F. Willis and A. Kumar at the School of Molecular and 
Cellular Biology, and the Astbury Centre for Structural Molecular Biology, 
University of Leeds, for their respective roles in the expression, purification 
and formulation of proteins and samples as outlined in the following steps.  
6.4.1. Bovine Serum Albumin 
Serum albumin is a blood plasma protein produced in abundance by the liver. 
In humans, serum album constitutes approximately 50% of all blood plasma 
protein [132]. Bovine serum albumin (BSA) is a serum albumin derived from 
cows. It is very well documented and understood [133, 134] and has been 
used in many previous flow studies [8, 135, 136] making it ideal to test the 
effectiveness of the current device.  
BSA is predominantly α-helical with 583 amino acids. It has a molecular weight 
of 66 kDa and a hydrodynamic radius of 3.5 nm. Figure 6-6 shows the tertiary 
structure of BSA. 
BSA was purified though a Superdex 200 (26/60) gel filtration column (GE 
Heathcare) equilibrated with 25 mM ammonium acetate buffer at pH 5.1 and 
stored in aliquots at −20 °C. The protein solution was then concentrated using 
Figure 6-6: Bovine serum albumin (BSA) topology diagram from the 
RCSB Protein Data Bank. ID code 3V03. Hydrodynamic radius of 3.5 
nm. 
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a centrifugal concentrator with a 30kDa cutoff filter (Merck Millipore). The 
solution was then filtered through a 0.22μm membrane (Merck Millipore) for 
the concentration to be determined using UV spectroscopy. The concentration 
was adjusted as necessary for the experiment. 
 
6.4.2. β2-Microglobulin 
Human β2-microglobulin (β2m) is a protein found on the surface of all 
nucleated cells and platelets in the human body [137]. It is a small protein, 
consisting only of 100 amino acids with a molecular mass of 11.86 kDa. It 
measures a mere 2.3nm in diameter with a hydrodynamic radius of 1.9 nm 
[138]. Figure 6-7 shows the tertiary structure of β2m. β2m is clinically 
significant as it is a constituent factor in in the formation of amyloid fibril 
aggregates during long-term courses of haemodialysis; a common 
complication known as dialysis-associated amyloidosis [139]. Dialysis is the 
extraction of whole blood from a patient, to be pumped through a series of 
filters, before being returning to the patient. It is therefore, the processing of 
biological material with multiple flow profiles resulting in the formation of 
unwanted aggregates. Hence, the flow induced aggregation of β2m will be 
studied here. 
 
Figure 6-7: β2-microglobulin (β2m) topology diagram from the RCSB 
Protein Data Bank. ID code: 1LDS. Hydrodynamic radius 1.9 nm. 
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The expression and purification of recombinant human β2m from a strain of 
Escherichia coli and has previously  been described [140, 141]. Extensional 
flow experiments were performed on β2m in filtered (0.22μm) and degassed 
25mM sodium phosphate buffer at  pH 7.2 [1]. 
 
6.4.3. Granulocyte Colony-Stimulating Factor 
Granulocyte colony-stimulating factor (GCSF) is a hormone consisting of 175 
residues. It measures 2.5 nm with a molecular weight of 18.8 kDa ad a 
hydrodynamic radius of 2 nm [142]. Its role as a hormone is to trigger bone 
marrow to produce stem cells and granulocytes, a type of white blood cell. 
Pharmacologically, GCSF is used to boost the number of white blood cells in 
patients undergoing chemotherapy to counter the effects of reduced immunity 
and low for more intensive treatment. Figure 6-8 shows the tertiary structure 
of GCSF. 
 
GCSF C3 [143] was overexpressed in BL21[DE3]pLysS cells transformed 
with a pET23a_G-CSF C3 vector and purified. The purification method can be 
found in the literature [1] and is reiterated below. 
Cell pellets were resuspended in lysis buffer (50mM TrisHCl, 5mM EDTA, 
2mM phenylmethanesulphonyl fluoride (PMSF) and 2mM benzamidine 
hydrochloride hydrate pH 8) at a ratio of 1g of cell pellet to 10mL of buffer and 
lysed by 5× 30 second periods of sonication on ice at 75% amplitude, using a 
Sonics Vibra-CellTM VCX-130PB sonicator with a 6mm diameter probe. 
Inclusion bodies were harvested by centrifugation at 15000rpm, 4°C for 30 
minutes, using a Beckman Coulter Avanti J-26 XP centrifuge with JLA 16.250 
Figure 6-8: Granulocyte colony-stimulating factor (GCSF) topology 
diagram from the RCSB Protein Data Bank. ID code: 5GW9. 
Hydrodynamic radius 2 nm. 
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rotor. Inclusion bodies were then washed by re-suspending in wash buffer 1 
(50mM TrisHCl, 5mM EDTA, 1% (v/v) triton X-100 pH 8) at a ratio of 1g of 
inclusion body pellet to 20mL of buffer and harvesting inclusion bodies by 
centrifugation as before. This wash step was repeated using wash buffer 2 
(50mM TrisHCl, 5mM EDTA, 4M urea pH 8). Washed inclusion bodies were 
resuspended in unfolding buffer (50mM TrisHCl, 5mM EDTA, 6M GdnHCl, 
10mM DTT pH 8) at a ratio of 1g of inclusion body pellet to 5mL of buffer and 
left to agitate overnight. The resuspended pellet was then centrifuged at 
15000rpm, 4°C for 1h, using a Beckman Coulter Avanti J-26 XP centrifuge 
with JA 25.50 rotor. The supernatant was diluted 1 in 10 with refolding buffer 
(50mM TrisHCl, 5mM EDTA, 0.9M L-arginine pH 8) and immediately dialysed 
into 5L of 20mM sodium phosphate, 20mM sodium acetate pH 4. After three 
dialysis 6 changes refolded G-CSF was centrifuged at 15000rpm for 30 
minutes and the supernatant was filtered through a 0.22μm filter. The filtrate 
was loaded onto a 5 mL HiTrapTM SP HP cation exchange column (GE 
Healthcare) at a flow rate of 5mL min-1 using an Äktaprime plus (GE 
Healthcare) system. A gradient of 0-100% elution buffer (20mM sodium 
phosphate, 20mM sodium acetate, 1M NaCl pH 4) was then run over 100mL, 
with 2mL fractions being collected. Fractions were pooled based on the results 
of SDS-PAGE analysis and desalted by dialysis. After desalting, pools were 
concentrated using Vivaspin 20 centrifugal concentrators with 5kDa MWCO 
PES membrane (Sartorius Stedim) until the protein concentration was approx. 
8-10mg mL-1 and snap frozen using dry ice and ethanol for storage at -80°C. 
Extensional flow experiments with G-CSF C3 were performed in filtered 
(0.22μm) and degassed 25mM sodium phosphate, 25mM sodium acetate 
buffer, pH 7.0.  
6.4.4. Model Antibodies 
Three model antibodies with known, yet varying propensities to aggregation 
were supplied by Medimmune. The typical tertiary structure of a monoclonal 
antibody is shown in Figure 6-9. 
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Two proteins were identical to each other with the exception of only six 
residues. The antibody designated MEDI1912_WFL was shown to possess 
three exposed hydrophobic binding sites at the locations  W30 and F31 in the 
complementarity-determining region (CDR) -1, and L56 in CDR-2 of each 
variable heavy domain. These sites were seen to be largely responsible for 
the protein’s high affinity for self-association and aggregation. To alleviate this 
effect, the three hydrophobic residues (W30, F31 and L56) were replaced 
systematically with other combinations of residues. The variant with the lowest 
aggregation propensity, MEDI1912_STT had mutated the tryptophan residue, 
W30, with serine, and both the phenylamine and leucine, F31 & L56, with 
threonine [144]. Both MEDI1912_WFL and MEDI1912_STT were selected for 
extensional flow analysis to determine whether the differing aggregation 
affinities of these two proteins could be detected. 
The third antibody supplied by Medimmune, designated mAb1, was selected 
for its low sequence identity with MEDI1912_WFL. mAb1 was representative 
of a protein which has been deemed fit for full-scale manufacture, having 
Figure 6-9: Example of a monoclonal antibody topology diagram from 
the RCSB Protein Data Bank. ID code: 1HZH. Hydrodynamic radius 
3.5 nm. 
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demonstrated greater than 95% monomeric purity post-process and a 
degradation rate of less than 2% per year in solution [1, 144]. 
The three IgGs were prepared by dialyzing into 0.22μm filtered and degassed 
150mM ammonium acetate buffer at pH 6.0, and diluting to a concentration of 
0.5mgmL-1. 
6.4.5. Summary of proteins 
The proteins to be used for flow induced aggregation are summarised in Table 
6-4.  
Protein BSA mAbs GCSF Β2m 
Amino Acids 583 ~1400 175 100 
Molecular weight 
(kDa) 
66 148 18.8 11.86 
Molar concentration 
at 1 mg·ml-1 
(µMol·ml-1) 
1.52x10-5 6.76x10-6 5.32x10-5 1.19x10-5 
Hydrodynamic 
radius (nm) 
3.5 6 2 1.9 
Extinction 
coefficient at 280nm 
(M-1·cm-1) 
43824 mAb1 = 207360 
WFL = 239440 
STT = 228440 
10220 20065 
Table 6-4: Summary of proteins for use in experiments 
 
6.5. Characterisation of Aggregated Protein 
6.5.1.  Nanoparticle Tracking Analysis (NTA) 
Native and stressed protein samples at a range of concentrations (1-10 mg·ml-
1)  were diluted in the ratios 1:2 and 1:5 for sample concentrations ≤5 mg·ml-
1 and >5 mg·ml-1 respectively. A Nanosight® LM10 (Malvern Instruments) 
equipped with a 642 nm laser was used and the resultant data analysed using 
NTA 2.3 software. 250 μL protein solution was injected into the sample 
chamber, ensuring no air enters the system. Three 90 second videos were 
recorded, analysed and averaged in the software for each sample. The 
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instrument parameters were set as follows: screen gain = 1, detection 
threshold = 10 nm, T=22 °C, viscosity = 0.95 cP and camera brightness = 4 - 
12 to minimise background noise. Particle size in NTA corresponds to the 
hydrodynamic diameter of the particles in nanometres. A 70% (v/v) ethanol 
solution was used to clean the device between samples and an air-duster was 
used to remove residual traces of ethanol from the inlets and O-ring followed 
by a buffer wash of the sample chamber prior to sample loading. The data 
was processed using Microsoft Excel® 2010 and plotted using Origin Pro® 
8.6 [1]. 
6.5.2. Transmission Electron Microscopy 
Transmission Electron Microscopy (TEM) is the technique of using “cathode 
rays”, i.e. beams of electrons, to excite a sample into producing a signal which 
can be recorded as an image. The advantage of using an electron as opposed 
to photons in the visible light spectrum (the excitation method of optical 
microscopy) is in the highly increased resolution available. The effective 
wavelength of an electron excited to 60 kV is 0.005 nm; one hundred-
thousandth that of green light [145]. 
20 μL protein solution, 5 and 10 mg·mL-1 samples were diluted 1:2 or 1:5 with 
their respective buffers was deposited onto carbon-coated EM grids for 45 
seconds at room temperature. Excess sample was blotted onto filter paper 
and the grid was washed with 3 × 20 μL of H2O, followed by staining in 10 μL 
of 2 % (w/v) uranyl acetate solution. Excess stain was removed by blotting 
and the grid allowed to air-dry. The grids were imaged using a JEOL 
JEM1400® transmission electron microscope at 120 kV. Images were 
recorded at 1000× and 10,000× magnification for each specimen using the 
AMT Image Capture Engine software Version 6.02 supplied with the 
instrument [1]. 
6.5.3. Insoluble Protein Pelleting Assay 
After subjecting the protein solution to the desired number of passes, the 
apparatus will be disassembled and 200 μL of protein solution will be 
subjected to  ultracentrifugation using a Beckmann Coulter Optima TLX 
Ultracentrifuge equipped with a TLA100 rotor at 30,000 rpm for 30 min at 4 
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°C. 150 μL of supernatant will then be removed and diluted to 2 mL for BSA 
or 250 μL for all other proteins in 6 M guanidine hydrochloride (Gdn HCl) 25 
mM TrisHCl buffer, pH 6. The pellet and remaining supernatant will be diluted 
in the same buffer to 2 mL (BSA) or 250 μL (all other proteins) and incubated 
overnight. The amount of protein in the pellet will then be calculated by 
measuring the protein concentration of this solution, the supernatant after 
ultracentrifugation, and the protein solution in the absence of extensional flow 
using UV-visible spectroscopy. This procedure will be performed in duplicate. 
UV-visible spectroscopy will provide a dimensionless measure of absorbance 
for the resuspended pellet and supernatant, 𝐴. By dividing the absorbance by 
the extinction coefficient, 𝜀 of units M-1·cm-1, and the path length, which was 
1 cm in the current work, the molecular concentration was obtained. As the 
concentration of the original sample was known, the percentage of insoluble 
protein contained within the pellet can be calculated. 
𝑐௙ =
𝐴௣ − 𝐴௦
𝜀 ∙ 𝑐଴
 
Where 𝑐௙ is the fraction of protein from the original sample which has 
aggregated and collected in the pellet, 𝐴௣ and 𝐴௦ are the absorbance of the 
resuspended pellet and the supernatant respectively, 𝜀 is the extinction 
coefficient of the protein, and 𝑐଴ is the original concentration of the sample. 
 
6.6. Experimental Plan 
A range of experiments are presented to test the effects of predominantly 
extensional flow on a range of proteins in solution in their native, folded state. 
The extensional flow will be produced by pumping the solution through an 
abrupt contraction, which will be modelled from a wide bore syringe flowing 
into a narrow capillary at a rate accurately controlled by an embedded micro 
controller. In-keeping with the aim of the project, this experiment was a step 
towards screening the structural stability of proteins. To that end these 
experiments will first attempt to impart a large amount of damage to the 
samples as a proof of concept. 
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The purpose of the extensional flow device was to explore the relationship 
between protein aggregation and extensional flow. The intensity of 
extensional flow was measured by the strain rate. The strain rate was shown 
to increase with flow rate. The amount of protein aggregation can then be 
related to strain rate by varying the flow rate for each sample. 
The protein was exposed to an extensional flow region every time it passes 
from a syringe barrel into the capillary. The number of passes is synonymous 
with exposure time to extensional flow. The effects of increased exposure time 
on aggregation can be explored by varying the number of passes per sample. 
The effects of strain rate magnitude on aggregation can be explored by 
varying plunger velocity. 
6.6.1. The Effects of Extensional Flow on Bovine Serum Albumin 
BSA aggregation dependence on exposure time to extensional flow 
and concentration 
BSA was prepared in samples of 1, 2, 5 and 10 mg·ml-1 and exposed to 500, 
1000, 1500 and 2000 passes through the extensional flow device at a plunger 
speed of 8 mms-1 for each concentration. Aggregation was quantified using 
the insoluble protein pelleting method. 
further samples were made up of the same concentrations and subjected to 
50, 100, 500, 1000 and 2000 passes. These samples were analysed by NTA 
and TEM. 
BSA aggregation dependence on strain-rate 
Samples were prepared at concentrations of 2.5 and 5 mg·ml-1 and subjected 
to 500 passes at plunger speeds of 2 – 16mms-1. Aggregation was quantified 
using the insoluble protein pelleting method. 
6.6.2. The Effects of Extensional Flow on Therapeutic Proteins 
mAb aggregation dependence on exposure time to extensional flow 
β2m and BSA will be prepared at 5 mg·ml-1. WFL, STT and mAb1 will be 
prepared at 0.5 mg·ml-1. All four therapeutic proteins, and BSA, will be 
subjected to 20 and 100 passes at plunger speed 8 mms-1. Aggregation was 
quantified using the insoluble protein pelleting method as well as TEM. 
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WFL was prepared at 0.5 mg·ml-1 and subjected to 10, 20, 50, 80 and 100 
passes at 8 mms-1 plunger velocity. Aggregation was quantified using the 
insoluble protein pelleting method. 
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6.6.3. Contraction Angle Experiments 
At this point it is still apparent that the increase in strain rate (i.e. extension) 
was applied by increasing the plunger velocity, and thus, increasing the flow 
rate. An increase in strain rate is, therefore, coupled to an increase in shear 
rate, as conservation of mass requires. 
A method was required that allows for extension to be varied independently 
of shear. To achieve this, a capillary was designed with an angled inlet to 
reduce the extensional flow, whist maintaining the maximum shear value 
within the capillary. The angled inlet geometry was produced out of stock 
nylon bar in two angles; 45° and 30°, relative to the axial flow direction. A 90° 
section was also produced to as a control, to eliminate the possibility that the 
material was responsible for any change in aggregation propensity.  
WFL was prepared at 0.5 mg·ml-1 and subjected to 50 passes at 8 mms-1 
plunger velocity through each contraction angle. Aggregation was quantified 
using the insoluble protein pelleting method. 
6.6.4. Control Experiments 
Shear dependence experiment 
As previously stated, an extensional flow field cannot exist without a 
component of shear. This was true within the extensional region of the current 
extensional flow device and cannot be avoided. Downstream of the 
extensional flow region, however, the sudden acceleration responsible for the 
extensional region was no longer acting and the flow becomes dominated by 
shear as the relatively high velocity fluid travels down a narrow capillary. 
The nature of the current device was such that the maximum shear cannot be 
altered without changing the maximum strain or device cross-sectional 
geometry. This presents a challenge for conducting a shear control 
experiment.  
One solution was to measure the magnitude of protein aggregation in 
response to exposure time to high-shear within the device. In the capillary the 
fluid was moving at a constant velocity, so time exposed to high-shear was 
proportional to the length of the capillary. A shear control experiment was 
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proposed to measure the extent of protein aggregation in relation to capillary 
length. If the protein was sensitive to shear, aggregation was seen to increase 
with capillary length. If the protein was unaffected by shear, and aggregation 
in shown to be independent of shear, it can be deduced that aggregation was 
dominated by the intensity of strain rate within the extensional flow region. 
BSA was prepared in samples of  5 mg·ml-1 and exposed to 1000 passes 
through the extensional flow device at a plunger speed of 8 mms-1 through 
capillaries of lengths 70 mm and 37.5 mm. Aggregation was quantified using 
the insoluble protein pelleting method. 
Dead volume experiment 
The same concentration of sample was made up to a larger volume. The 
excess volume of sample was distributed evenly between both syringes. The 
syringe plungers will travel the exact same distance as they did for other 
experiments, but the extra volume of sample will always remain in the syringe. 
This means that there will always be a greater distance between the inlet and 
the stagnation point that forms at the downstream syringe plunger face. 
STT was prepared in samples of 0.5 mg·ml-1 and exposed to 200 passes 
through the extensional flow device at a plunger speed of 8 mms-1. The 
experiment was carried out with the standard volume, allowing the entire 
sample to pass from one capillary to the other 200 times, and again with 
excess sample volume, leaving a 10 mm gap (approx. 0.08 ml) in the syringe 
after each pass. Aggregation was quantified using the insoluble protein 
pelleting method. 
6.7. Summary 
From previous work it is clear that extensional flow has been considered and 
explored experimentally. However, analysis of the papers suggest that the 
presence of external factors have not been satisfactorily controlled. To that 
end, equipment and a methodology have been designed to minimise non-
extensional fluid stresses where possible, and to take account of non-
extensional flow profiles where they were unavoidable. Initial tests were 
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carried out to assess the suitability of the equipment. The results from which 
were used to inform the final design and methodology. 
A number of limitations have been identified in the current methodology. 
These have been fully explored and mitigated where possible with the use of 
control experiments. 
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7. Experimental Results 
7.1. Introduction 
Preceding this chapter is a detailed experimental methodology. In that section, 
an experimental plan was laid out to test the validity of the device and the 
theory surrounding it. A number of experiments were proposed; some were 
intended to test the applicability of a technique whilst others were carried out 
extensively to provide comparisons between experimental variables. 
Credit is due to L. F. Willis and A. Kumar at the School of Molecular and 
Cellular Biology, and the Astbury Centre for Structural Molecular Biology, 
University of Leeds, for their respective roles in processing and preparing the 
necessary data for this chapter. 
7.2. The Effects of Extensional Flow on Bovine Serum 
Albumin 
7.2.1. BSA Aggregation Dependence on Exposure Time and 
Concentration 
As discussed in the Experimental Design, Methods and Materials section, 
BSA is a well characterised and understood protein, having been involved in 
multiple flow studies. The heritage of BSA makes it an ideal protein for initial 
assessment of the device, and its ability to induce protein aggregation through 
extensional flow. 
Insoluble protein pelleting method 
BSA was prepared in samples of 1, 2, 5 and 10 mg·ml-1 as detailed in the 
Protein Selection, Specification and Formulation section and exposed to 500, 
1000, 1500 and 2000 passes through the extensional flow device at a plunger 
speed of 8 mms-1 for each concentration. These number of passes equate to 
the total exposure times to the extensional flow region of 9, 18, 27, and 36 ms 
respectively, at a centreline strain-rate of 11,750 s−1 as shown in Table 7-1. 
The sample was also exposed to a maximum shear rate of 52,000 s−1 during 
every pass [1]. The total times of exposure were equivalent to 19.9, 39.7, 
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59.55 and 79.4 s for the four pass number respectively. These are presented 
in Table 7-1. 
Table 7-1: Accumulative time samples were exposed to strain and 
shear environment  
Aggregation was quantified using the insoluble protein pelleting method and 
the percentage of protein left in solution after stressing was plotted in Figure 
7-1. These data show that the extensional flow device can induce protein 
aggregation. The percentage amount of insoluble material increases with 
pass number and with concentration [1].  
For concentrations of 1 mg·ml-1, the percentage of soluble BSA remains within 
error of 100% until it was exposed to 2000 passes. Concentrations of 2 mg·ml-
1 show a slightly higher sensitivity to lower number of passes with a steady 
downward trend in the averaged data, although results for 500, 1000 and 1500 
passes were in error of each other. This suggests a downward trend for 
exposures in excess of 1000 passes for concentrations of 2 mg·ml-1.  
For concentrations of 5 mg·ml-1, a consistent, steady decrease in soluble BSA 
can be seen as pass number increases, whereas for the 10 mg·ml-1 
concentration the rate of aggregation was seen to increase with pass number. 
 
Number of 
passes 
Exposure time to 11,750 s-1 
strain-rate (ms) 
Exposure time to 52,000 s-1 
sheer-rate (s) 
500 9 19.9 
1000 18 39.7 
1500 27 59.55 
2000 36 79.4 
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Qualitative analysis of BSA 
To determine how the dispersity of BSA changes with increasing pass number 
samples were be made up of 1, 2, 5 and 10 mg·ml-1 concentrations and 
subjected to 50, 100, 500, 1000 and 2000 passes at 8 mm·s−1. The experiment 
was carried out twice and samples were analysed with nanoparticle tracking 
analysis (NTA) and transmission electron microscopy (TEM). 
NTA visualizes particles with hydrodynamic diameters of 10–2,000 nm, 
allowing for sizing and numeration of polydisperse colloidal solutions [1, 104]. 
Monomeric BSA has a hydrodynamic radius (Rh) of ∼3.5 nm and so was 
undetectable by this method. 
Hydrodynamic diameter frequency histograms for BSA solutions are 
presented in Figure 7-3. A general increase in number of particles can be seen 
with increasing concentration and pass number. Concentrations of 5 mg·ml−1 
show an increase in particle size in the range of 40 nm to >1 μm with 
increasing pass number. Unstressed BSA or BSA subjected to fewer than 50 
Figure 7-1: percentage of BSA remaining in solution after 500, 1000, 
1500 and 2,000 passes at 8 mm s−1 at a protein concentration of 1 
(black), 2 (red), 5 (blue), or 10 (magenta) mg·ml−1 [1]. 
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passes, yielded no detectable particles. The total number of aggregates was 
also found to increase with increasing pass number and with increasing BSA 
concentration. The width of the error bars also increases with the number of 
passes, suggesting an increase in sample dispersity [1]. 
Figure 7-4 shows the TEM images taken of BSA concentrations ranging from 
1 – 10 mg·ml-1, and from 50 – 2000 passes. The images support the data 
collected from NTA experiments in Figure 7-2 and Figure 7-3 in that larger 
particles were present after increased numbers of passes and at higher 
concentrations, and that their frequency also appears to increase [1]. 
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Figure 7-2: BSA aggregation analysed by NTA. The experiments were 
performed at the number of passes indicated at different BSA 
concentrations. The plunger velocity in all cases was 8 mm s-1 
(strain rate = 11750 s-1 and shear rate = 55200 s-1). (A) and (B) at 
1mg·mL-1, (C) and (D) at 2 mg·mL-1, (E) and (F) at 5 mg·mL-1 and 
(G) and (H) at 10mg·mL-1 of BSA. Note: very few or no aggregates 
(< 5 particles) were observed for BSA when fewer than 50 passes 
were applied, rendering the particle tracking analysis statistically 
invalid [1]. 
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Figure 7-4: TEM images of BSA after extensional flow at the protein 
concentration and pass number stated. The plunger velocity in all 
experiments above was 8 mm s-1 (strain rate = 11750 s-1, shear rate = 
52000 s-1). Images taken at 10000× magnification, scale bar = 500 nm [1]. 
Figure 7-3: Total number of 10–2,000 nm particles tracked by NTA in 1, 2, 
5, and 10 mg·mL−1 BSA solutions after 50–2,000 passes at 8 mm·s−1. 
Error bars represent the error from two independent experiments [1]. 
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7.2.2. BSA Aggregation Dependence on Strain-Rate 
The purpose of this experiment was to identify the relationship between strain-
rate and aggregation. To increase strain rate, the solution was pumped 
through the contraction at a higher flow rate. 
Samples of BSA were prepared at concentrations of 2.5 and 5 mg·ml-1 and 
subjected to 500 passes at plunger speeds of 2 – 16mms-1. Aggregation was 
quantified using the insoluble protein pelleting method. The results are plotted 
in Figure 7-5. 
For both concentrations, the percentage of insoluble aggregate remains low 
below plunger speeds of 10mm·s-1. 
Both concentrations show a steady rate of aggregation with respect to plunger 
velocity for speeds greater than 8mm·s-1 
The percentage of insoluble aggregate as a fraction of the original sample that 
forms at plunger speeds of 10 – 14 mms-1 was greater for the lower 
concentration sample. However, the total mass of aggregate in the pellet was 
very similar across the two concentrations. 
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Figure 7-5: Percentage of insoluble aggregate after 500 passes of BSA 
in solution at concentrations of 2.5 and 5 mg·ml-1 for plunger 
speeds from 2 – 16 mms-1. 
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7.3. The Effects of Extensional Flow on Therapeutic 
Proteins 
7.3.1. Comparison of therapeutic proteins  
β2m and BSA were prepared at 5 mg·ml-1. WFL, STT and mAb1 was prepared 
at 0.5 mg·ml-1. All four therapeutic proteins, and BSA, were subjected to 20 
and 100 passes at plunger speed 8 mms-1. Aggregation was quantified using 
the insoluble protein pelleting method as well as TEM. 
β2m at 5 mg·ml−1 was found to be more sensitive than BSA yielding 2 % and 
10 % insoluble after 20 or 100 passes, respectively, compared with 1% and 
1.5% of BSA [Figure 7-6 A)]. Visualization of these aggregates by TEM 
revealed short, needle-like fibrils, similar to those found in the joints of patients 
undergoing long-term dialysis [1, 146]. 
GCSF [143] was found to be extremely sensitive to the effects of extensional 
flow. After 20 passes of GCSF C3 at a concentration of 0.5 mg·ml−1 through 
the device, 20% of the sample rendered insoluble [Figure 7-6 A) and C)], 
increasing to 40% after 100 passes. The aggregation-prone WFL was reduced 
to ∼45% and ∼15% of soluble protein after 20 and 100 passes, respectively 
[Figure 7-6]. This was noteworthy given the low concentration of protein used 
(0.5 mg mL−1). mAb1 yielded significantly less insoluble material with ∼15% 
and ∼25% in the pellet after 20 and 100 passes respectively. STT exhibited 
even less susceptibility, yielding only ∼2% and ∼5% insoluble material after 
20 and 100 passes, respectively. It was evident that biopharmaceuticals with 
diverse structures, such as the α-helical G-CSF C3 and the β-sheet mAbs, 
were all prone to extensional flow-induced aggregation. It also shows that 
aggregation propensity of IgGs that differ only at three positions in the CDR 
loops of each VH domain show remarkably different responses to 
hydrodynamic flow [1]. 
 
 
 
 
- 138 - 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 7-6: A) Percentage of protein remaining in solution after 0, 20, 
or 100 passes at a plunger velocity of 8 mm·s−1. B–E) TEM images 
of β2m, G-CSF C3, mAb1, and WFL after 100 passes. The grids 
were imaged at 10,000× magnification. (Scale bar = 500 nm) [1]. 
A 
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7.3.2. mAb Aggregation dependence on velocity 
STT and WFL were almost identical versions of the same IgG, with only six 
differing residues between them. WFL is known to be sensitive to flow 
whereas STT shows more resilience to processing. In previous experiments, 
both proteins showed pass-number dependent aggregation to different 
degrees, as expected.  
In the current experiment, samples of WFL and STT were prepared at 0.5 
mg·ml-1. The IgGs were subjected to a number of passes, STT to 100 and 200 
passes, and the more sensitive WFL to 50 and 80 passes [Figure 7-7 a)–d) 
respectively]. For all experiments, plunger speeds were varied from 2 - 16 
mms-1 to identify any relationship between flow rate and aggregation. 
Aggregation was quantified using the insoluble protein pelleting method. 
STT demonstrated flow rate dependent aggregation for both 100 and 200 
passes [Figure 7-7 a), b) respectively]. In both instances, the protein showed 
a very gradual increase in average aggregation with flow rate up to plunger 
speeds of 10 mm·s-1. So gradual in fact, that with error taken into account, this 
trend was almost statistically irrelevant. As plunger speed increases beyond 
10 mm·s-1, however, aggregation shows a stronger correlation with plunger 
speed up to 16 mm·s-1. For STT after 200 passes [Figure 7-7 b)] the rate of 
aggregation with respect to plunger speed decreases for the highest speed. 
This was due to the percentage of soluble aggregate tending to zero, hence 
there was little more aggregation to occur. 
Contrary to STT, WFL shows no sign of flow rate dependent aggregation. After 
50 passes [Figure 7-7 c)] WFL consistently returns between 40 – 60 % 
insoluble aggregate irrespective of plunger velocity. Similarly after 80 passes 
[Figure 7-7 d)] WFL consistently produces a pellet containing 65 – 75 % 
insoluble aggregate. 
To study this further, WFL was subjected to a pass number experiment as 
follows. 
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Figure 7-7: Speed dependent studies of STT (a, b) and WFL (c, d), both 
at 0.5 mg·ml-1. 
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7.3.3. Further study of WFL 
In the previous experiment, WFL aggregation was seen to be independent of 
plunger velocity whilst showing some dependence on the number of passes 
through the device. To explore this further, WFL was prepared at 0.5 mg·ml-1 
and subjected to 10, 20, 50, 80 and 100 passes at 8 mms-1 plunger velocity. 
Aggregation was quantified using the insoluble protein pelleting method. 
As before, aggregation was seen to increase with the number of passes as 
shown in Figure 7-8. This differs, however, from previous pass number 
dependent aggregation seen in BSA [Figure 7-1 and Figure 7-5] in that BSA 
aggregation was only pass number dependent above a certain number of 
passes, whereas WFL shows pass number dependence from 10 passes. 
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Figure 7-8: percentage of insoluble aggregation of WFL for a 
concentration of 0.5 mg·ml-1 solution exposed to varying 
pass number at 8 mm·s-1. 
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7.4. Results from contraction angle experiments 
In the previous experiment, WFL was shown to be independent of plunger 
velocity, with aggregation shown to vary with number of passes only. In the 
experiment WFL was subjected to 50 passes through varying contraction 
angles. By varying the contraction angle and maintain the plunger speed, the 
maximum strain-rate was varied whilst maximum shear remains constant. 
 WFL was prepared at 0.5 mg·ml-1 and subjected to 50 passes at 8 mms-1 
plunger velocity through contraction angles of 90°, 45° and 30°. Aggregation 
was quantified using the insoluble protein pelleting method. 
For the 90° contraction, identical to that formed by the glass capillary and 
syringe barrel in previous experiments,  the percentage of insoluble aggregate 
present after 50 passes [Figure 7-9] is similar to that seen in the previous WFL 
pass number dependent experiments [Figure 7-7 c), Figure 7-8]. As 
contraction angle, and strain rate, were reduced, the percentage of insoluble 
aggregate decreases proportionally. 
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Figure 7-9: Percentage of  in soluble aggregate in WFL 0.5 mg·ml-1 
samples after being subjected to various contraction angles at 8 
mm·s-1 plunger speeds. 
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7.5. Results from control experiments 
7.5.1. Shear dependence of BSA aggregation 
This experiment was designed to study the link between aggregation and 
exposure time to shear. The extensional flow device was largely the same, 
with a glass capillary connecting the two syringes as before. In the control 
experiment the syringe length was halved, reducing the exposure time to the 
high shear region 2-fold. 
BSA was prepared in samples of  5 mg·ml-1 and exposed to 1000 passes 
through the extensional flow device at a plunger speed of 8 mms-1, and 100 
passes though the device at 16 mm·s-1. Capillaries of lengths 70 mm (full-
length) and 37.5 mm (half-length) were used. Aggregation was quantified 
using the insoluble protein pelleting method. 
The degree of aggregation was found to be similar for full and half-length 
capillaries at 8 and 16 mm s−1 [1]. Given the error, any difference in the 
average amount of aggregation observed between the differing capillary 
lengths were statistically irrelevant. This shows that BSA aggregation when 
subjected to a combination of shear- and extension-dominated flow regimes, 
was independent of shear exposure time. The clear driver of BSA aggregation 
was strain rate, and exposure time to high strain. 
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Figure 7-10: BSA 5 mg·ml-1 stressed for 1000 passes at 8 mm·s-1 and 
100 passes at 16 mm·s-1. Halving the exposure time to shear flow 
using a 37.5-mm instead of a 75-mm capillary for the control 
experiment [1]. 
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7.5.2. Stagnation point dependence of STT aggregation 
It was determined through CFD simulation of the device, that a region of 
extensional flow exists within the downstream syringe. This was the result of 
a stagnation point forming on the receding plunger face as it was impacted by 
a jet of fluid exiting the capillary. The extensional strength was shown to be 
proportional to the plunger distance from the jet outlet, i.e. the capillary exit. 
The control experiment to discount the effects of stagnation on aggregation 
was, therefore, to repeat the conventional reciprocating experiment whilst 
maintaining a 10 mm fluid-filled gap between the jet outlet and the plunger 
face. The sample size was increased to accommodate an extra 10 mm of 
sample in both syringes. The same volume of sample was passed through the 
extensional flow device as for the conventional experiments. If the mass of 
aggregate per unit sample volume was greater for the standard volume 
experiment, this would suggest that the stagnation point was a factor in 
aggregation. In order to measure this, the measured pellet concentration was 
corrected to take into account the excess volume. Therefore, it was purely 
mass of insoluble aggregate that was important here, not percentage of total 
sample. 
STT was prepared in samples of 0.5 mg·ml-1 and exposed to 200 passes 
through the extensional flow device at a plunger speed of 8 mms-1. The 
experiment was carried out with the standard volume, allowing the entire 
sample to pass from one syringe to the other 200 times. The experiment was 
repeated with excess sample volume, leaving a 10 mm gap (approx. 0.08 ml) 
in the syringe after each pass. Aggregation was quantified using the insoluble 
protein pelleting method. 
By percentage, the amount of aggregate in the smaller, standard volume was 
higher [Figure 7-12]. When the data was normalised to take into account the 
difference in volume [Figure 7-11], the data shows that, on average, the 
excess volume experiment produced more aggregated material than the 
standard volume experiment, although the standard volume result does fall 
within the error of the excess volume result. 
- 145 - 
 
 
If the stagnation point was responsible for increasing aggregation, the excess 
volume sample would be expected to show a reduction in aggregation as the 
strain rate weakens with distance from the jet. The evidence suggests that the 
presence of a stagnation point in the downstream syringe has negligible effect 
on protein aggregation within the current device. 
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Figure 7-11: STT 0.5 mg·ml-1 subjected to 200 passes with a standard 
volume, and an excess volume normalised to take into account the 
different sample volumes. This is the ratio of mass of insoluble 
aggregate. 
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Figure 7-12: STT 0.5 mg·ml-1 subjected to 200 passes with a standard 
volume, and an excess volume. 
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8. Discussion 
Work prior to this study has demonstrated that hydrodynamic forces were 
capable of inducing unfolding in long chain molecules such as DNA [147, 148], 
polymers [149], von Willebrand factor (VWF) [150], as well as other proteins 
[8]. The specific flow mechanism which causes unfolding however, has not 
been made clear. To investigate this, a device was designed to vary different 
aspects of the fluid profile, namely shear and extensional flow. The device 
was used to subject natively folded globular proteins to well-defined shear and 
extensional flows at high strain rates. The device successfully demonstrated 
that the protein bovine serum albumin (BSA) will aggregate when exposed to 
extensional flow. The device also demonstrated that the degree of 
aggregation of BSA was independent of exposure time to shear dominated 
environments over the time periods used in our study. 
In other studies it has been shown that over extended periods of time (10s of 
minutes), exposure to high shear environments will result in BSA aggregation 
[151]. This is not surprising when we consider other globular proteins, such as 
VWF and spider silk, have evolved to aggregate readily under relatively low 
exposure times to shear stress [51, 152]. Although such proteins can be 
considered atypical of globular molecules, it is compelling evidence to suggest 
that the mechanisms which allow sensitivity to shear are likely to be present 
in a range of proteins, albeit at a much more subtle level [1]. 
8.1. Tensile stress 
Experiments carried out on a range of proteins has demonstrated that the 
magnitude of aggregation is dependent on a variety of factors. These include 
size and concentration, as well as the structure and surface topology of the 
folded molecule. Experiments comparing the sensitivity of WFL and STT also 
demonstrated the importance of the precise sequence of the protein [1]. 
Further work by L. F. Willis and A. Kumar [1] using in situ cystine labelling has 
demonstrated that extensional flow likely catalyses the unfolding process, 
subject to a critical energy transfer rate that had to be overcome for partial 
unfolding to result in irreversible aggregation. 
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It follows then, that hydrodynamic unfolding of proteins through extensional 
flow shares some common ground with mechanical protein unfolding through 
means such as optical tweezers and atomic force microscopy which can 
induce conformational changes, modify stability, and stimulate biochemical 
responses [153]. In such methods, the tensile force required to “pull apart” 
specific structures within a molecule are quantifiable. Typically, full unfolding 
of a particularly “strong” β-sheet region occurs in the region of 50 – 200 pN of 
directly applied force [154]. 
To allow for engineering analysis, one study [4], discusses the model 
approximation of a bead necklace, shown in Figure 8-1, consisting of 𝑁 
residues where each residue is represented as a bead separated from its 
neighbours by an average centre-to-centre distance 𝑑. The protein is 
assumed to form two approximately equal bunches with a linking chain of 𝑛 
beads between them. The protein is subjected to tension caused by an 
extensional flow characterised by ?̇? = 𝑑𝑣௫ 𝑑𝑥⁄ , where 𝑥 is taken to be the 
direction parallel to the linking chain. An equation for tensile stress is 
presented for the linking chain of length ~𝑛𝑑 between the two equally sized 
clusters of radius 𝑎. The extensional flow can be expressed as the difference 
between the flow velocities experienced by the two clusters at their relative 
locations (𝑣ଶ − 𝑣ଵ) = ?̇? 𝑛𝑑. Tension can be calculated as 
where 𝜂 is the dynamic viscosity of the fluid, which can be taken as that of 
water ~1 mPa·s. 
The maximum strain rate ?̇? has been solved for the extensional flow device 
using CFD analysis. For a typical plunger velocity of 8 mm·s, ?̇? ≈ 12000 s-1. If 
a typical mAb molecule were to be crudely approximated into a dumb-bell 
model, the values of a and nd could be approximated to 5 and 10 nm 
respectively. Using these values in Equation 8-1 a tensile force of the order 5 
fN; four orders of magnitude below the 50 pN required to fully unfold a 
structurally sound β-sheet structure. This implies that the aggregation 
witnessed during experiments is the product of partial unfolding of native 
protein. 
 𝑇 ≈ 6𝜋𝜂𝑎(𝑣ଶ − 𝑣ଵ) 2⁄ = 3𝜋𝜂𝑎 ?̇? 𝑛𝑑 Equation 8-1 
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8.2. Aggregation in terms of energy 
Following from a discussion that solely focuses on the tensile force applied to 
a single molecule, a global energy approach was considered. The global 
energy required to propel a protein-sized fluid packet of radius 3.5 nm through 
either the acceleration required at the extensional flow region, or through the 
high shear capillary region can be calculated as 
𝐸௦ =
𝑃௛𝑉௦
?̇?
 
where 𝑉𝑠 is the volume of the sphere occupied by a protein, ?̇? is the volumetric 
flow rate of the device and 𝑃ℎ is the hydraulic power of the device. The 
hydraulic power can be calculated as 
𝑃௛ = ?̇?∆𝑃 
where ∆𝑃 is the pressure drop. The pressure drop can be taken over the short 
distance that comprises the extensional flow region, or the entire length of the 
capillary depending on which energy is being calculated. The pressure drop 
is calculated from CFD simulation. 
Figure 8-2 (A) shows the energy dissipated at the contraction and throughout 
the capillary in terms of the Boltzmann constant, kB T.  This indicates not only 
that the global energy in the extensional region is insufficient to completely 
unfold a protein (∼2.7 kB T at 8 mms−1, taking into account the very small 
proportion of this energy was absorbed into the structure), but that the 
Figure 8-1: Model for denaturation of a protein by an elongational flow: a 
protein of N residues (depicted as spheres, with centre-to-centre 
separation d) divides into two clusters, separated by a linker of ~n 
residues and length ~nd. The velocity field v leads to a tension in the 
linker which can be calculated [4] 
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energies in the shear and extensional region are relatively similar. This is 
interesting, given the experimental findings that suggest large disparities in 
the abilities for these different regions to induce aggregation. 
The time over which these respective energies were imparted to the flow was 
then considered. The rate of energy transfer as the fluid passes through the 
extensional flow region is high, given that it is proportional to the gradient of 
the pressure drop. Figure 8-2 (B) shows the energy transfer rate E/(kB T·t) in 
reciprocal seconds (s−1), where t is the time taken to traverse the capillary or 
the extensional flow regions. This shows the rate at which energy is introduced 
to the protein solution. This is especially relevant as a perturbed structure will 
only be able to dissipate energy at a finite rate. This analysis demonstrates  
that the rate of energy transfer by extensional flow is in fact orders of 
magnitude larger than that of shear [1]. 
 
 
Figure 8-2: Energy distribution in the extensional flow device. (A) The 
average energy dissipated within the extensional region (red line) 
versus that within the shear region (black line) for a single pass for 
a protein with a diameter of 3.5 nm as a function of plunger velocity. 
(B) Average rate of energy dissipation within the extensional region 
(red line) and within the shear region (black line) per protein volume 
as a function of plunger velocity . 
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8.3. Strain rate distribution at the capillary inlet 
The lack of evidence relating aggregation to extensional flow in-and-around 
the stagnation point may seem counterintuitive to the premise of this work. An 
explanation as to why the transitory extensional flow region is seen to drive 
aggregation, whilst a stagnating extensional flow region is not, can be found 
with further analysis of their respective flow fields. More specifically, the 
answer is found by identifying the regions with greatest mass flow rate. 
Starting with the transitory extensional flow region around the capillary 
entrance; from the computational study it is clear that there is a wide range in 
strain rate magnitudes occurring across the capillary inlet radius. The highest 
of which, seen in an extremely localised point at the inlet corner can be 
dismissed as an erroneous artefact; the product of post-process arithmetic 
applied to numerical results at an extremity. This analysis does not, however, 
carry into the bulk of the flow. The strain rate is seen to increase with radial 
(sr) displacement from the axis of symmetry. Strain rate is related to regions 
of high acceleration and, comparing the strain profiles in Figure 5-8 to the 
velocity profiles in Figure 5-5, it is clear that the region of high strain 
correspond with areas of high contrast in the velocity plots. 
To explain this phenomena, the flow through the capillary inlet should be 
examined in terms of the upstream flow that feeds into it. 
It is clear that the fluid velocity in the syringe region is relatively slow; a plunger 
moving at 8 mms-1 produces a maximum fluid velocity of 16 mms-1 in the 
syringe compared with 3500 mms-1 along the capillary. Despite this the 
capillary inlet profile is heavily influenced by the conditions upstream in the 
syringe barrel. 
Figure 8-3 shows the velocity profile inside the barrel of a syringe, 100mm 
upstream of the capillary inlet. The profile is taken at a location such that there 
is sufficient distance from the upstream plunger for uniform, laminar flow to 
fully develop. The profile is also sufficiently upstream of the capillary inlet so 
as to avoid regions of perturbed flow. The velocity profile spans the radius of 
the syringe, with radial position (Sr) =0mm located at the axis of symmetry (i.e. 
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the centre of the syringe barrel) and Sr =2.305mm representing the syringe 
wall. Velocity (uz) is the fluid velocity parallel to the syringe wall (z-direction). 
A parabolic velocity profile is produced with maximum velocity occurring at the 
centre of the syringe barrel, with velocity reducing quadratically to zero at the 
wall. This is in keeping with laminar flow conditions and is not in any way 
exceptional until it is considered in its 3-dimensional form. In 3D, a velocity 
profile sketches out an area through which a volume of fluid travels per unit 
time, producing a volumetric flow rate (Q) measured in cubic meters per 
second or litres per second.  
𝑄 = 𝑢𝑎 
Because the current problem is axisymmetric, it follows that the radial section 
that carries the largest flow rate (i.e. the region of maximum mass flux (rQ,max)) 
is not the same as the region of maximum velocity. 
 
This is because the circular area through which the maximum velocity material 
travels is very small, resulting in a low mass flux for that region.  
If the syringe radius were divided into increments of equal length, then the 
area swept out by each increment length would increase. To calculate the flow 
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Figure 8-3: Radial velocity profile for undisturbed flow thorough the 
upstream syringe, typical of a syringe moving at 8 mms-1. 
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rate associated with each radial increment, the corresponding area is 
multiplied by the average flow velocity across that increment. 
Figure 8-4 shows the cumulative flow rate distribution with respect to radial 
position within the syringe. The total flow rate from the graph is 132.6 µLs-1. 
Calculating the mass flow rate using equation # gives a flow rate of 133.5 µLs-
1. The discrepancy is due to stationary fluid confined to the pipe wall by friction, 
slightly reducing the “effective” radius and the total mass freely flowing through 
the section. 
 
The region near the centre of the syringe (Sr = 0mm) can be seen to make 
little contribution to the total flow rate despite the high speeds associated with 
it. For radial positions 1mm<Sr<1.5mm, contributions to the total flow rate are 
high as fluid is relatively free to move and cross-sectional area is large enough 
to accommodate substantial mass flux. Near the wall (Sr=2.305mm) the 
available area is at its largest but frictional effects drastically reduce the fluid 
velocity, resulting in minimal contributions to mass flux. 
Figure 8-5 shows the standard distribution of Q with respect to Sr normalised 
to the maximum incremental value of flow rate. From Figure 8-5, the region of 
maximum mass flux, rQ,max, is located at Sr=1.342mm, or at 57.45% across 
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position for undisturbed flow through the upstream syringe. 
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the radius. This indicates that mass flux is skewed towards the lower velocity 
region.  
 
This explains why the capillary inlet is seen to have such high velocity regions 
near the extremities. To satisfy conservation of mass, the mass flux across 
any two cross-sectional areas had to equate. The ratio of cross-sectional 
areas from the syringe to capillary is 538:1, meaning that the average velocity 
had to increase by 538 times. The fluid at the centre of the syringe is readily 
available, traveling faster than its radially displaced neighbours and in the right 
direction. But, as Figure 8-5 show, there isn’t enough material at the axis to 
satisfy mass conservation. In order to supply the capillary with the amount of 
fluid necessary to maintain this flow rate the slow moving fluid in the outer 
42.55%- radius, which constitutes the majority of material in the continuum, is 
drawn inward toward the capillary where is experiences the sudden 
acceleration required to fulfil the need for mass conservation. 
This is further evidenced when the streamline paths are taken into account. A 
streamline that passes through the region of maximum mass flux at Sr=1.324 
mm along the syringe can be followed until it reaches the capillary inlet. The 
same streamline crosses the inlet at a radial position of 0.111mm; just 14 
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microns from the inlet peak velocity region at 0.125 mm. Furthermore, if the 
highest velocity point at the inlet Sr = 0.125 mm is traced back along a 
streamline to a region of unperturbed flow within the syringe, it is found to 
travel at a distance of 1.575 mm from the axis. A region with 94% of the 
maximum mass flux. 
In conclusion, evidence suggests that the regions of high strain at the 
peripheries of the capillary inlet are caused by the requirement of slow-moving 
fluid in the outer regions of the syringe, responsible for the majority of total 
mass flux, to accelerate suddenly in order to continue supplying the large 
volumes required to satisfy mass conservation.  
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9. Conclusions 
9.2. Summary 
9.2.1. Extensional flow induced aggregation in BSA 
BSA aggregation correlated with concentration and exposure time to 
extensional flow. At a concentration of 1 mg·ml-1, BSA remained in solution 
until exposed to 2000 passes. Concentrations of 2 mg·ml-1 showed higher 
sensitivity to pass number, with a steady downward trend in the averaged 
data. For concentrations of 5 mg·ml-1 a steady decrease in soluble BSA was 
seen as pass number increased. 10 mg·ml-1 concentration saw greatest rate 
of aggregation with pass number. 
BSA aggregation also correlated with strain rate. Samples of BSA at 
concentrations of 2.5 and 5 mg·ml-1 subjected to 500 passes at plunger 
speeds of 2 – 16mms-1 both resulted in aggregation. The percentage of 
insoluble aggregate remains low below plunger speeds of 10mms-1, this 
indicated an energy threshold needed to be overcome to trigger flow induced 
aggregation. 
9.2.2. Extensional flow induced aggregation in therapeutic 
proteins 
5 mg·ml−1 β2m produced 2% and 10% insoluble aggregated after 20 or 100 
passes, respectively. TEM images showed short, needle-like fibrils. 0.5 
mg·ml−1 GCSF C3 produced 20% insoluble aggregate after 20 passes. This 
increased to 40% after 100 passes. 0.5 mg mL−1 WFL produced ∼55% and 
∼85% aggregate after 20 and 100 passes, respectively. 0.5 mg mL−1 mAb1 
yielded ∼15% and ∼25% insoluble protein after 20 and 100 passes. STT 
produced only ∼2% and ∼5% insoluble material. 
9.2.3. Antibody conformation affects flow sensitivity 
STT demonstrated flow rate dependent aggregation for both 100 and 200 
passes in flow rates up to plunger speeds of 10 mms-1. Plunger speeds greater 
than 10 mms-1, showed a stronger correlation with aggregation up to 16 mms-
1. WFL, however, did not demonstrate flow rate dependent aggregation. After 
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50 passes, WFL consistently produced between 40 – 60 % insoluble 
aggregate irrespective of plunger velocity. This trend was repeated at 80 
passes.  
Further investigation into WFL presented aggregation increase with number 
of passes. the behaviour was different to BSA in that BSA aggregation was 
only pass number dependent above a certain number of passes, whereas 
WFL showed pass number dependence from 10 passes. 
These findings are important because STT and WFL differ by only six residues 
in some 1400. 
9.2.4. Strain trumps shear 
0.5 mg·ml-1 WFL subjected to 50 passes at 8 mms-1 plunger velocity through 
the 90° nylon constriction returned identical results to  the longer, glass 
capillary experiments with longer shear exposure times. As the contraction 
angle and, therefore, the strain rate were reduced through 45° and 30°, the 
percentage of insoluble aggregate decreased proportionally. This 
demonstrated a strain rate dependence over a shear rate dependence. 
9.1.5. Successful validation 
5 mg·ml-1 BSA exposed to 1000 passes at a plunger speed of 8 mms-1, and 
100 passes at 16 mms-1 through capillaries of lengths 70 mm and 37.5 mm. 
The degree of aggregation was within error for both full and half-length 
capillaries at 8 and 16 mm s−1.This showed that BSA aggregation when 
subjected to a combination of shear- and extension-dominated flow regimes, 
is independent of shear exposure time. BSA aggregation was therefore driven 
by strain rate. 
0.5 mg·ml-1 STT exposed to 200 passes at a plunger speed of 8 mms-1 was 
carried out with the standard experimental volume, and repeated with an 
excess sample volume, leaving a 10 mm gap in the syringe after each pass. 
Normalised data taking into account the difference in volume showed that, on 
average, the excess volume experiment produced more aggregated material 
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than the standard volume experiment. Therefore, the intensity of the 
stagnation point was not responsible for increasing aggregation. 
9.3. Future Work 
The extensional flow device presented in the current work has successfully 
proved the concept of a benchtop application that is capable of probing the 
stability of proteins in the presence of fluid forces. It has highlighted the 
necessity for detailed characterisation of the flow field when interpreting the 
behaviour of proteins in flow, and has demonstrated the importance of 
extensional flow in the production of aggregation in hydrodynamic systems. 
The device did however present some drawbacks which had to be taken into 
account during the experimental campaign. One of which was the presence 
of the high shear region within the capillary. A control experiment was 
implemented to address this, however, this only reduced the exposure time to 
high shear without reducing the magnitude of shear itself. 
Another hindrance was the inclusion of a stagnation point that varied in 
intensity with time during each pass through the device. Again, a control 
procedure was built into the experimental procedure and aggregation was 
found to be independent of the stagnation point. This however, is almost 
certainly not the case for all proteins. 
A further shortcoming of the device, and indeed, the methodology, stems from 
limited information the user can extract about the pathways to aggregation. It 
was seen that a 0.8 ml sample of some protein or another will, over time, 
undergo some conformational change over a series of passes back and forth 
through a region of high stress. In between stress events, the sample dwells 
in a relatively spacious reservoir where it is free to disperse and mix. This 
allows for aggregated particles to seed further aggregation. information about 
this pathway is not captured in the current methodology. 
A more subtle event is also left unexplored; the presence of reversible 
conformational changes. If the flow field is indeed imparting enough energy to 
partially unfold a molecule, it stands to reason that a proportion of these will 
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revert to their native state after the stress is removed. This event remains 
uncaptured by the current methodology. 
To address these issues, a further study into the effects of extensional flow on 
conformation change and aggregation of proteins would require a 
fundamentally different device. Such a device would expose a solution to a 
high strain environment whilst reducing exposure time to high shear to a 
minimum. The device would have to perform without the presence of a 
stagnation point, and ideally subject the sample to multiple passes though an 
extensional flow profile without allowing it to dwell in a reservoir so as to 
prevent the effects of seeding. The device would also allow for revisable 
conformational changes to be probed; this would require the use of in-situ 
characterisation techniques. Such a device would greatly improve upon the 
progress made in the current work.  
- 159 - 
 
 
List of References 
1. Dobson, J., et al., Inducing protein aggregation by extensional flow. 
Proceedings of the National Academy of Sciences, 2017. 114(18): p. 
4673-4678. 
2. Thomas, C.R. and D. Geer, Effects of shear on proteins in solution. 
Biotechnology Letters, 2011. 33(3): p. 443-56. 
3. Ratanji, K.D., et al., Immunogenicity of therapeutic proteins: Influence 
of aggregation. Journal of Immunotoxicology, 2014. 11(2): p. 99-109. 
4. Jaspe, J. and S.J. Hagen, Do protein molecules unfold in a simple 
shear flow? Biophysical Journal, 2006. 91(9): p. 3415-24. 
5. Bee, J.S., et al., Effects of surfaces and leachables on the stability of 
biopharmaceuticals. Journal of Pharmaceutical Sciences, 2011. 
100(10): p. 4158-4170. 
6. Dragovic, R.A., et al., Sizing and phenotyping of cellular vesicles 
using Nanoparticle Tracking Analysis. Nanomedicine: 
Nanotechnology, Biology and Medicine, 2011. 7(6): p. 780-788. 
7. Buss, N.A.P.S., et al., Monoclonal antibody therapeutics: history and 
future. Current Opinion in Pharmacology, 2012. 12(5): p. 615-622. 
8. Simon, S., et al., Physical degradation of proteins in well-defined fluid 
flows studied within a four-roll apparatus. Biotechnology and 
Bioengineering, 2011. 108(12): p. 2914-2922. 
9. Larson, J.W., et al., Single DNA molecule stretching in sudden mixed 
shear and elongational microflows. Lab Chip, 2006. 6(9): p. 1187-99. 
10. Erickson, H.P., Size and Shape of Protein Molecules at the 
Nanometer Level Determined by Sedimentation, Gel Filtration, and 
Electron Microscopy. 2009. 11: p. 32-51. 
11. Zhu, C., G. Bao, and N. Wang, CELL MECHANICS: Mechanical 
Response, Cell Adhesion, and Molecular Deformation. Annual 
Review of Biomedical Engineering, 2000. 2(1): p. 189-226. 
12. Schroeder, C.M., E.S.G. Shaqfeh, and S. Chu, Effect of 
Hydrodynamic Interactions on DNA Dynamics in Extensional Flow:  
Simulation and Single Molecule Experiment. Macromolecules, 2004. 
37(24): p. 9242-9256. 
13. Hassager, O., Kinetic theory and rheology of bead‐rod models for 
macromolecular solutions. I. Equilibrium and steady flow properties. 
The Journal of Chemical Physics, 1974. 60(5): p. 2111-2124. 
14. Jahn, T.R. and S.E. Radford, The Yin and Yang of protein folding. 
FEBS Journal, 2005. 272(23): p. 5962-5970. 
15. Tipping, K.W., et al., Amyloid Fibres: Inert End-Stage Aggregates or 
Key Players in Disease? Trends in Biochemical Sciences, 2015. 
40(12): p. 719-727. 
16. Pace, C.N., et al., Forces contributing to the conformational stability of 
proteins. The FASEB Journal, 1996. 10(1): p. 75-83. 
17. Farber, P.J. and A. Mittermaier, Side chain burial and hydrophobic 
core packing in protein folding transition states. Protein Science : A 
Publication of the Protein Society, 2008. 17(4): p. 644-651. 
18. Fink, A.L., Protein aggregation: folding aggregates, inclusion bodies 
and amyloid. Folding and Design, 1998. 3(1): p. R9-R23. 
- 160 - 
 
 
19. Deng, H.-X., et al., Conversion to the amyotrophic lateral sclerosis 
phenotype is associated with intermolecular linked insoluble 
aggregates of SOD1 in mitochondria. Proceedings of the National 
Academy of Sciences, 2006. 103(18): p. 7142-7147. 
20. Lee, R.E.C., et al., Metacaspase Yca1 is required for clearance of 
insoluble protein aggregates. Proceedings of the National Academy of 
Sciences, 2010. 107(30): p. 13348-13353. 
21. Ayazi Shamlou, P., et al., Turbulent breakage of protein precipitates 
in mechanically stirred bioreactors. Bioprocess Engineering, 1996. 
14(5): p. 237-243. 
22. Krebs, M.R.H., et al., Formation and seeding of amyloid fibrils from 
wild-type hen lysozyme and a peptide fragment from the β-domain 
11Edited by P. E. Wright. Journal of Molecular Biology, 2000. 300(3): 
p. 541-549. 
23. Han, H., P.H. Weinreb, and P.T. Lansbury, The core Alzheimer's 
peptide NAC forms amyloid fibrils which seed and are seeded by β-
amyloid: is NAC a common trigger or target in neurodegenerative 
disease? Chemistry & Biology, 1995. 2(3): p. 163-169. 
24. Bee, J.S., et al., Response of a concentrated monoclonal antibody 
formulation to high shear. Biotechnology and Bioengineering, 2009. 
103(5): p. 936-943. 
25. Haynes, C.A. and W. Norde, Globular proteins at solid/liquid 
interfaces. Colloids and Surfaces B: Biointerfaces, 1994. 2(6): p. 517-
566. 
26. Norde, W., My voyage of discovery to proteins in flatland …and 
beyond. Colloids and Surfaces B: Biointerfaces, 2008. 61(1): p. 1-9. 
27. Mahdi, J.G., et al., The historical analysis of aspirin discovery, its 
relation to the willow tree and antiproliferative and anticancer 
potential. Cell Proliferation, 2006. 39(2): p. 147-155. 
28. Walsh, G., Biopharmaceuticals : biochemistry and biotechnology. 1st 
ed. 1998, Chichester: Wiley. 431. 
29. Bliss, M., The history of insulin. Diabetes Care, 1993. 16(Supplement 
3): p. 4-7. 
30. Smith, K.A., Edward Jenner and the small pox vaccine. Frontiers in 
Immunology, 2011. 2. 
31. Smith, K.A., <Smallpox can we still learn from the journey to 
eradication.pdf>. Indian Journal of Medical Research, 2013. 137(1): p. 
895 - 899. 
32. Swazey, J.P., J.R. Sorenson, and C.B. Wong, Risks and Benefits, 
Rights and Responsibilities - History of the Recombinant DNA 
Research Controversy. Southern California Law Review, 1978. 51(6): 
p. 1019-1078. 
33. Cohen, S.N., A.C.Y. Chang, and L. Hsu, Nonchromosomal Antibiotic 
Resistance in Bacteria: Genetic Transformation of Escherichia coli by 
R-Factor DNA. Proceedings of the National Academy of Sciences, 
1972. 69(8): p. 2110-2114. 
34. Sefik, S.A., Monoclonal antibodies: the story of a discovery that 
revolutionized science and medicine. Nature Reviews Immunology, 
2004. 4(2): p. 153-156. 
- 161 - 
 
 
35. Jing, L. and Z. Zhenping, Research and development of next 
generation of antibody-based therapeutics. Acta Pharmacologica 
Sinica, 2010. 31(9): p. 1198-1207. 
36. Rodrigues, M.E., et al., Technological progresses in monoclonal 
antibody production systems. Biotechnology Progress, 2010. 26(2): p. 
332-351. 
37. Crommelin, D.J.A. and R.D. Sindelar, Pharmaceutical biotechnology: 
an introduction for pharmacists and pharmaceutical scientists. 2002, 
London: Taylor & Francis. 
38. Cromwell, M.M., E. Hilario, and F. Jacobson, Protein aggregation and 
bioprocessing. The AAPS Journal, 2006. 8(3): p. E572-E579. 
39. Magnin, A.A., P.S. Wah, and P. Dennis, Pasteurization of 
immunoglobulin solutions. 1989, Google Patents. 
40. Tolbert, W. and C. Prior, Perfusion Culture, in Advanced Research on 
Animal Cell Technology, A.A. Miller, Editor. 1989, Springer 
Netherlands. p. 119-145. 
41. Hung, C.H., et al., Process for purifying recombinant proteins, and 
products thereof. 1988, Google Patents. 
42. Rathore, N. and R.S. Rajan. Current perspectives on stability of 
protein drug products during formulation, fill and finish operations. 
2008. 2540 Olentangy River Road, P.O. Box 3337, Columbus, OH 
43210-3337, United States: American Chemical Society. 
43. Charm, S.E. and B.L. Wong, Shear effects on enzymes. Enzyme and 
Microbial Technology, 1981. 3(2): p. 111-118. 
44. Thomas, C.R., A.W. Nienow, and P. Dunnill, Action of shear on 
enzymes: Studies with alcohol dehydrogenase. Biotechnology and 
Bioengineering, 1979. 21(12): p. 2263-2278. 
45. Tirrell, M. and S. Middleman, Shear modification of enzyme kinetics. 
Biotechnology and Bioengineering, 1975. 17(2): p. 299-303. 
46. Holford, N.H. and L.B. Sheiner, Understanding the dose-effect 
relationship: clinical application of pharmacokinetic-pharmacodynamic 
models. Clin Pharmacokinet, 1981. 6(6): p. 429-53. 
47. Oliva, A., et al., Effect of high shear rate on stability of proteins: 
kinetic study. Journal of Pharmaceutical and Biomedical Analysis, 
2003. 33(2): p. 145-155. 
48. Arora, D., M. Behr, and M. Pasquali, A Tensor-based Measure for 
Estimating Blood Damage. Artificial Organs, 2004. 28(11): p. 1002-
1015. 
49. Westein, E., et al., Atherosclerotic geometries exacerbate 
pathological thrombus formation poststenosis in a von Willebrand 
factor-dependent manner. Proc Natl Acad Sci U S A, 2013. 110(4): p. 
1357-62. 
50. Atkins, E.D.T. and M.A. Taylor, Elongational flow studies on DNA in 
aqueous solution and stress-induced scission of the double helix. 
Biopolymers, 1992. 32(8): p. 911-923. 
51. Rammensee, S., et al., Assembly mechanism of recombinant spider 
silk proteins. Proc Natl Acad Sci U S A, 2008. 105(18): p. 6590-5. 
52. Charm, S.E. and B.L. Wong, Enzyme inactivation with shearing. 
Biotechnology and Bioengineering, 1970. 12(6): p. 1103-1109. 
- 162 - 
 
 
53. Lencki, R.W., A. Tecante, and L. Choplin, Effect of shear on the 
inactivation kinetics of the enzyme dextransucrase. Biotechnology 
and Bioengineering, 1993. 42(9): p. 1061-1067. 
54. Chi, E., et al., Physical Stability of Proteins in Aqueous Solution: 
Mechanism and Driving Forces in Nonnative Protein Aggregation. 
Pharmaceutical Research, 2003. 20(9): p. 1325-1336. 
55. Ashton, L., et al., Shear-Induced Unfolding of Lysozyme Monitored In 
Situ. Biophysical Journal, 2009. 96(10): p. 4231-4236. 
56. Bekard, I.B., et al., The effects of shear flow on protein structure and 
function. Biopolymers, 2011. 95(11): p. 733-745. 
57. Thomas, C.R. and P. Dunnill, Action of shear on enzymes: Studies 
with catalase and urease. Biotechnology and Bioengineering, 1979. 
21(12): p. 2279-2302. 
58. van der Veen, M.E., et al., Shear-Induced Inactivation of α-Amylase in 
a Plain Shear Field. Biotechnology Progress, 2004. 20(4): p. 1140-
1145. 
59. Charm, S.E. and B.L. Wong, Shear Degradation of Fibrinogen in the 
Circulation. Science, 1970. 170(3956): p. 466-468. 
60. Charm, S.E. and C.J. Lai, Comparison of ultrafiltration systems for 
concentration of biologicals. Biotechnology and Bioengineering, 1971. 
13(2): p. 185-202. 
61. Peterson, D.M., et al., Shear-Induced Platelet-Aggregation Requires 
Vonwillebrand-Factor And Platelet Membrane Glycoprotein-Ib And 
Glycoprotein-IIB-IIIA. Blood, 1987. 69(2): p. 625-628. 
62. Ikeda, Y., et al., The role of von Willebrand factor and fibrinogen in 
platelet aggregation under varying shear stress. The Journal of 
Clinical Investigation, 1991. 87(4): p. 1234-1240. 
63. Higdon, J.J.L., The Kinematics of the 4-Roll Mill. Physics of Fluids a-
Fluid Dynamics, 1993. 5(1): p. 274-276. 
64. Müller, A.J., J.A. Odell, and A. Keller, Elongational flow and rheology 
of monodisperse polymers in solution. Journal of Non-Newtonian 
Fluid Mechanics, 1988. 30(2): p. 99-118. 
65. Janssen, J.M.H., G.W.M. Peters, and H.E.H. Meijer, An opposed jets 
device for studying the breakup of dispersed liquid drops. Chemical 
Engineering Science, 1993. 48(2): p. 255-265. 
66. Haward, S.J., et al., Optimized Cross-Slot Flow Geometry for 
Microfluidic Extensional Rheometry. Physical Review Letters, 2012. 
109(12): p. 128301. 
67. Balducci, A.G., J. Tang, and P.S. Doyle, Electrophoretic Stretching of 
DNA Molecules in Cross-Slot Nanoslit Channels. Macromolecules, 
2008. 41(24): p. 9914-9918. 
68. Skalak, R. and S. Chien, Capillary-Flow - History, Experiments and 
Theory. Biorheology, 1981. 18(3-6): p. 307-330. 
69. Cathey, C.A. and G.G. Fuller, The optical and mechanical response 
of flexible polymer solutions to extensional flow. Journal of Non-
Newtonian Fluid Mechanics, 1990. 34(1): p. 63-88. 
70. Hudson, S.D., et al., A Microliter Capillary Rheometer for 
Characterization of Protein Solutions. Journal of Pharmaceutical 
Sciences, 2015. 104(2): p. 678-685. 
- 163 - 
 
 
71. Liu, J., et al., Reversible self-association increases the viscosity of a 
concentrated monoclonal antibody in aqueous solution. Journal of 
Pharmaceutical Sciences, 2005. 94(9): p. 1928-1940. 
72. Kelly, S.M., T.J. Jess, and N.C. Price, How to study proteins by 
circular dichroism. Biochimica et Biophysica Acta (BBA) - Proteins 
and Proteomics, 2005. 1751(2): p. 119-139. 
73. Schmid, F.-X., Biological Macromolecules: UV-visible 
Spectrophotometry, in eLS. 2001, John Wiley & Sons, Ltd. 
74. Nicoli, D.F. and G.B. Benedek, Study of thermal denaturation of 
lysozyme and other globular proteins by light-scattering spectroscopy. 
Biopolymers, 1976. 15(12): p. 2421-2437. 
75. Oliva, A., M.a. Llabrés, and J.B. Fariña, Comparative study of protein 
molecular weights by size-exclusion chromatography and laser-light 
scattering. Journal of Pharmaceutical and Biomedical Analysis, 2001. 
25(5–6): p. 833-841. 
76. Wang, L., R.D. Vigil, and R.O. Fox, CFD simulation of shear-induced 
aggregation and breakage in turbulent Taylor–Couette flow. Journal 
of Colloid and Interface Science, 2005. 285(1): p. 167-178. 
77. Nesbitt, W.S., et al., A shear gradient-dependent platelet aggregation 
mechanism drives thrombus formation. Nat Med, 2009. 15(6): p. 665-
673. 
78. Delaunay, D., et al., Mapping of protein fouling by FTIR-ATR as 
experimental tool to study membrane fouling and fluid velocity profile 
in various geometries and validation by CFD simulation. Chemical 
Engineering and Processing: Process Intensification, 2008. 47(7): p. 
1106-1117. 
79. Brückl, L., et al., The Effect of Shear on the Structural Conformation 
of rhGH and IgG1 in Free Solution. Journal of Pharmaceutical 
Sciences. 105(6): p. 1810-1818. 
80. Wang, W., Protein aggregation and its inhibition in biopharmaceutics. 
International Journal of Pharmaceutics, 2005. 289(1–2): p. 1-30. 
81. S Hartmann, H.K., Best practices in assessment of developability of 
biopharmaceutical candidates, in Developability of Biotherapeutics: 
Computational Approaches, S.K.S. Sandeep Kumar, Editor. 2015, 
CRC Press. 
82. Schermeyer, M.-T., et al., Squeeze flow rheometry as a novel tool for 
the characterization of highly concentrated protein solutions. 
Biotechnology and Bioengineering, 2016. 113(3): p. 576-587. 
83. Negrini, R., S. Aleandri, and M. Kuentz, Study of Rheology and 
Polymer Adsorption Onto Drug Nanoparticles in Pharmaceutical 
Suspensions Produced by Nanomilling. Journal of Pharmaceutical 
Sciences, 2017. 106(11): p. 3395-3401. 
84. Petrie, C.J.S., One hundred years of extensional flow. Journal of Non-
Newtonian Fluid Mechanics, 2006. 137(1–3): p. 1-14. 
85. Tanner, R.I. and R.R. Huilgol, On a classification scheme for flow 
fields. Rheologica Acta, 1975. 14(11): p. 959-962. 
86. Zienkiewicz, O.C., R.L. Taylor, and P. Nithiarasu, Finite Element 
Method for Fluid Dynamics (6th Edition). Elsevier. 
- 164 - 
 
 
87. Falkovich, G., Fluid Mechanics - A Short Course for Physicists. 
Cambridge University Press. 
88. Kundu, P.K. and I.M. Cohen, Fluid Mechanics (4th Edition). Elsevier. 
89. Astarita, G. and G. Greco, Excess Pressure Drop in Laminar Flow 
through Sudden Contraction. Newtonian Liquids. Industrial & 
Engineering Chemistry Fundamentals, 1968. 7(1): p. 27-31. 
90. Sylvester, N.D. and S.L. Rosen, Laminar flow in the entrance region 
of a cylindrical tube: Part I. Newtonian fluids. AIChE Journal, 1970. 
16(6): p. 964-966. 
91. Lighthill, J., An informal introduction to theoretical fluid mechanics. 
1986: Oxford University Press,New York, NY; None. Medium: X; Size: 
Pages: 260. 
92. Abdelall, F.F., et al., Pressure drop caused by abrupt flow area 
changes in small channels. Experimental Thermal and Fluid Science, 
2005. 29(4): p. 425-434. 
93. Spadiut, O., et al., Microbials for the production of monoclonal 
antibodies and antibody fragments. Trends in Biotechnology, 2014. 
32(1): p. 54-60. 
94. Wang, W., S. Nema, and D. Teagarden, Protein aggregation—
Pathways and influencing factors. International Journal of 
Pharmaceutics, 2010. 390(2): p. 89-99. 
95. Roberts, C.J., Protein aggregation and its impact on product quality. 
Current Opinion in Biotechnology, 2014. 30: p. 211-217. 
96. Carpenter, J.F., et al., Overlooking subvisible particles in therapeutic 
protein products: Gaps that may compromise product quality. Journal 
of Pharmaceutical Sciences, 2009. 98(4): p. 1201-1205. 
97. Randolph, T.W. and J.F. Carpenter, Engineering challenges of protein 
formulations. AIChE Journal, 2007. 53(8): p. 1902-1907. 
98. Li, Y. and C.J. Roberts, Lumry−Eyring Nucleated-Polymerization 
Model of Protein Aggregation Kinetics. 2. Competing Growth via 
Condensation and Chain Polymerization. The Journal of Physical 
Chemistry B, 2009. 113(19): p. 7020-7032. 
99. Wang, W., Instability, stabilization, and formulation of liquid protein 
pharmaceuticals. International Journal of Pharmaceutics, 1999. 
185(2): p. 129-188. 
100. Mahler, H.-C., et al., Protein aggregation: Pathways, induction factors 
and analysis. Journal of Pharmaceutical Sciences. 98(9): p. 2909-
2934. 
101. Scott, D.J., et al., Low resolution solution structure of the apo form of 
Escherichia coli haemoglobin protease Hbp11Edited by M. F. Moody. 
Journal of Molecular Biology, 2002. 315(5): p. 1179-1187. 
102. Tsutomu Arakawa, J.S.P., Daisuke Ejima, Kouhei Tsumoto, and 
Fumio Arisaka, Aggregation Analysis of Therapeutic Proteins, Part 2 
Analytical Ultracentrifugation and Dynamic Light Scattering. 
BioProcess International, 2007. 5(4): p. 36 - 47. 
103. Liu, J., J.D. Andya, and S.J. Shire, A critical review of analytical 
ultracentrifugation and field flow fractionation methods for measuring 
protein aggregation. The AAPS Journal, 2006. 8(3): p. E580-E589. 
- 165 - 
 
 
104. Filipe, V., A. Hawe, and W. Jiskoot, Critical Evaluation of Nanoparticle 
Tracking Analysis (NTA) by NanoSight for the Measurement of 
Nanoparticles and Protein Aggregates. Pharmaceutical Research, 
2010. 27(5): p. 796-810. 
105. Wright, B.C.M., NanoparticleTracking AnalysisA Review of 
Applications and Usage 2010 – 2012. 2012, NanoSight Ltd: Minton 
Park, London Road, 
Amesbury, Wiltshire, SP4 7RT. 
106. Chan, M.Y., et al., Particle Sizing of Nanoparticle Adjuvant 
Formulations by Dynamic Light Scattering (DLS) and Nanoparticle 
Tracking Analysis (NTA), in Vaccine Adjuvants: Methods and 
Protocols, C.B. Fox, Editor. 2017, Springer New York: New York, NY. 
p. 239-252. 
107. Hawe, A., et al., Taylor Dispersion Analysis Compared to Dynamic 
Light Scattering for the Size Analysis of Therapeutic Peptides and 
Proteins and Their Aggregates. Pharmaceutical Research, 2011. 
28(9): p. 2302-2310. 
108. Joubert, M.K., et al., Classification and Characterization of 
Therapeutic Antibody Aggregates. Journal of Biological Chemistry, 
2011. 286(28): p. 25118-25133. 
109. Vasudev, R., S. Mathew, and N. Afonina, Characterization of 
Submicron (0.1–1 μm) Particles in Therapeutic Proteins by 
Nanoparticle Tracking Analysis. Journal of Pharmaceutical Sciences, 
2015. 104(5): p. 1622-1631. 
110. Simonian, M.H., Spectrophotometric Determination of Protein 
Concentration, in Current Protocols in Food Analytical Chemistry. 
2001, John Wiley & Sons, Inc. 
111. Layne, E., [73] Spectrophotometric and turbidimetric methods for 
measuring proteins, in Methods in Enzymology. 1957, Academic 
Press. p. 447-454. 
112. Gill, S.C. and P.H. von Hippel, Calculation of protein extinction 
coefficients from amino acid sequence data. Analytical Biochemistry, 
1989. 182(2): p. 319-326. 
113. Mayerhöfer, T.G., H. Mutschke, and J. Popp, Employing Theories Far 
beyond Their Limits—The Case of the (Boguer-) Beer–Lambert Law. 
ChemPhysChem, 2016. 17(13): p. 1948-1955. 
114. COMSOL, COMSOL Multiphysics Users Guide. 2012. 
115. Sparrow, E.M., S.H. Lin, and T.S. Lundgren, Flow Development in the 
Hydrodynamic Entrance Region of Tubes and Ducts. The Physics of 
Fluids, 1964. 7(3): p. 338-347. 
116. Weissberg, H.L., End Correction for Slow Viscous Flow through Long 
Tubes. The Physics of Fluids, 1962. 5(9): p. 1033-1036. 
117. Holmes, D.B., Experimental studies on laminar flows in ducts, in 
Applied Sciences. 1967, Delftsche Uitgevers Maatschappij 
118. Steinhauer, T., et al., Membrane fouling during ultra- and 
microfiltration of whey and whey proteins at different environmental 
conditions: The role of aggregated whey proteins as fouling initiators. 
Journal of Membrane Science, 2015. 489: p. 20-27. 
- 166 - 
 
 
119. Kelly, S.T. and A.L. Zydney, Mechanisms for BSA fouling during 
microfiltration. Journal of Membrane Science, 1995. 107(1): p. 115-
127. 
120. Narendranathan, T.J. and P. Dunnill, The effect of shear on globular 
proteins during ultrafiltration: Studies of alcohol dehydrogenase. 
Biotechnology and Bioengineering, 1982. 24(9): p. 2103-2107. 
121. Hung, J.J., et al., High concentration tangential flow ultrafiltration of 
stable monoclonal antibody solutions with low viscosities. Journal of 
Membrane Science, 2016. 508: p. 113-126. 
122. G., B.J., et al., Determining Antibody Stability: Creation of Solid‐Liquid 
Interfacial Effects within a High Shear Environment. Biotechnology 
Progress, 2007. 23(5): p. 1218-1222. 
123. Gleason, C., et al., Probing Shear Thinning Behaviors of IgG 
Molecules at the Air–Water Interface via Rheological Methods. 
Langmuir, 2016. 32(2): p. 496-504. 
124. Company, H. 1 mL, Model 1001 RN Valco VISF-1 SYR, Large 
Removable NDL, 22 ga, 0.75 in, point style 3. 2016 2016 [cited 2017 
25/08/2017]; Available from: 
https://www.hamiltoncompany.com/search/search_results/1-mL-
Model-1001-RN-Valco-f-VISF1-SYR-Large-Removable-NDL-22-ga-
075-in-point-style-3. 
125. Bunker, B.C., et al., The effect of molecular structure on borosilicate 
glass leaching. Journal of Non-Crystalline Solids, 1986. 87(1): p. 226-
253. 
126. Budig, P.K. The application of linear motors. in Proceedings IPEMC 
2000. Third International Power Electronics and Motion Control 
Conference (IEEE Cat. No.00EX435). 2000. 
127. Kushner, D., The making of arduino. IEEE Spectrum, 2011. 26. 
128. Corporation, A., 8-bit AVR Microcontrollers ATmega328/P  
DATASHEET COMPLETE, Atmel, Editor. 2016. 
129. Arduino. ARDUINO UNO REV3 Code: A000066. 2017 2017 [cited 
2017 25/08/2017]; Available from: https://store.arduino.cc/arduino-
uno-rev3. 
130. Schmalz, B. Easy Driver Stepper Motor Driver.  25/08/2017]; An Open 
Source Hardware Stepper Motor Drive Project]. Available from: 
http://www.schmalzhaus.com/EasyDriver/. 
131. Roeraade, J., Cutting of glass and fused silica capillaries. Journal of 
High Resolution Chromatography, 1983. 6(3): p. 140-144. 
132. Farrugia, A., Albumin Usage in Clinical Medicine: Tradition or 
Therapeutic? Transfusion Medicine Reviews, 2010. 24(1): p. 53-63. 
133. Wright, A.K. and M.R. Thompson, Hydrodynamic structure of bovine 
serum albumin determined by transient electric birefringence. 
Biophysical Journal, 1975. 15(2): p. 137-141. 
134. Bloomfield, V., The structure of bovine serum albumin at low pH. 
Biochemistry, 1966. 5(2): p. 684-689. 
135. Ueki, T., et al., Aggregation of bovine serum albumin upon cleavage 
of its disulfide bonds, studied by the time-resolved small-angle x-ray 
scattering technique with synchrotron radiation. Biophysical 
Chemistry, 1985. 23(1): p. 115-124. 
- 167 - 
 
 
136. Maruyama, T., et al., Mechanism of bovine serum albumin 
aggregation during ultrafiltration. Biotechnology and Bioengineering, 
2001. 75(2): p. 233-238. 
137. Hewitt, E.W., The MHC class I antigen presentation pathway: 
strategies for viral immune evasion. Immunology, 2003. 110(2): p. 
163-169. 
138. Narang, D., A. Singh, and S. Mukhopadhyay, Stepwise unfolding of 
human β2-microglobulin into a disordered amyloidogenic precursor at 
low pH. European Biophysics Journal, 2017. 46(1): p. 65-76. 
139. Miyata, T., et al., beta 2-Microglobulin modified with advanced 
glycation end products is a major component of hemodialysis-
associated amyloidosis. Journal of Clinical Investigation, 1993. 92(3): 
p. 1243-1252. 
140. Tipping, K.W., et al., pH-induced molecular shedding drives the 
formation of amyloid fibril-derived oligomers. Proceedings of the 
National Academy of Sciences, 2015. 112(18): p. 5691-5696. 
141. Kad, N.M., et al., β2-microglobulin and its deamidated variant, N17D 
form amyloid fibrils with a range of morphologies in vitro11Edited by 
J. Thornton. Journal of Molecular Biology, 2001. 313(3): p. 559-571. 
142. Jing, W., et al., Synthesis and characterization of heparosan-
granulocyte-colony stimulating factor conjugates: a natural sugar-
based drug delivery system to treat neutropenia. Glycobiology, 2017. 
27(11): p. 1052-1061. 
143. Buchanan, A., et al., Improved drug-like properties of therapeutic 
proteins by directed evolution. Protein Engineering, Design and 
Selection, 2012. 25(10): p. 631-638. 
144. Dobson, C.L., et al., Engineering the surface properties of a human 
monoclonal antibody prevents self-association and rapid clearance in 
vivo. 2016. 6: p. 38644. 
145. Brian J. Ford, S.B., David C. Joy. electron microscope. January 16, 
2014  [cited 2017 August 06, 2017]; Available from: 
https://www.britannica.com/technology/electron-microscope. 
146. Mangione, P.P., et al., Structure, Folding Dynamics, and 
Amyloidogenesis of D76N β2-Microglobulin: roles of shear flow, 
hydrophobic surfaces, and α-crystallin. Journal of Biological 
Chemistry, 2013. 288(43): p. 30917-30930. 
147. Zhang, H., et al., Prediction of Shear Damage of Plasmid DNA in 
Pump and Centrifuge Operations Using an Ultra Scale-Down Device. 
Biotechnology Progress, 2007. 23(4): p. 858-865. 
148. Meacle, F.J., et al., Degradation of supercoiled plasmid DNA within a 
capillary device. Biotechnology and Bioengineering, 2007. 97(5): p. 
1148-1157. 
149. Odell, J.A., et al., Degradation of polymer solutions in extensional 
flows. Macromolecules, 1990. 23(12): p. 3092-3103. 
150. Springer, T.A., von Willebrand factor, Jedi knight of the bloodstream. 
Blood, 2014. 124(9): p. 1412-1425. 
151. Bekard, I.B., et al., Bovine serum albumin unfolds in Couette flow. 
Soft Matter, 2012. 8(2): p. 385-389. 
- 168 - 
 
 
152. Sing, C.E. and A. Alexander-Katz, Elongational Flow Induces the 
Unfolding of von Willebrand Factor at Physiological Flow Rates. 
Biophysical Journal, 2010. 98(9): p. L35-L37. 
153. Chen, Y., S.E. Radford, and D.J. Brockwell, Force-induced 
remodelling of proteins and their complexes. Current Opinion in 
Structural Biology, 2015. 30(Supplement C): p. 89-99. 
154. Best, R.B., et al., Force mode atomic force microscopy as a tool for 
protein folding studies. Analytica Chimica Acta, 2003. 479(1): p. 87-
105. 
 
